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ABSTRACT 
 
The study of cancer metabolism is at the forefront of cancer research today. Ever since the initial 
studies made by the Nobel laureate Otto Warburg, scientists have tried to understand how a cancer 
cell shapes its metabolism, in order to cope with stressful conditions and oncogenic demand. A 
key aspect in tumor development is the acquisition of migratory and invasive capabilities, which 
ultimately empower cancer cells with the ability to spread and create metastases in distant sites.  
In this thesis, I will focus on studying the metabolism of cancer cells. Specifically, I will try to 
understand the metabolic processes that influence the capacity of cancer cells to invade adjacent 
tissues, which is the first step of metastasis formation. 
In order to attain my objectives, I set out two questions that were specifically addressed in chapters 
3.1 and 3.2 respectively: 
- How does altered metabolism affect the cancer cell phenotype? 
- How does a more aggressive cancer cell phenotype regulate metabolism? 
For the first question, we generated an in vitro model comprised of cybrid cell lines, where we 
induced a metabolic injury –oxidative phosphorylation dysfunction – arising as a consequence of 
a mitochondrial DNA (mtDNA) mutation. In this model, by comparing wild-type against mutant 
mtDNA in the same nuclear background, we concluded that defective oxidative phosphorylation 
endows cancer cells an increased capacity to move and migrate, having also a positive impact on 
their capacity to form metastasis. 
When addressing the second question, we took in consideration that, in epithelial-derived cancers, 
the formation of metastasis has been associated with transdifferentiation towards a mesenchymal 
phenotype, i.e. epithelial-to-mesenchymal transition (EMT). On this basis, we took advantage and 
optimized a model of EMT, where we characterized the metabolic changes that occur during this 
transition, in an attempt to identify the metabolic traits that are fundamental for the EMT-related 
migration and invasion. Our results showed an enrichment of the UDP-glucose pathway in cells 
undergoing EMT, namely high levels of UDP-glucose and upregulation of UGP2, the enzyme 
that catalyzes UDP-glucose production. We could further demonstrate that the expression of 
UGP2 is required for EMT in an ERK2-driven model. Finally, our results suggest that UGP2 
might be modulating the production of hyaluronan, which may be a key modulator of EMT.  
In summary, we believe that the works laid in this thesis provide new insights about the role 
played by altered metabolism in the oncogenic properties of cancer cells. Most importantly, they 
raise new questions and open avenues for research that can bring light into the determinants of 
cancer cells. 
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RESUMO 
 
Atualmente, o estudo do metabolismo do cancro está na linha da frente da investigação em cancro. 
Desde os estudos iniciais do investigador laureado com o prémio Nobel, Otto Warburg, que os 
cientistas tentam perceber de que maneira a célula cancerígena adequa o seu metabolismo às 
condições de stress e sinais oncogénicos a que está sujeita. Um dos aspetos principais no 
desenvolvimento tumoral é a aquisição de capacidade migratória e invasiva, que permite às 
células cancerígenas disseminarem-se e formar metástases em órgãos distantes.  
Nesta tese, irei focar-me no estudo do metabolismo das células cancerígenas. Em particular, vou 
tentar identificar os processos metabólicos que influenciam a capacidade das células cancerígenas 
de invadir os tecidos adjacentes, o primeiro passo na formação de metástases. 
De modo a atingir os meus objetivos, formulei duas questões que são respondidas nos capítulos 
3.1 e 3.2, respetivamente: 
- Como é que o metabolismo alterado afeta o fenótipo da célula cancerígena? 
- Como é que uma célula mais agressiva regula o seu metabolismo? 
De maneira a responder à primeira questão, construímos um modelo in vitro de linhas células 
cibridas, onde gerámos um problema metabólico – disfunção na fosforilação oxidativa – em 
consequência de uma mutação no ADN mitocondrial.  Neste modelo, comparando o ADN 
mitocondrial normal com o ADN mutado, perante o mesmo conteúdo nuclear, concluímos que 
uma fosforilação oxidativa deficiente leva a uma capacidade de movimento e migração 
aumentada e também tem um impacto positivo na capacidade de formar metástases.  
Para responder à segunda questão, tivemos em consideração que, em cancros originados de 
tecidos epiteliais, a formação de metástases está frequentemente associada a uma 
transdiferenciação para um fenótipo mesenquimal, i.e. transição epitélio-mesenquimal (TEM). 
Nesta base, tirámos partido e otimizámos um modelo de TEM, em que caracterizamos as 
alterações metabólicas que ocorrem durante esta transição, de maneira a identificar traços 
metabólicos fundamentais para a migração e invasão associadas à TEM. Os nossos resultados 
mostraram um enriquecimento na via da UDP-glucose nas células em TEM, nomeadamente 
níveis elevados de UDP-glucose e uma sobreexpressão da UGP2, a enzima que catalisa a 
formação de UDP-glucose. Demonstrámos posteriormente que a expressão da UGP2 é necessária 
para a TEM num modelo onde este processo é induzido pela ERK2. Por fim, os nossos resultados 
sugerem que UGP2 intervêm na modelação da produção de ácido hialurónico, um mediador 
importante durante a TEM.  
Concluindo, acreditamos que o trabalho desta tese providenciou novas perspetivas sobre o papel 
do metabolismo alterado nas propriedades oncogénicas das células cancerígenas. De salientar que 
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estas levantam novas questões e abrem novas perspetivas de investigação que podem trazer luz 
aos determinantes das células cancerígenas. 
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PROLOGUE 
 
According to the World Health Organization, cancer is the second main cause of death worldwide 
and the number of people affected by this disease is expected to increase by 70% in 20 years. The 
most lethal types of cancer are those of the lung, liver, colon/rectum, stomach and breast (World 
Health Organization 2018).  
Cancer is a generic term for a large group of diseases, characterized by an abnormal cell growth 
that occurs as consequence of genetic alterations and environmental deregulation of homeostasis 
and that does not respect the tissue borders and spreads. Cancers can be divided, according to the 
tissue of origin, into several major subtypes: carcinomas (epithelial tissue), sarcomas (connective 
tissue), lymphomas (lymphatic system), leukemias (bone marrow), myelomas (plasma cells of 
bone marrow) and mixed types (World Health Organization 2013). Metastasis is the major cause 
of cancer-related deaths (World Health Organization 2018). In epithelial-derived cancers, 
metastasis constitutes a multi-step cascade that includes the detachment of the primary tumor cells 
and invasion of the surrounding tissue, the intravasation into the circulatory system and the 
formation of a secondary tumor colony in a lymph node or at a distant site. In the case of distant 
metastasis, cells traveling in the bloodstream have to extravasate through the vascular walls to 
form a new tumor. Several studies have demonstrated that carcinoma cells that locate at the 
invasive front of primary tumors acquire a mesenchymal phenotype and that epithelial to 
mesenchymal transition (EMT) is an important process enabling metastasis (Thiery et al. 2009) 
(Fig. 1).  
 
 
Fig. 1: Process of metastasis. EMT, epithelial to mesenchymal transition; ECM, extracellular 
matrix. 
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The present thesis will focus on cancer metabolism, as a crucial aspect of tumorigenesis and 
cancer progression. Chapter 1.1 will describe the alterations in metabolism that characterize 
cancer cells. In this thesis, I was particularly interested in the metabolic alterations during 
metastasis formation, more specifically in its first step when cancer cells migrate and invade the 
surrounding tissue of the primary tumor (chapter 1.2) and where EMT is one of the cellular 
programs that empowers cancer cells with migratory capacity (chapter 1.3). The results section 
of this thesis contains two studies on cancer metabolism (in a scientific manuscript format) aiming 
at answering the following questions: what are the consequences for cancer cell behavior when 
the cellular metabolism is modulated? (chapter 3.1) and what are the metabolic alterations upon 
the acquisition of a more aggressive phenotype? (chapter 3.2). Finally, chapter 4 contains a 
general discussion of both studies. Two papers that were used for the introduction and discussion 
of this thesis, and where I am first author, are attached at the end of the thesis (annexes I and II). 
One relates to the screening of mutations in metabolic enzymes (succinate dehydrogenase) in 
Portuguese paraganglioma patients, where we discovered a new succinate dehydrogenase B 
founder mutation. The other is a thorough literature review about the metabolism that 
characterizes EMT. 
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1.1 - CANCER METABOLISM 
 
1.1.1 - Cancer metabolism – overview 
The metabolism of tumors has been subject of study since the beginning of the twentieth century. 
The pioneer in the field, Otto Warburg, described a high consumption of glucose and release of 
lactate by malignant cells, when compared with non-neoplastic cells, even in presence of oxygen 
(Warburg 1924); this phenomenon is known as aerobic glycolysis or the “Warburg effect”. 
Warburg hypothesized that this aerobic glycolysis was irreversible and due to an impairment of 
mitochondrial respiration  (Warburg 1956). Nowadays, with an exponential interest in this field 
of research and the inclusion of the “reprogramming of energy metabolism” as a hallmark of 
cancer (Hanahan and Weinberg 2011), a more complex picture has emerged.  
The adaptation of the cellular metabolism is very important in the sense that it allows cells to 
maintain cellular homeostasis and survive under different environmental conditions, being part 
of the adjustment to a phenotype alteration. Therefore, during malignant transformation and tumor 
progression, cancer cells rely on specific changes in metabolic activity in order to meet their 
energetic demands and biomass production. Nowadays, we know that these changes are not 
limited to carbohydrates metabolism but they also include lipids, nucleotide, amino acid, as well 
as alterations in reductive equivalents and redox power. Besides, different types of tumors display 
different metabolic adaptations and even within the tumor microenvironment there is a metabolic 
cooperation between cancer cells and the cells that constitute the tumor stroma. The role of 
metabolism in tumorigenesis is also linked to other aspects of a cancer such as stemness, 
exosomes, angiogenesis, immune escape, among other. Importantly, cancer cell metabolism 
reflects the stage of the tumor, implying that it may vary according to the proliferation rate, and 
to the migratory and invasive capacities of cancer cells. Indeed, much less is known about the 
metabolism of migratory cancer cells and of those that are detaching from the primary tumor, as 
the first step of secondary tumor sites colonization.  
 
1.1.2 - Once upon a time, there was a scientist named Warburg 
In the first half of the twentieth century, the German scientist Otto Warburg described a 
phenomenon that would alert the scientific community for the metabolism of tumors (Warburg 
1924). Measuring oxygen consumption and lactate production simultaneously in tumor slices, 
Warburg reported that, even in the presence of oxygen, proliferating tumor cells consumed 
glucose at a much higher rate when compared with normal cells and secreted most of the glucose-
derived carbon in the form of lactate (Warburg 1924; Warburg and Minami 1923). A century ago, 
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Louis Pasteur had already demonstrated that fermentation was reduced by the presence of oxygen, 
being pyruvate conducted to the mitochondria to be oxidized (Racker 1974). The “Pasteur effect” 
reflects the versatility and dynamic nature of metabolism which, in this case, plays an important 
role in maintaining energy production throughout a range of oxygen concentrations in mammalian 
cells (Gatenby and Gillies 2004). However, Warburg pointed out that, in the case of tumor cells, 
this increased glycolysis happens even in aerobic conditions. Warburg proposed that this “aerobic 
glycolysis” was due to an impairment in respiration and it was a driving force of tumorigenesis 
(Warburg 1956). 
After a period with declining interest on the metabolism of cancer cells, where cancer research 
focused on the genetic basis of the disease, a new imaging technique based on Warburg’s principle 
brought it up to the stage again. PET (positron emission tomography) is based on the detection of 
photons released by annihilation of positrons emitted by radiopharmaceuticals. 18F-
fluorodeoxyglucose (18F-FDG), the most commonly used PET tracer, is a glucose analogue whose 
use has shown that most primary and metastatic human cancers have a significantly increased 
glucose uptake (Kelloff et al. 2005; Som et al. 1980). The success of this technique in the 
detection, classification, staging and therapeutic management of tumors was actually one of the 
reasons for the reemergence of the interest for tumor metabolism. Besides, the discovery of 
oncogenic mutations in mitochondrial metabolic enzymes and the association of the “Warburg 
effect” with mutations in “classical” oncogenes and tumor suppressor genes, boosted not only the 
exploration of the mitochondrial function in tumor cells but also travelling beyond the 
bioenergetics point of view to the general metabolism of tumor cells. In fact, in 2011, the 
reprogramming of energy metabolism was considered as one of the “emerging” common traits of 
cancer cells (Hanahan and Weinberg 2011). 
 
1.1.3 - Cancer metabolism – what do we know today? 
Nowadays, we realize that cancer metabolism is incredibly complex. According to Hanahan and 
Weinberg, carcinogenesis is associated with self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals and limitless replicative potential (Hanahan and Weinberg 2000). These 
characteristics must be tightly associated with a metabolic reprogramming, since cells require 
biosynthetic precursors as building blocks to fuel cell growth. So, in the recent years cancer 
metabolism has been heavily studied under the perspective of its role in supporting the increased 
anabolic needs of enhanced proliferation (Vander Heiden, Cantley, and Thompson 2009). 
In mammalian cells, the uptake of nutrients is controlled by growth factor signaling; however, 
cancer cells accumulate oncogenic alterations that lead to aberrantly activated signaling 
pathways, providing them some independence from these external requirements (Hanahan and 
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Weinberg 2000; Thompson 2011). Indeed, the reprogramming of tumor metabolism has been 
shown to be under the control of various oncogenic signals (Edinger and Thompson 2002; Levine 
and Puzio-Kuter 2010; Thompson 2011). Oncogenic KRas, for example, enhances glycolysis in 
several cell types and, in the case of pancreatic ductal adenocarcinoma (PDAC), it diverts the 
glycolytic flux towards anabolic pathways, such as the hexosamine biosynthetic pathway (HBP) 
for protein glycosylation and pentose phosphate pathway (PPP) for ribose production (Racker, 
Resnick, and Feldman 1985; Ying et al. 2012; Yun et al. 2009). In mutant KRas, p53 null lung 
tumors, glucose metabolism is also rewired in low- and high-grade lesions and modulated by 
mutant KRas allelic content. In fact, a higher mutant KRas (G12D) copy number is associated 
with a glycolytic phenotype and with an increased flux of glucose metabolism towards 
tricarboxylic (TCA) cycle and glutathione synthesis. Besides, the KRas mutant high-grade lung 
tumors showed a high sensitivity to combined glucose and glutathione depletion (Kerr et al. 
2016). Conversely, recent evidence in yeast shows that, Ras is activated by a high glycolytic rate 
through one of its intermediates, fructose 1,6-bisphosphate, suggesting a reciprocal stimulatory 
signaling loop between cell proliferation and glycolysis (Peeters et al. 2017). 
Phosphatidylinositol 3-kinase (PI3K)/Akt signaling is another pathway that modulates cellular 
metabolism. Akt activity can induce glucose transporter (GLUT) 1 expression and trafficking, 
increase glycolytic rates and promote glucose consumption and lactate production. Moreover, its 
pro-survival role requires the presence of glucose in the culture medium, the induction of 
glycolysis and maintenance of a physiologic mitochondrial potential (Barthel et al. 1999; Plas et 
al. 2001; Rathmell et al. 2003). 
The oncogene c-Myc stimulates glutamine utilization through the coordinate expression of genes 
necessary for cells to engage in glutamine catabolism (Wise et al. 2008). For example, c-Myc can 
upregulate glutaminase (GLS) by regulating miR-23a and miR-23b, being glutamine and GLS 
required for Myc-mediated cancer cell proliferation and survival (Gao et al. 2009). The translation 
efficiency of c-Myc is, in turn, regulated by mTOR/S6K1 signaling, via eIF4B, leading to a 
mTOR-dependent control of the glutamine flux through regulation of GLS (Csibi et al. 2014). 
mTOR, a signaling pathway implicated in cancer, can indeed regulate metabolism in multiple 
ways (Gomes and Blenis 2015). For example, mTORC1, through S6K1 or ATF4 can also induce 
pyrimidine and purine synthesis, respectively, thus fueling nucleic acid biosynthesis and 
promoting anabolic growth (Ben-Sahra et al. 2013, 2016; Robitaille et al. 2013).  
p53 has also been shown to regulate metabolism (Flöter, Kaymak, and Schulze 2017), for example 
through the induction of TP53-induced glycolysis and apoptosis regulator (TIGAR) and 6-
phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 (PFKFB4) (Bensaad et al. 2006; Ros et al. 
2017). TIGAR is a fructose-2,6-bisphosphatase domain containing protein, which leads to a 
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decrease of the glycolytic byproduct fructose-2,6-bisphosphate - a phosphofructokinase-1 
activator - increasing substrate delivery to the oxidative PPP. p53-induced TIGAR expression 
seems to be important to reduce the levels of reactive oxygen species (ROS) after exposure to 
DNA damaging agents (Bensaad et al. 2006). In cancer cells, p53 represses the transcription of 
PFKFB4, an enzyme that also regulates the concentration of the fructose-2,6-bisphosphate. 
Interestingly, loss of p53 function in cancer cells leads to PFKFB4 upregulation and, in this 
context, the enzyme is working as a phosphatase, negatively regulating fructose-2,6-biphosphate 
levels. In p53-deficient cancer cells, PFKFB4 is regulating PPP and NAPDH levels and is 
essential for the viability of these cells (Ros et al. 2017). Besides, p53 wild-type (and not the p53 
mutant V122A) inhibits the PPP, through inhibition of glucose-6-phosphate dehydrogenase 
(G6PD) (Jiang et al. 2011).  
It is thus clear that the genetic alterations characteristics of cancer cells are able to shape the 
metabolism of cells. This is epitomized in certain tumors, such as hereditary 
paragangliomas/phaeochromocytomas (associated with succinate dehydrogenase [SDH] 
mutations) and malignant gliomas (associated with isocitrate dehydrogenase [IDH] mutations), 
where mutations in metabolic enzymes are crucial elements to drive tumorigenesis and can create 
metabolic vulnerabilities (Gottlieb and Tomlinson 2005).  
On the other hand, metabolic plasticity governs the ability of cells to survive the environment 
where they are inserted in, indicating that the metabolism of cancer cells is also tailored according 
to extrinsic factors, like nutrient and oxygen availability, interaction with the cellular and non-
cellular stromal components.  
While the study of the metabolic rewiring of cancer cells has provided major breakthroughs, most 
of the research concerns the link between the metabolic alterations of cancer cells and their 
proliferative capacity, while much less is known about the metabolism of cancer cells in the 
metastasis process. 
The next sub-sections describe in more detail the most relevant metabolic phenotypes within the 
context of this thesis. 
 
Glycolytic phenotype 
 
Glycolysis 
Glycolysis is a central metabolic pathway of the cell, which occurs in the cytoplasm. The 
catabolism of glucose into pyruvate produces intermediate metabolites for several anabolic 
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reactions, generating also 2 molecules of ATP (adenosine triphosphate) and 2 NADH (the reduced 
form of nicotinamide adenine dinucleotide) per molecule of glucose. The glycolytic pyruvate can 
be further oxidized in the mitochondria in the TCA cycle where ATP production is maximized.  
Alternatively, pyruvate can be converted into lactate in the cytoplasm by lactate dehydrogenase 
(LDH), with the regeneration of NAD+ (the oxidized form of nicotinamide adenine dinucleotide) 
from NADH. 
Glucose is imported into the cell by GLUTs. After entering the cells, glucose is immediately 
phosphorylated into glucose 6-phosphate via phosphate transfer from ATP, by hexokinase (HK). 
This irreversible first step of the glycolytic pathway reaction is very important because it prevents 
glucose from exiting the cell, promoting the formation of a concentration gradient that facilitates 
glucose uptake and allowing the utilization of glucose by several major pathways. In some 
contexts, isoforms I and II of HK can physically and functionally interact with the mitochondria, 
promoting the ‘open’ configuration of the voltage-dependent anion channel (VDAC) that enables 
anionic metabolite exchange across the outer mitochondrial membrane. This is thought to allow 
a preferred access of HK to ATP synthesized in the mitochondria via the mitochondrial adenine 
nucleotide translocator; conversely, the ADP (adenosine diphosphate) generated by HK can be 
channeled back into the mitochondrion to support oxidative phosphorylation (OXPHOS) (Robey 
and Hay 2006). Glucose-6-phosphate is metabolized through a series of steps to generate pyruvate 
(Fig. 2). Another rate-controlling enzyme of glycolysis is phosphofructokinase (PFK) that 
exhibits a complex regulatory behavior, reflecting its ability to integrate many different signals 
from different pathways. PFK catalyzes the transfer of γ-phosphate from ATP to fructose-6-
phosphate, generating fructose-1,6-bisphosphate and ADP. The reverse reaction is catalyzed by 
the rate limiting reaction of gluconeogenesis pathway, fructose-1,6-biphosphatase (FBP). 
Pyruvate kinase (PK) is also a major regulatory enzyme of glycolysis. 
 
22 
 
 
Fig. 2: Glycolysis. 
 
The metabolism of glucose (and glutamine) is important to provide the reducing power, either in 
the form of NADH or FADH2 (reduced form of flavin adenine dinucleotide), in this way driving 
ATP production through OXPHOS, which is essential for several anabolic reactions and for 
maintaining the redox capacity of cells. Besides, glucose (and glutamine) oxidation also produces 
NADPH (the reduced form of nicotinamide adenine dinucleotide phosphate), which provides 
reducing power for a wide variety of biosynthetic reactions and helps maintaining the cellular 
redox capacity. 
 
Aerobic glycolysis in cancer cells 
The preference of cancers for aerobic glycolysis over OXPHOS has triggered an enormous 
interest. Since this question has been addressed from different angles, it increased our 
understanding of the role of metabolism in tumorigenesis and exposed its plastic nature. 
As previously mentioned, the fact that tumors show an increase in glucose uptake has been 
confirmed by the successful use of 18F-FDG PET, which has become a clinical valuable tool 
(Kelloff et al. 2005). In fact, glucose uptake is positively correlated with increased tumor 
aggressiveness and worse prognosis (defined by invasion, tumor size and metastasis) in gastric 
cancer (Mochiki et al. 2004), breast cancer (Alberini et al. 2009), oesophageal cancer (Kato et al. 
2005), oral squamous cell carcinoma (Kunkel et al. 2003), soft tissue sarcomas (Schwarzbach et 
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al. 2005), among others. Besides, genes involved in glycolysis are overexpressed several human 
cancers (Altenberg and Greulich 2004). The advances in technology for the analysis of metabolic 
fluxes in situ revealed that increased glycolysis and lactate production is a feature of non-small 
cell lung cancer (NSCLC) (Davidson et al. 2016; Fan et al. 2009; Hensley et al. 2016). This was 
also shown using flux analysis in oncogenic PDAC tumor cells (Ying et al. 2012).  
While the preference for a glycolytic metabolism over a more energy-profiting respiration can be 
regarded as an energetic constraint, cancer cell proliferation does not seem to be limited by ATP 
production (Lunt and Vander Heiden 2011). Although a fast glycolytic rate can supply high 
amounts of ATP (Pfeiffer, Schuster, and Bonhoeffer 2001), in fact glycolysis does not seem the 
major contributor of ATP in several cancer cells (Zu and Guppy 2004). Moreover, other 
proliferating cells, besides cancer cells, use aerobic glycolysis regardless of the nutrient and 
oxygen availability (Vander Heiden, Cantley, and Thompson 2009). 
Why increased glycolysis? Much attention has been paid to the benefits of increased glycolysis 
in the context of the tumor microenvironment, especially during restriction in oxygen availability. 
The growth of the tumor mass and the fact that the microenvironment of a solid tumor generally 
has a disorganized microvasculature, creates regions of hypoxia (Carmeliet and Jain 2000; 
Helmlinger et al. 1997). Besides, fluctuations in tumor microvessel flow rate can also generate 
intermittent or perfusion-limited hypoxia (Kimura et al. 1996). Therefore, several authors have 
proposed that the glycolytic phenotype and a lower dependence on aerobic respiration confers a 
selective advantage for survival and proliferation during somatic evolution of cancer, within the 
unique tumor microenvironment (Gatenby and Gillies 2004; Hsu and Sabatini 2008). One of the 
most important modulators of the cellular transcriptional response to hypoxia and regulator of 
cellular metabolism is the hypoxia-inducible factor 1 (HIF-1). HIF-1 is a transcription factor first 
described by Semenza & Wang (Semenza and Wang 1992) and constitutes one of three 
mammalian HIF isoforms (Kaelin Jr. and Ratcliffe 2008). It binds to hypoxia-responsive elements 
(HRE) upon formation of a heterodimer composed by the constitutive β subunit (also known as 
aryl hydrocarbon receptor nuclear translocator) and the α subunit. A crucial mechanism involved 
in oxygen regulation of HIF activity is mediated by prolyl hydroxylase domain enzymes (PHD) 
and the E3 ubiquitin ligase, von Hippel-Lindau (VHL). Under normoxia, HIF-1α is targeted for 
proteasomal degradation by VHL, in consequence of its oxygen-dependent proline hydroxylation 
catalyzed by PHD. In low oxygen tension conditions, prolyl hydroxylation of HIF-1α is impaired, 
VHL cannot bind to the newly synthesized subunit, resulting in HIF-1α stabilization and 
accumulation in the cytosol. Eventually this subunit is translocated to the nucleus where it binds 
to the constitutively active HIF-1β subunit to form an active transcription factor (Kaelin Jr. and 
Ratcliffe 2008). HIF-1α can also be stabilized by numerous molecular players of signaling 
pathways dysregulated in cancer, in an oxygen independent manner (Gatenby and Gillies, 2004).  
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HIF is thought to play a role in the development of cancers from the von-Hippel Lindau spectrum, 
which are characterized by VHL loss-of-function mutations, as well as those developing upon 
SDH or fumarate hydratase (FH) mutations (Gottlieb and Tomlinson 2005). In the these, 
mitochondrial metabolism appears to be involved in HIF regulation during normoxia, through the 
generation of Krebs cycle intermediates such as succinate, fumarate and α-ketoglutarate (α-KG) 
(Pollard et al. 2005; Selak et al. 2005) and possibly ROS, although still controversial (Iommarini 
et al. 2017). 
HIF-1 is important for promoting a shift towards certain forms of carbon metabolism and ATP 
production such as glycolysis, by regulating the transcription of metabolic genes such as the 
glycolytic enzymes HKI, HKII and PFK, besides GLUT1 and LDHA (Hu et al. 2003; Semenza 
2003). 
Finally, it has been argued that suppression of OXPHOS protects cells from production of 
cytotoxic levels of ROS caused by hypoxia, besides preserving oxygen for other oxygen-mediated 
reactions and to avoiding necrotic death (Frezza and Gottlieb 2009). 
Another component of the “Warburg effect” is the increased secretion of lactate, which can be 
produced from pyruvate through the action of LDH. LDH oxidizes NADH to NAD+, contributing 
to replenishing the NAD+ pools to sustain glycolysis. Moreover, it has been proposed that 
proliferating cancer cells tend to shuttle pyruvate into the production of lactate to avoid the 
negative regulation by high levels of ATP generated by the OXPHOS chain, if pyruvate integrates 
the TCA cycle (Pavlova and Thompson 2016). Lactate can also conduct an HIF-independent 
hypoxic response that promotes angiogenesis and tumor cell growth. This is mediated by NDRG, 
an oxygen-regulated protein and a substrate of the PHD2/VHL system, whose binding to lactate 
allows its accumulation during hypoxia, leading to the activation of the Raf- extracellular signal–
regulated kinase (ERK) pathway and the expression of angiogenic marker genes (Lee et al. 2015). 
HIF-1 (and other oncogenes like c-Myc) are able to induce LDHA expression, thus acting as 
cellular hubs that connect the oncogenic signaling pathways with the metabolic pathways (Firth, 
Ebert, and Ratcliffe 1995; Semenza et al. 1996; Shim et al. 1997). 
One of the consequences of the increased production of lactate by tumor cells is the reduction of 
intracellular pH, which is controlled by intracellular pH regulating systems such as cell membrane 
proton exchangers. In fact, cancer overexpress several of these acid extruders, like H+-ATPases, 
the Na+–H+ exchanger and the bidirectional lactate/H+ symporters monocarboxylate transporters 
1 and 4 and it has been suggested that a higher intracellular pH in cancer cells may be permissive 
for tumorigenesis (Webb et al. 2011), since the inhibition of these adaptive mechanisms can 
impair tumor growth (Parks et al. 2017). Interestingly, an acid pH also induces the production of 
L-2-hydroxyglutarate (L-2-HG) (the D-2-HG enantiomer) which leads to the stabilization of HIF, 
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even in normoxic conditions. In these conditions, the production of this metabolite is catalyzed 
by LDHA which preferentially reduces α-KG at lower pH (Intlekofer et al. 2017).  
After being produced, lactate is secreted and, therefore, increased lactate production contributes 
to extracellular acidosis. Extracellular lactate signals for angiogenesis, by inducing vascular 
endothelial growth factor (VEGF) expression (Fukumura et al. 2001; Xu, Fukumura, and Jain 
2002) and acts as a cancer cell metabolic fuel (Kennedy et al. 2013; Sonveaux et al. 2008). 
Besides, acidosis promotes extracellular matrix (ECM) remodeling and stimulates acid-activated 
proteases to facilitate tumor cell invasion and dissemination (Busco et al. 2010; Kato et al. 1992; 
Rozhin et al. 1994). Lactate also affects non-tumor cells from the microenvironment, which will 
be discussed later in this chapter, in the section “Metabolism of tumors: much more than cancer 
cells”.  
Acidosis can also be promoted by the mitochondrial metabolism, through the formation of carbon 
dioxide. This is due to the release of carbon dioxide and generation of protons and bicarbonate 
by a class of extracellular carbonic anhydrases (Swietach, Vaughan-Jones, and Harris 2007). 
Carbonic anhydrase IX (CAIX) expression is increased in tumors (Swietach, Vaughan-Jones, and 
Harris 2007) and its activity is important for tumor cell survival, controlling the intracellular pH 
(Chiche et al. 2009). In turn, hypoxia also activates the HIF-1 pathway, which upregulates CAIX 
and leads to additional exacerbation of tumor acidosis (Dayan et al. 2006).  
Although in proliferating cancer cells the glucose-derived lactate has important oncogenic effects, 
a significant fraction of glucose carbon, in the form of glycolytic intermediates, is shunted into 
multiple biosynthetic pathways instead of giving rise to pyruvate. Research has shown that these 
glycolytic intermediates provide essential anabolic support for cell proliferation and tumor 
growth.  
 
Other destinies for glucose (anabolism) 
Glucose is one of the most abundant nutrients in plasma and its major role in cellular metabolism 
is illustrated by the fact that it is the most well-studied metabolite concerning cancer. However, 
glucose or, more specifically, its phosphorylated form - glucose-6-phosphate - can be metabolized 
in many different pathways in the cell, in order to support the production of intermediates for the 
synthesis of lipids, proteins and nucleic acids. Here, I will briefly describe the most relevant 
pathways in cancer and for this thesis: PPP, serine synthesis, HBP and uridine diphosphate 
(UDP)-glucose pathway (Fig. 3). 
Pyruvate kinase (PK) is a highly regulated enzyme that has a crucial role in balancing the outputs 
of glycolysis, having been proposed to favor this anabolic metabolism. This enzyme catalyzes the 
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last step of glycolysis by converting phosphoenolpyruvate into pyruvate, generating ATP. There 
are several isoforms of PK and some types of cancer express the M2 splice isoform, a less active 
form of the enzyme (Christofk, Vander Heiden, Harris, et al. 2008). The expression of PKM2 in 
cancer cells is associated with the aerobic glycolysis (Christofk, Vander Heiden, Harris, et al. 
2008). Although a lower PK activity seems counter-intuitive, it has been proposed that PKM2 
expression promotes anabolic processes since it causes a build-up of glycolytic intermediates, 
which is important for a proliferating cancer cell. For example, a reduced PK activity can promote 
serine biosynthesis and support proliferation in conditions where serine is limiting (Chaneton et 
al. 2012). However, this concept is still matter of debate and PKM2 seems not to be essential in 
some cancer types such as in mouse breast cancer or Apc loss-driven colon cancer models 
(Israelsen et al. 2013; Lau et al. 2017). Indeed, PKM2 null mice are viable and develop 
spontaneous hepatocellular carcinomas (HCC) (Dayton et al. 2016). Interestingly, PKM2 also 
integrates signaling inputs, since its activity can be regulated not only by metabolites such as the 
allosteric activator fructose-1,6-bisphosphate and serine (Chaneton et al. 2012; Jurica et al. 2018), 
but also by tyrosine kinase signaling, which phosphorylates and inhibits the formation of the 
active tetrameric PKM2 (Christofk, Vander Heiden, Wu, et al. 2008; Hitosugi et al. 2009).  
 
 
Fig. 3: Glucose fates in the cells: glycolysis, PPP, HBP, serine synthesis and UDP-glucose. 
Ellipsis (and the arrows before and after) represent multiple reactions. G6P, glucose-6-phosphate; 
F6P, fructose-6-phosphate; 3-PG, 3-phosphoglycerate; G1P, glucose-1-phosphate; UDP-
GlcNAc, UDP-N-acetylglucosamine; UGP2, UDP-glucose pyrophosphorylase 2.  
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Pentose phosphate pathway (PPP) and serine synthesis 
Glucose-6-phosphate can be diverted to the PPP, which converts glycolytic intermediates into 
ribose-5-phosphate, in this way generating reducing equivalents and intermediates important for 
the synthesis of lipids and nucleotides and for redox control. The PPP is thus crucial in sustaining 
cell survival and proliferation. The PPP has two phases: the oxidative, which is the major source 
of NAPDH  and the non-oxidative that does not produce NADPH (Fan et al. 2014; Stincone et al. 
2015). The PPP is frequently altered in the setting of cancer. For example, the first and the rate 
limiting enzyme G6PD is inhibited by wild-type p53, which can result in PPP increased flux in 
cancer, since p53 is known to be one of the most altered genes in cancer (Jiang et al. 2011). In the 
context of PDAC, there seems to be a decoupling between the oxidative and non-oxidative phases, 
and an increased glucose flux towards the non-oxidative PPP, possibly to sustain ribose 
biogenesis (Ying et al. 2012). Moreover, the expression of the PPP enzyme transaldolase is 
positively correlated with hepatocellular carcinoma progression and metastasis and it has been 
considered a biomarker since it can be detected in patients serum (Wang et al. 2011). 
The amino acid serine can be synthetized de novo using the glycolytic intermediate 3-
phosphoglycerate, via three sequential enzymatic reactions, the first of which is catalyzed by the 
NAD+-dependent enzyme 3-phosphoglycerate dehydrogenase (PHGDH). This pathway also 
produces α-KG, which is important for TCA cycle anaplerosis of glutamine-derived carbon and 
confers the ability to cells to grow in the absence of extracellular serine (Possemato et al. 2011). 
De novo serine synthesis has been shown to be altered in cancer, for example through PHGDH 
copy number gain (Mullarky et al. 2011; Possemato et al. 2011) or through activation of a 
transcriptional program dependent on the transcription factor NRF2 (nuclear factor erythroid-2–
related factor 2) (DeNicola et al. 2015). Serine is an important amino acid for the synthesis of 
purines and thymidine, since it can produce one carbon units, through the folate metabolism, 
either in the mitochondria or in the cytosol. Tumors cells can rewire the folate pathway to meet 
high proliferation demands in nutrient-replete conditions (Ducker et al. 2016). The mitochondrial 
folate-mediated NADPH production also has a role in controlling oxidative stress that may limit 
melanoma metastasis (Piskounova et al. 2015). The importance of serine and glycine for 
proliferative metabolism has been recently highlighted in a study that shows that dietary serine 
and glycine removal was sufficient to reduce tumor growth and increase survival in intestinal 
cancer (driven by Apc inactivation) or lymphoma (driven by Myc activation) (Maddocks et al. 
2017).  
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Hexosamine biosynthetic pathway (HBP) 
Fructose-6-phosphate can also be used in HBP, which comprises the series of metabolic reactions 
that produce UDP-N-acetylglucosamine (UDP-GlcNAC), which is a substrate for O-
glycosylation, N-glycosylation and O-GlcNAcylation and for the formation of 
glycosaminoglycans and proteoglycans (Pinho and Reis 2015). HBP pathway receives input from 
glucose, amino acids (namely glutamine), nucleotides and fatty acid metabolic pathways, thus it 
can be considered an efficient nutrient sensor. Nutrient depletion, namely glucose or amino acid 
depletion can induce O-GlcNAcylation through an increase in glutamine-fructose-6-phosphate 
transaminase 1, the first and the rate-limiting enzyme of the HBP (Chaveroux et al. 2016). 
The HBP was shown to be altered in cancer, as evidenced in PDAC, where oncogenic KRas 
redirects glucose metabolism toward HBP (Ying et al. 2012). Moreover, the O-linked β-N-
acetylglucosamine transferase (OGT) (glycosyltransferase that catalyzes the transfer of GlcNAc 
from UDP-GlcNAc to serine/threonine residues of target proteins) was shown to be 
overexpressed in breast cancer cells and in lung, colon and prostate cancer tissue (Caldwell et al. 
2010; Itkonen et al. 2013; Mi et al. 2011). Besides, OGT is required for breast cancer growth in 
vivo, for invasion in lung and colon cancer cells and for soft-agar growth in all three cancer types 
(Caldwell et al. 2010; Mi et al. 2011). In this setting, the HBP through OGT modulates the activity 
of oncogenic proteins like FoxM1 and c-Myc and cell cycle progression (Caldwell et al. 2010; 
Itkonen et al. 2013). In cancer cells, HBP also regulates glycolysis, in a process mediated by 
OGT, HIF and GLUT1. Indeed, the inhibition of O-GlcNAcylation by OGT knock-down leads 
to an increase in the levels of α-KG, which in turn resulted in HIF-1α degradation (Ferrer et al. 
2014).  
 
UDP-glucose metabolism 
Glucose-6-phosphate can be deviated to the production of UDP-glucose through the pathway I 
will refer to as “UDP-glucose pathway”. UDP-glucose is a key intermediate in several processes, 
namely the formation of glycogen, the production of UDP-galactose, the formation 
glycosaminoglycans and proteoglycans. UDP-glucose is produced by the enzyme UDP-glucose 
pyrophosphorylase 2 (UGP2) from glucose-1-phosphate, which in turn, derives from glucose-6-
phosphate (see Fig. 17 from Results section, chapter 3.2). UGP2 is the only human enzyme able 
to catalyze this reaction (Führing et al. 2015).  
Glycogen synthesis occurs in the cytosol, initiated by glycogenin, followed by glycogen synthase 
that elongates the glucose chain by attaching UDP-glucose units through α-1,4 glycocidic linkage. 
Several types of cancers have shown to present high glycogen content, which can be partially the 
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result of hypoxia that increases cell storages of glycogen, promoting cancer cell survival (Zois 
and Harris 2016). 
In addition to glycogen, UDP-glucose can generate UDP-glucuronate and UDP-galactose. UDP-
galactose supplies galactose moiety for the formation of lactose, glycolipids (cerebrosides), 
proteoglycans and glycoproteins, while UDP-glucuronate is the donor substrate for 
glucuronidation reactions, which are important for the deoxification of liophilic hormones and 
xenobiotics. Additionally, UDP-glucuronate participates in the synthesis of extracellular 
glycosaminoglycans (such as heparan sulfate and hyaluronan) and of proteoglycans (Kjellén and 
Lindahl 1991), both of which have important roles in carcinogenesis, for example in the 
acquisition of a migratory phenotype by breast cancer (Nikitovic et al. 2014). UDP-glucuronate 
is exclusively synthesized by UDP-glucose dehydrogenase (UGDH) (Sommer, Barycki, and 
Simpson 2004), an enzyme whose expression is stimulated by androgen and specifically drives 
excess steroid elimination through glucuronidation, in prostate tumor cell lines (Wei et al. 2009). 
Clinical and cellular consequences associated with defective UGDH function implicate stable but 
dynamic association of subunits and suggest that sustaining robust UGDH activity might yield 
useful therapeutic applications. UDP-glucuronate together with the HBP product UDP-GlcNAc, 
are the precursors of the hyaluronan (HA) molecule (Weissmann et al. 1954). HA is a large, 
negatively charged polysaccharide that participates in defining the properties of pericellular 
matrices - space filling, hydration and provision of a matrix through which cells can migrate - and 
in transducing signals in proliferating and migrating cells. HA is extruded through the plasma 
membrane onto the cell surface or into the extracellular matrix while it is being synthesized (Toole 
2004), having been extensively implicated in cancer progression (Toole, Biswas, and Gross 1979; 
Toole 2004). 
 
Mitochondria 
Mitochondria are highly dynamic organelles with a crucial role in the maintenance of cellular 
homeostasis and in regulating cell fate and function. They are considered the “powerhouses of 
the cell”, as they convert intermediate metabolites, derived from nutrients, into energy in the 
presence of oxygen - a process termed aerobic respiration. Besides, mitochondria generate 
metabolites that participate in lipid and nucleotides synthesis. Mitochondria actually house 
several metabolic pathways such as the TCA cycle, the OXPHOS pathway, fatty acid β-oxidation, 
parts of the one-carbon metabolism, amino acid metabolism, urea cycle, among others. The 
number of mitochondria present in each cell can vary from hundreds to thousands, according to 
the metabolic requirements. Each mitochondrion, in turn, has multiple molecules of its own DNA 
- the mitochondrial DNA (mtDNA) (Legros et al. 2004; Veltri, Espiritu, and Singh 1990). 
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Mitochondria are not simply static and isolated organelles, rather forming highly branched, 
dynamic and motile structures, being the entire mitochondrial population in constant flux, driven 
by continual fusion and division of mitochondria (Chan 2006).  
Mitochondria are signaling organelles, providing cues to the cytosol and initiating biological 
events under homeostatic and stress conditions (Chandel 2014). Mitochondria regulate 
programmed cell death, calcium signaling and they are also a major source of ROS, namely 
superoxide, which originate upon electron leakage from the electron transport chain (ETC). There 
are different species of ROS and, not only they damage DNA but they can also modify other 
macromolecules like proteins and lipids. ROS-mediated cell signaling can be pro-tumorigenic 
until a certain threshold (Weinberg et al. 2010), and when in excess, ROS can be highly damaging 
to macromolecules (Hamanaka and Chandel 2010).  
 
Mitochondria structure and mtDNA 
Mitochondria are bounded by two membranes, the outer and the inner mitochondrial membranes. 
The outer mitochondrial membrane is more permeable than the inner membrane and contains 
several proteins and protein-channels like VDAC. The inner mitochondrial membrane area is 
increased by a large number of infoldings or cristae that protrude into the mitochondrial matrix 
and maximize its function (Brandt et al. 2017). This membrane contains components of 
mitochondrial metabolism, such as the complexes of the ETC, the ATP synthase complex, the 
mitochondrial pyruvate carrier, components of fatty acid oxidation and transport system, and the 
uncoupling proteins. The matrix is where the mtDNA is localized and where several molecules 
such as pyruvate and fatty acids are metabolized (Lodish et al. 2013). 
The mammalian mtDNA is a maternally inherited circular double-stranded molecule, which has 
approximately 16,600 base pairs in humans (Falkenberg, Larsson, and Gustafsson 2007). The 
mtDNA was the first human genome to be sequenced (Anderson et al. 1981) and it encodes 13 
peptide-producing proteins, 2 ribosomal RNA and 22 transfer RNA (tRNA) required for their 
translation (Taanman 1999) (Fig 4). There are several nuclear gene products that play a role in 
the assembly of the OXPHOS, in the replication of the mtDNA and in the transcription and 
translation of the mtDNA encoded genes (Kelly and Scarpulla 2004; Scarpulla 2006). Because of 
its limited repair ability, lack of protective histones proteins and high rate of ROS generation in 
mitochondria, mtDNA is more susceptible to oxidative damage and has a higher mutation rate 
compared with nuclear DNA (Lee and Wei 2009). Moreover, considering the fact that mtDNA 
lacks sizeable introns, mtDNA mutations have a high probability of changing the amino acid 
composition of the encoded proteins. Thus, many of the mtDNA mutations are likely to have 
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physiological consequences and might confer a cellular advantage or disadvantage in growth or 
survival. 
 
 
Fig. 4: Human mtDNA. It contains 13 peptide-producing proteins, 2 rRNA (names in blue) and 
22 tRNAs (represented by blue rectangles). D-loop is a non-coding region. rRNA, ribosomal 
RNA; tTNA, transfer RNA COX, cytochrome c oxidase; CYTB, cytochrome b; ND, NADH 
dehydrogenase. 
 
Mitochondrial metabolism 
Among the several metabolic reactions taking place in the mitochondria, the TCA cycle and the 
OXPHOS will be described in more detail, since they are object of study of this thesis. 
In the TCA cycle (also called the Krebs cycle), carbon fuels like carbohydrates, fatty acids and 
amino acids are oxidized, most of them entering the cycle as acetyl-coenzyme A (acetyl-CoA). 
The TCA cycle can also produce precursors for the generation of lipids, proteins modifications 
or signaling molecules. Furthermore, some reactions can replenish components of the TCA cycle, 
a process known as anaplerosis. In the OXPHOS, high energy electrons are donated to the ETC 
to generate a proton gradient across the membrane that culminates in the generation of ATP and 
concomitant transfer of electrons to oxygen.  
 
TCA cycle and OXPHOS 
Pyruvate is the end product of glycolysis and occupies a key node in the regulation of carbon 
metabolism, since it is at the intersection of several catabolic and anabolic pathways. Pyruvate 
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can be utilized for mitochondrial acetyl-CoA generation, which is then subjected to oxidation in 
the TCA cycle.  
Import of pyruvate across the inner mitochondrial membrane requires the mitochondrial pyruvate 
carrier (Bricker et al. 2012; Herzig et al. 2012), after which it is oxidized to acetyl-CoA by the 
PDH complex. Acetyl-CoA is subsequently converted to citrate via condensation with 
oxaloacetate (OAA) by citrate synthase. In turn, citrate is converted, by aconitase, to isocitrate, 
which in turns generates α-KG through IDH. This enzyme is one of the main points of regulation 
of the TCA activity and during this reaction NAD+ or NADP+ is reduced to NADH or NADPH, 
respectively. α-KG dehydrogenase generates succinyl-CoA from the oxidation of α-KG, reducing 
NAD+ to NADH. The reaction of succinyl CoA synthetase, the formation of succinate from 
succinyl CoA, is linked to a substrate-level phosphorylation of GDP to GTP, which is 
energetically equivalent to the formation of ATP. The next reaction is catalyzed by SDH, which 
is an enzyme that not only belongs to the TCA cycle but also in inserted in the ETC, constituting 
complex II. In the TCA cycle, it catalyzes the oxidation of succinate to fumarate, concomitant 
with the reduction of FAD to FADH2. Then, water is added to fumarate, converting it to malate. 
In the last step of the TCA cycle, OAA is regenerated by oxidation of malate. Another molecule 
of NAD+ or NADP+ is reduced to NADH or NADPH in the process (Fig. 5). 
In some conditions, the uptake of pyruvate by the mitochondria can be bypassed by several 
alternative pathways that feed the TCA cycle and the OXPHOS-mediated generation of ATP. 
These include the malic enzyme, the pyruvate-alanine cycle, glutamine or fatty acids (Bender and 
Martinou 2016). 
Electrons obtained from the oxidative reactions of the TCA cycle are shuttled through 
NAD+/NADH and FAD/FADH2 to the ETC, creating an electrochemical gradient that fuels ATP 
production. 
The multimeric protein complexes that constitute the ETC carry out redox reactions, where 
electrons are transferred from the reductive equivalents (NADH and FADH2) to the electron final 
acceptor (oxygen), in a process named oxidative phosphorylation (OXPHOS) (Hatefi 1985). The 
ETC is composed of 77 nuclear encoded and 13 mtDNA encoded subunits that assemble and 
function as a large complex. These subunits are organized into four complexes: complex I or 
NADH:ubiquinone oxiredutase, complex II or SDH, complex III or ubiquinol-cytochrome c 
oxiredutase and complex IV or cytochrome c oxidase (COX). These complexes are formed by 
flavoproteins, ubiquinone (or coenzyme Q), cytochromes, iron-sulfur proteins and cupric protein, 
being cytochrome c and ubiquinone two mobile components.  
Complexes I and II accept electrons from NADH from FADH2, respectively, and both complexes 
transfer them to the ubiquinone pool. This molecule is thus reduced, being named ubiquinol. 
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Ubiquinol, a motile and hydrophobic molecule donates the electrons to complex III. Electrons 
then move to cytochrome c and are transferred to complex IV, where they reduce molecular 
oxygen to water. As the electrons flow in the ETC, the released energy is used by complexes I, 
III and IV to pump protons across the inner mitochondrial membrane to the intermembrane space. 
The ETC generates, therefore, a proton concentration gradient and an electric potential (voltage 
gradient), collectively called proton-motive force. This chemiosmotic coupling is responsible for 
driving the energy-requiring process, ATP synthesis. ATP synthase complex (sometimes referred 
to as complex V) is a member of ATP-powered proton pumps. Protons flow back to the matrix 
through ATP synthase promoting ATP synthesis by the enzyme (Fig 5). Matrix ATP is then 
exchanged for cytosolic ADP by the inner membrane ADP/ATP translocase (Lodish et al. 2013).  
 
 
Fig. 5: TCA cycle and ETC (simplified versions). The mtDNA-encoded proteins that constitute 
the complexes are depicted. NADH dehydrogenase, ND; COX, cytochrome c oxidase; O2, 
oxygen; H2O, water; CytC, cytochrome c; H+, protons. 
 
The OXPHOS produces up to 38 molecules of ATP as energy currency, while glycolysis yields 
2 ATP per molecule of glucose, being, therefore, OXPHOS considered much more efficient. 
Owing its central role in metabolism, defects in the mitochondrial respiratory chain underlie a 
spectrum of human conditions, mostly related with degenerative disease and affecting primarily 
high energy-demanding tissues such as skeletal muscle, cardiac muscle and brain. Besides 
degenerative conditions, one must ask:  
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What about mitochondrial metabolism in cancer? 
Warburg speculated that the aerobic glycolysis phenotype of cancer cells was triggered by a 
OXPHOS-impairing mitochondrial defect (Warburg 1956); however, Warburg himself failed to 
demonstrate defective respiration as a general feature of malignant cells (Koppenol, Bounds, and 
Dang 2011). In fact, many studies have analyzed mitochondrial function of cancer cells and 
showed that mitochondrial defects do not account for the phenomenon in general (Crabtree 1929). 
Indeed, respiration and other mitochondrial activities are often required for tumor growth. For 
example, intermediates from the TCA cycle are essential to complement other metabolites from 
glycolysis, supporting diverse pathways required for proliferation (Ahn and Metallo 2015). 
Proliferating cancer cells appear to reprogram their metabolism towards favoring glycolysis in a 
regulated way, instead of an adaptation to a OXPHOS dysfunction, and the majority of cancers 
are able to revert back to OXPHOS when lactic acid generation is inhibited (Fantin, St-Pierre, 
and Leder 2006). A study using a tetracycline-inducible KRas-driven PDAC mouse model 
showed that, upon oncogene ablation, the surviving cells, responsible for tumor relapse and with 
cancer stem cell features, have more active mitochondria, a strong reliance on mitochondrial 
respiration and impaired glycolysis (Viale et al. 2014). Birsoy et al. used a continuous-flow 
culture system to expose several cell lines to low glucose media and showed that OXPHOS is the 
key metabolic process required for optimal proliferation of cancer cells under glucose limitation. 
The low-glucose sensitivity was associated with deficiencies in glucose utilization or mtDNA 
mutations in complex I genes (Birsoy et al. 2014). Besides, cancers are heterogenous and dynamic 
entities, where different  types of metabolism coexist (Hensley et al. 2016; Viale et al. 2014).  
Nevertheless, certain malignancies indeed harbor mitochondrial defects that make aerobic 
glycolysis a crucial adaptation. Mitochondrial dysfunction can be due to genetic alterations, either 
in mtDNA or in nuclear DNA encoded mitochondrial proteins, or to biochemical defects of 
mitochondria caused by deregulated pathways and oncogenic activation or inactivation of tumor 
suppressor genes. The presence of mtDNA mutations has been recognized in a wide variety of  
human cancers (Copeland et al. 2002; Fliss et al. 2000; He et al. 2010; Petros et al. 2005). An 
interesting study stressed the role of mtDNA mutations in tumor progression. By exchanging the 
mtDNA of two mouse cell lines with different metastatic potentials, the capability to metastasize 
in vivo accompanied the mtDNA (Ishikawa et al. 2008). It was also demonstrated that the 
metastatic cell lines harbored a defective mitochondrial complex I, caused by a mtDNA mutation. 
Such mtDNA mutation triggered ROS overproduction which, in turn, upregulate nuclear genes 
such as HIF-1α and VEGF, involved in neoangiogenesis and, consequently, regulate tumor cell 
metastasis (Ishikawa et al. 2008).  
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The analysis of mtDNA mutations and their relevance for tumorigenesis is usually performed 
using cybrid cell lines. Cybrids are cytoplasmatic trans-mitochondrial hybrids, which are created 
by repopulating a cell line depleted of mtDNA, termed ρ0 (rho 0), with exogenous human 
mitochondria, as it was first demonstrated by King and Attardi (King and Attardi 1989). Since 
then, the use of cybrid technology has been growing exponentially. Indeed, ρ0 cells can be fused 
with an enucleated cell line or even platelets that carry the desirable mtDNA mutations. 
Importantly, this technology allows the differentiation of the effects caused by mtDNA mutations 
from those caused by nuclear DNA, since the cybrids cell lines have the same nuclear background 
(Swerdlow 2007).  
Mitochondrial defects can also arise from genetic alterations in the genes that encode TCA cycle 
proteins. These will be described below in the next section. 
Mitochondrial metabolism is also important to feed other anabolic pathways. For example, 
aspartate (that can be produced from the TCA intermediate OAA) has been shown to be one of 
the key players in cancer cell proliferation and dependent on the presence of an electron acceptor 
by two back-to-back studies (Birsoy et al. 2015; Sullivan et al. 2015). Indeed, respiration has an 
important role in sustaining cancer cell proliferation because it produces electron acceptors for 
aspartate synthesis (Birsoy et al. 2015; Sullivan et al. 2015). Upon OXPHOS inhibition, cells 
become dependent on the production of aspartate from OAA through the aspartate transaminase 
GOT1 in the cytosol (Birsoy et al. 2015). In PDAC, oncogenic KRas redirects glutamine 
metabolism towards the production of aspartate, which is further metabolized in the cytosol into 
OAA by GOT1, and finally generating malate and pyruvate, in order to maintain a high 
NADPH/NADP+ ratio and the cellular redox state (Son et al. 2013).  
 
Metabolic enzymes as tumor suppressors or oncogenes 
The first example of causality between mitochondrial dysfunction and tumorigenesis was the 
observation that the genes encoding for SDH and FH predispose to hereditary neoplasias (Gottlieb 
and Tomlinson 2005). In fact, the identification of mutations in genes that encode mitochondrial 
metabolic enzymes was key to reinforce the role of metabolism in tumorigenesis.  
SDH, or complex II of the respiratory chain, is an heterotetrameric enzyme and the only ETC 
complex whose subunits are all encoded by the nuclear DNA. This complex, which establishes a 
direct link between the TCA cycle and the OXPHOS, in mammals is classically formed by four 
structural subunits - SDHA, SDHB, SDHC, SDHD and several prosthetic groups – and assembled 
by several proteins such as SDHAF1 and SDHAF2 (Rutter, Winge, and Schiffman 2010). SDHA 
is the catalytic unit responsible for oxidation of succinate to fumarate, collecting the resulting 
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electrons and reducing FAD. Then the electrons are transferred to the iron-sulphur centers in 
SDHB (iron-sulphur protein). Finally, the electrons are moved to the cytochrome b and 
ubiquinone-associated components SDHC and SDHD, which anchor this complex to the 
mitochondrial inner membrane.  
Germline mutation in the genes encoding SDH subunits are predominantly linked to the 
development of inherited phaeochromocytoma and/or paraganglioma. Loss of function mutations 
have been characterized in SDHA, SDHB, SDHC and SDHD genes, as well as in the assembly 
factor SDHAF2 (Astuti, Douglas, et al. 2001; Astuti, Latif, et al. 2001; Baysal et al. 2000; 
Burnichon et al. 2010; Gimm et al. 2000; Hao et al. 2009; Niemann and Müller 2000). 
Paragangliomas and phaeochromocytomas are rare tumors that arise in the autonomous nervous 
system, specifically from extra-adrenal thoracic and abdominal paraganglia and from the 
sympathetic lineage-derived cells from the adrenal medulla. The distinction between 
paraganglioma and phaeochromocytoma is based on their site of origin: phaeochromocytomas 
develop in the medulla of the adrenal gland, while the term paragangliomas is used for tumors 
that arise in extra-adrenal paraganglia, occurring in the abdominal region or in the head and neck 
region, a distinction that also reflects differences in tumor behavior (Dahia 2014). 
We identified a founder SDHB mutation in Portuguese paraganglioma and pheochromocytoma 
patients (Martins and Nunes et al. 2013 - manuscript in annex I). Our patient cohort of these 
neuroendocrine neoplasias showed a high prevalence of germline SDH mutations (20 out of 37 
patients; 54.1%), a finding that is most likely due to the prevalence of a single deletion in SDHB 
that encompasses the promotor region plus exon 1. This deletion accounted for 55% of all patients 
with SDH mutations. The observation that the deleted allele shows the same haplotype in all 
patients suggested a founder effect for this particular deletion, being the first SDHB founder 
mutation described in the Portuguese population (Martins and Nunes et al. 2013 - manuscript in 
annex I). 
In addition to mutations in hereditary neoplasias, SDH is also found downregulated in sporadic 
cancer such as HCC, where it is associated with advanced tumor stage and poor survival (Tseng 
et al. 2018). Decreased SDHB in HCC cells also leads to bioenergetic and an increase in glycolytic 
enzymes (Tseng et al. 2018). 
The enzymatic reaction subsequent to SDH is catalyzed by FH that converts fumarate into malate. 
Germline heterozygous mutations in FH were found to cause hereditary leiomyomatosis and renal 
cell cancer syndrome, a hereditary cancer syndrome characterized by the presence of benign 
tumors of the skin and uterus, and a highly malignant form of renal cell cancer (The Multiple 
Leiomyoma Consortium 2002). 
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The mechanism of tumorigenesis in these cancer syndromes is still matter of debate. It has been 
suggested that loss-of-function mutations lead to an accumulation of succinate and fumarate, 
inhibit prolyl hydroxylases and consequently result in HIF-1α stabilization and HIF-1 activation 
(Isaacs et al. 2005; Pollard et al. 2005; Selak et al. 2005). A ROS-dependent mechanism for HIF-
1α stabilization has also been proposed for SHDB mutations (Guzy et al. 2008). In the case of FH 
mutations, fumarate accumulation can dysregulate the metabolism of cells. For example, it has 
been shown that fumarate can cause the succination of proteins - a non-enzymatic covalent 
modification of reactive cysteine residues - like aconitase 2 or iron-sulfur cluster biogenesis 
family of proteins, impairing their enzymatic activity, which results in altered of TCA cycle 
function, complex II inhibition and decreased respiration (Frezza et al. 2011; Ternette et al. 2013; 
Tyrakis et al. 2017). Interestingly, it has been shown that concomitant loss of complex I activity 
is necessary for the metabolic phenotype of SDH mutant tumors (Lorendeau et al. 2017). 
Additionally, both SDH and FH loss have been associated with epithelial to mesenchymal 
transition (EMT), which confers migratory and invasive properties to cancer cells, which is 
described in more detail in the discussion of this thesis (Aspuria et al. 2014; Sciacovelli et al. 
2016; Tseng et al. 2018; Wang, Chen, and Wu 2016). 
Another striking example that links mitochondrial dysfunction with tumorigenesis was the 
groundbreaking discovery of IDH mutations, first in brain tumors, and then in other cancer types 
(Balss et al. 2008; Borger et al. 2012; Kosmider et al. 2010; Mardis et al. 2009; Watanabe et al. 
2009; Yan et al. 2009). Mutations in IDH1 and IDH2, which encode the (predominantly) cytosolic 
and mitochondrial forms of NADP+-dependent IDH, respectively, were shown to be very frequent 
events in malignant gliomas, in particular astrocytomas and oligodendrogliomas (Yan et al. 2009). 
Interestingly, these IDH1 and IDH2 mutations give rise to neomorphic enzymes that produce D-
2-HG instead of α-KG (Dang et al. 2009). This oncometabolite can function as a competitive 
inhibitor of α-KG-dependent dioxygenases, including histone demethylases and the 5-
methylcytosine dioxygenases TET (ten-eleven translocation) enzymes (Figueroa et al. 2010; Xu 
et al. 2011), having an important impact on DNA epigenetic and protein posttranslational 
modifications. 2-HG is a chiral molecule and has an L- enantiomer produced by LDHA or malate 
dehydrogenase, which besides being a potent inhibitor of α-KG-dependent enzymes, also leads 
to the stabilization of HIF (Intlekofer et al. 2017; Xu et al. 2011). L-2-HG is associated with brain 
and renal cancers (Haliloglu et al. 2008; Shim et al. 2014). 
The role of succinate, fumarate or 2-HG as oncometabolites illustrates how metabolic enzymes 
can promote transformation through non-metabolic effects.  
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Glutamine 
Glutamine metabolism in cancer cells has been the subject of a lot of research in the last years. 
Glutamine metabolism provides both anaplerotic and NADPH demands of growth, allowing cells 
to use glucose carbon to build nucleic acids and lipids, while contributing for protein synthesis.  
Glutamine metabolism can be used to support the nitrogen demand imposed by nucleotide 
synthesis, or for the maintenance of nonessential amino acid pools and nitrogenous biomolecules 
(Meng et al. 2010; Zetterberg and Engström 1981). Glutamine can be converted directly into 
glutamate by GLS, which in turn can produce α-KG by several enzymes such as glutamate 
dehydrogenase (GDH) or transaminases. Mammary proliferating cells shift from a nitrogen-
wasting mode, where α-KG is preferentially produced from glutamate by GDH, to a mode where 
this reaction is catalyzed by transaminases in a nitrogen-sparing mode, in order to synthesize 
nonessential amino acid (Coloff et al. 2016).  
Tumor cells consume large amounts of glutamine, which can provide both carbon and nitrogen 
(Sauer, Stayman, and Dauchy 1982). For instance, glioblastoma cells show a high rate of 
glutamine metabolism that is used, not only for protein and nucleotide biosynthesis, but also to 
produce NADPH to fuel lipid synthesis (and nucleotide biosynthesis) (DeBerardinis et al. 2007). 
Pancreatic tumors harboring an oncogenic KRas are dependent on glutamine metabolism and 
specifically on the cytosolic conversion of glutamine-derived aspartate into OAA, malate and 
then pyruvate. This is important to increase the NADPH/NADP+ ratio and maintain the redox 
control (Son et al. 2013). However, the use of GLS inhibitors has shown no antitumor properties 
in an in vivo model of PDAC, indicating that cancer cells can rewire their metabolism in order to 
utilize the available nutrients to sustain proliferation (Biancur et al. 2017). Moreover, glutamate 
is highly secreted by triple-negative breast cancer cells and promotes HIF-1α stabilization in a 
paracrine way. This happens because extracellular glutamate inhibits cystine uptake through the 
xCT glutamate-cystine antiporter, causing intracellular cysteine depletion which directly inhibits 
the HIF-α prolyl-hydrolase, EglN1 (Briggs et al. 2016). Glutamate is also a precursor of 
glutathione, a major cellular antioxidant (Welbourne 1979). Glutathione is one of several 
glutamine metabolism products that directly control ROS levels. Glutathione levels play an 
important role in tumorigenesis and drug resistance (Godwin et al. 1992).  
The high glutamine consumption in vitro may, however, be a consequence of the culture media 
conditions. NSCLC do not seem to rely on glutamine for growth since GLS inhibitors are not 
very effective in slowing tumor growth; furthermore, when nutrient tracing was performed in 
vivo, glucose, rather than glutamine, contributes more for the formation of TCA cycle 
intermediates in NSCLC tumors (Davidson et al. 2016). The same resistance to GLS inhibitors 
has also been described in a mouse model of PDAC (Biancur et al. 2017). In fact, when NSCLC 
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cells were cultured in adult bovine serum, whose composition is more similar to human plasma 
than the standard media, they consumed less glutamine and responded to GLS inhibitors in a 
similarly way to how on-site tumors. After deconvoluting the differences in the cell culture 
conditions, cystine seems to account for the differential glutamine anaplerosis and dependence of 
these different environments (Muir et al. 2017).  
Research on glutamine highlighted the fact that nutrients other than glucose play an important 
role in cancer cells and prompted interest in other metabolites like serine and glycine, branched 
chain amino acids, lactate, acetate and other fatty acids as cancer fuels. 
 
Metabolism of tumors: much more than cancer cells 
Cancer cell metabolism can be modulated by the microenvironment, namely through the 
availability of nutrients and the presence of other cell types. Tumors, like an organ, are complex 
ecosystems, being composed of much more than solely cancer cells. They integrate several 
different cell types such as immune cells, endothelial cells, fibroblasts, normal epithelial cells, 
among others (Egeblad, Nakasone, and Werb 2010). Cells that constitute the tumor stroma 
compete with tumor cells for nutrients, oxygen and space, while secreting growth factors, 
cytokines, ECM components and metabolites, in this way promoting tumor heterogeneity and 
shaping the metabolic requirements of cancer cells.  
A metabolic symbiosis between the stroma and cancer cells has in fact been described.  It has 
been proposed that stromal cells exhibit aerobic glycolysis and promote tumor growth by the 
secretion of energy-rich metabolites, such as pyruvate and lactate, which are used by tumor cells. 
This phenomenon has been named “the reverse Warburg effect” (Pavlides et al. 2009).  
The metabolism of cancer cells can also regulate a phenomenon called “epithelial defence against 
cancer” (EDAC) that characterizes the initial stages of carcinogenesis and refers to the 
competition between normal cells and the transformed epithelial cells for survival and space, 
which results in the non-immune elimination of cancer cells from epithelial tissues. Ras-
transformed cells, where EDAC has been shown, present increased glycolysis and reduced 
mitochondrial function, characterized by PDK4 upregulation, a metabolism that is potentiated by 
the neighboring normal epithelial cells and it is determinant for their elimination by apical 
extrusion (Kon et al. 2017).   
The metabolism of tumor cells can also alter stromal cells’ function. For example, lactate 
produced by cancer cells can modulate the immune response, since it enhances the production of 
proinflammatory cytokines by monocytes and macrophages stimulated with Toll-like receptor 
ligands (Shime et al. 2008). Besides, the microenvironment acidification, resulting from the lactic 
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acid secreted by tumor cells, leads to an upregulation of arginase 1 in tumor-associated 
macrophages, which is characteristic of the M2 phenotype (Ohashi et al. 2013). The metabolism 
of cancer cells can also contribute for immune escape. Indeed, tumor extracellular acidity is 
associated with an impaired effector function of CD8+ tumor specific T lymphocytes in human 
and mouse (Calcinotto et al. 2012). Moreover, glucose consumption by tumors metabolically 
restricts CD8+ T cells, leading to their dampened mTOR activity, glycolytic capacity, and 
interferon-γ production, thereby allowing tumor progression (Chang et al. 2015). 
Phosphoenolpyruvate, a glycolytic intermediate, is important for CD4+ T cells anti-tumor activity, 
because it sustains calcium-NFAT signaling and T cell activation by repressing sarco/ER Ca2+-
ATPase-mediated calcium re-uptake to the endoplasmic reticulum (Ho et al. 2015).  
Not only immune cells, but also fibroblasts are affected by lactate. It has been shown increased 
levels of lactate stimulate hyaluronic acid production by fibroblasts, which may contribute for 
increased tumor cell invasiveness (Stern et al. 2002). Lactate promotes angiogenesis by 
stabilizing NDRG3 protein, which binds c-Raf to mediate hypoxia-induced activation of Raf-
ERK pathway in tumor cells (Lee et al. 2015). Besides, lactate-induced signaling in endothelial 
cells may stabilize HIF-1α and activate an autocrine NFB/interleukine-8 pathway (Sonveaux et 
al. 2012; Végran et al. 2011).  
 
Summing up, since the first experiments made by Otto Warburg, research on tumor metabolism 
has experienced a huge rise, to the point of being considered a hot-topic in cancer research. In 
accordance with the fact that cellular metabolism is dynamically modulated and adjusted in 
response to various conditions, tumors show metabolic adaptations that result from a combination 
of the tissue of origin, the genetic alterations they acquire and their surroundings. Although we 
know better how genetic alterations and stromal cells can tailor cellular metabolism, exposing 
metabolic vulnerabilities, much less is known about the influence of the cell lineage.  
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1.2 - CELL MIGRATION 
 
1.2.1 - How do cells migrate? 
Cells can adopt different strategies to migrate, engaging on various signaling programs, 
depending on the ECM nature. Tumor cells, for example, can present several types of cell 
movement, from individual to collective and from amoeboid to mesenchymal migration (Friedl 
and Alexander 2011). Migration and invasion (the latter also referred to as invasive or 
mesenchymal migration) are two denominations commonly used to distinguish the coordinated 
cell adhesion and contractility of cells from the movement that also involves proteolytic 
remodeling of the ECM. Amoeboid movement, which is less dependent on proteases, is 
characterized by the loss of cell polarity, detachment from the ECM - leading to a rounded 
morphology - and movement through the path of least resistance and has been reported in vivo in 
leukocytes and also in tumors (especially liquid tumors) (Friedl and Wolf 2003). On the other 
hand, migration that implies matrix-degrading enzymes is particularly relevant in the context of 
cancer metastasis. 
Invasive migration of single cells is intimately related with cell adhesion and cell polarity and 
implies a change in cells’ shape and stiffness, in order to interact with the surrounding tissue 
structures. This process encompasses the formation a leading edge protrusion mediated by the 
polymerization of actin; adhesion to ECM which is generally mediated by integrins; contact-
dependent ECM cleavage by physical force or proteases; cytoskeleton contraction (mediated by 
actomyosin) of the cell body increasing longitudinal tension; and finally, trailing edge detachment 
and retraction, with final translocation of the cell body (Friedl and Wolf 2003) (Fig 6). 
 
 
Fig. 6: Invasive migration mechanism by the formation of pseudopod protrusions. ECM, 
extracellular matrix. 
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Mechanistically, invasive migration requires the interaction with the ECM through integrins (in 
most situations) that become locally enriched, cluster and stabilize forming a focal contact. 
Besides, invasive migration entails a dynamic cascade of cytoskeleton rearrangements 
coordinated by Rho family GTPases. These key effectors of migration will be now described in 
more detail.   
 
1.2.2 - Key effectors in migration 
Integrins 
Integrins are key elements for invasive migration, as they generate the adhesive interaction and 
traction toward the ECM substrate (Palecek et al. 1997). The importance of integrin-β1 for cell 
migration and for in vitro invasiveness was first highlighted in studies using anti-integrin 
antibodies, where it was shown that they can block cell migration and invasion (Yamada et al. 
1990). In breast cancer cells, integrin-β1 was shown to be required for 3D matrigel invasion and 
for the contraction of the rear pole of the invading cell (Poincloux et al. 2011). Integrins are 
transmembrane proteins that bind extracellularly to the ECM components, such as fibronectin, 
laminin, vitronectin, collagen and various other adhesive glycoproteins (Humphries, Byron, and 
Humphries 2006). They form heterodimers composed of α and β chains, and the existence of 
several of α and β subunits generates numerous combinations with different properties 
(Humphries, Byron, and Humphries 2006). For example, integrin-β1 dimerizes with several α 
subunits, including integrin-α5 and, in that case, mediates fibronectin-dependent migration, 
constituting a prototypic integrin-ligand pair (Takagi et al. 2003). Upon binding to the ECM, 
integrin dimers form clusters in the cell membrane and, through their intracellular domains bind 
several cytoskeletal-associated and adaptor proteins, including talin, paxillin, kindlin, vinculin 
and BCAR1 (breast cancer anti-estrogen resistance 1; also called p130Cas) that ultimately control 
cytoskeletal organization and intracellular signaling (Geiger, Spatz, and Bershadsky 2009). 
Integrins can sometimes be classified according to the structural basis of the molecular interaction 
between them and the ligand partner. For example, several members of the integrin family, such 
as integrins β1α5 and β1α8, recognize an adhesive epitope composed by the three peptides 
arginine-glycine-aspartic acid (RGD) in ECM molecules (Humphries, Byron, and Humphries 
2006). Furthermore, integrins are highly regulated molecules. Integrins are glycoproteins and it 
has been shown that in the case of integrin-β1, N-glycosylation is determinant for its function 
(Isaji et al. 2009). Finally, integrins not only regulate intracellular signaling pathways that control 
cytoskeletal organization, force generation but also cell proliferation and survival  (Lane et al. 
2010; Moreno-Layseca and Streuli 2014; Sethi et al. 1999). 
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As previously mentioned, integrins transduce signals from the extracellular environment, through 
the association of their intracellular domain with adaptor proteins that connect the integrin to the 
cytoskeleton, cytoplasmic kinases, and transmembrane growth factor receptors. The dynamic 
intracellular structures formed by the links between integrins and the actin cytoskeleton, which 
transmit and respond to mechanical forces, are denominated focal adhesions (Bershadsky, 
Balaban, and Geiger 2003). Focal adhesion kinase (FAK) and Src are two protein kinases 
commonly activated by integrin signaling and regulate migration by phosphorylation events. FAK 
can have a kinase dependent or kinase independent function. The kinase dependent functions of 
FAK have a major role in migration, particularly the autophosphorylation site on tyrosine (Y) 
397, which occurs after clustering, was shown to be specifically relevant to increase migration 
(Cary, Chang, and Guan 1996; Ritt, Guan, and Sivaramakrishnan 2013; Toutant et al. 2002). 
Clustering in the lipid biolayer and consequent activation of FAK was shown to be induced by 
phosphatidylinositol 4,5-bisphosphate, which promotes efficient autophosphorylation of Y397 
and likely enhances integrin clustering as well as the scaffolding function of FAK (Goñi et al. 
2014). Besides, growth factor receptor signaling such as platelet-derived growth factor (PDGF) 
receptor, epidermal growth factor (EGF) receptor, hepatocyte growth factor (HGF)/Met and RET 
kinase can also trigger FAK activation (Chen and Chen 2006; Plaza-Menacho et al. 2011; Sieg et 
al. 2000). The phosphorylation of residue Y397 of FAK creates a docking site for proteins with 
Src homology 2 domains, including Src family kinases and PI3K (Cary, Chang, and Guan 1996; 
Chen et al. 1996; Cobb et al. 1994). After binding to FAK, Src phosphorylates several tyrosines, 
such as the ones located in the activation loop (Y576 and Y577) which confer full catalytic 
activity (Calalb, Polte, and Hanks 1995). The activity of Src is indeed required for integrin-
regulated spreading and migration (Cary et al. 2002). The activated FAK/Src complex has been 
implicated in the tyrosine phosphorylation of several focal adhesion proteins, such as paxillin 
(Schaller and Parsons 1995) and p130Cas (Tachibana et al. 1997).   
 
Rho GTPases 
Downstream effectors of integrins and FAK include the small Rho family GTPases, which 
reinforce cell protrusion and rear contraction. This family of small signaling G proteins, which 
also regulates cell adhesion and polarity, includes several subfamilies being RhoA, Rac-1 and 
Cdc42 the most studied members. Rho, via the Rho kinase promotes the formation of cytoplasmic 
stress fibers, stabilization of focal contacts into mature focal adhesions and cell body contraction 
through activation of the actomyosin cytoskeleton (Amano et al. 1997; Kimura et al. 1996), being 
associated with rounded/amoeboid form of movement (Sahai and Marshall 2003). On the other 
hand, Rac1 is regulated by DOCK3 (dedicator of cytokinesis 3), in association with the adaptor 
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molecule NEDD9 (neural precursor cell expressed, developmentally down-regulated 9) and, 
together with WASF2 (WAS protein family member 2), drives mesenchymal movement and 
suppress amoeboid movement (Sanz-Moreno et al. 2008). Rac-1 and Cdc42 are considered the 
main regulators of membrane protrusions into lamellipodia and filipodia (Aspenström 1999), 
although this may be context-dependent (Borm et al. 2005). Rho GTPases can be activated in 
response to growth factors and respective receptors (Nobes et al. 1995; Ridley and Hall 1992). 
 
Matrix metalloproteinases (MMPs) 
One of the key steps in invasive migration is the ECM degradation that modifies the molecular 
and mechanical tissue properties, allowing space for the advancing cells or groups of cells (Friedl 
et al. 1997; Wolf et al. 2007). For this to happen, cell surface proteases become engaged with 
extracellular scaffold proteins that compose the ECM and execute locally controlled proteolysis 
(Friedl and Wolf 2003). The proteolysis is catalyzed by several proteases such as matrix 
metalloproteinases (MMPs), serine and cysteine proteases and ADAMs (a disintegrin and 
metalloproteases). MMPs are zinc-dependent endopeptidases. They are synthetized as inactive 
zymogens, activated by proteinase cleavage and can either be secreted or stay covalently linked 
to the cell membrane. MMPs cleave not only ECM structural proteins, but also other proteinases, 
growth-factor-binding proteins, growth-factors, receptor tyrosine kinases, as well as cell-adhesion 
molecules, such as E-cadherin, integrins or CD44. Their activity can be regulated by endogenous 
inhibitors such as α2-macroglobulin or thrombospondin-2 (Egeblad and Werb 2002). Therefore, 
MMPs also promote invasion by activating signaling pathways involved in invasion. Moreover, 
ECM degradation generates biologically active epitopes of ECM components with adhesion- or 
migration-promoting effects (Giannelli et al. 1997; Kenny et al. 2008). Together, the degradation 
of the ECM creates a pro-invasive microenvironment, that is particularly relevant for cancer cell 
invasion.  
 
1.2.3 - Cancer metastasis 
As previously mentioned, there are several types of cell movements implicated in cancer invasion 
and metastasis. Metastasis in epithelial tumors is a complex and multistep process (Fig. 1) that is 
not fully understood. However, cell migration is widely recognized to be an important prerequisite 
for cells to be able leave the primary tumor and colonize secondary tumor sites (Sträuli and Weiss 
1977). One of the cellular programs that enables cells to acquire migratory features is EMT and 
it will be discussed in chapter 1.3. 
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The molecules that mediate migration are commonly dysregulated during cancer. MMPs are 
overexpressed in many human cancers, having been considered hallmarks of cancer due to their 
“path-clearing” role and their signaling properties (Egeblad and Werb 2002). For example, several 
MMPs are overexpressed in breast malignant tumors as compared with normal tissue (Garbett, 
Reed, and Brown 1999) and some of them are actually expressed by components of the tumor 
microenvironment (Iwata et al. 1996). It has also been shown in several tissue types that MMPs 
promote carcinogenesis (Egeblad and Werb 2002). The deficiency of MMP-9 in a transgenic 
mouse model of skin cancer results in reduced keratinocyte hyperproliferation at all neoplastic 
stages and a decreased incidence of invasive tumors. Interestingly, the tumors that arise in the 
absence of MMP-9 are of a more advanced stage than those that arise in wild-type mice. 
Moreover, the restoration of MMP-9 expression by bone-marrow transplantation of MMP-9-
expressing cells leads to a restoration of skin carcinogenesis (Coussens et al. 2000).  
Not only MMPs but many of the previously described migration effectors are commonly altered 
in cancer and play an important role in carcinogenesis. Cancer progression is frequently 
characterized by changes in the composition and organization of ECM. Fibronectin, for example, 
promotes epithelial cell growth during mammary gland tumorigenesis (Williams et al. 2008) and, 
in ovarian cancer, it is secreted by mesothelial cells mediating cancer cell invasion (Kenny et al. 
2014). The molecules that transduce the signals conveyed by cell adhesion to the ECM also 
influence tumorigenesis and progression. Integrin-αvβ3 is more expressed in angiogenic blood 
vessels compared to quiescent preexisting blood vessels and it is required for their infiltration into 
the tumor mass (Brooks, Clark, and Cheresh 1994). The same integrin was also shown to be 
required for prostate cancer bone metastasis by promoting the adhesion and migration of cancer 
cells to the bone microenvironment and subsequent tumor growth (McCabe et al. 2007). Integrin-
α5β1 mediates breast cancer cell migration and invasion induced by angiopoietin-2 and the 
downstream signaling cascade involving Akt, glycogen synthase kinase (GSK)-3β, Snail, and E-
cadherin (Imanishi et al. 2007). During the process of metastasis formation in the lungs, integrin-
β1 and FAK play an important role in adhesion-related signaling events and proliferation after 
extravasation. The expression of integrin-β1 induces the activation of FAK that regulates the 
proliferation of cancer cells scattered within the ECM (Shibue and Weinberg 2009). Preclinical 
and clinical trials of small molecule FAK inhibitors that affect both tumor cell and stroma, have 
demonstrated that FAK can be an effective cancer target in various cancers (Yoon and Dehart et 
al. 2015). Interestingly, FAK seems to have a role in modulating cellular metabolism glucose, 
lipid and glutamine metabolism that contributes for tumor cell rapid growth, survival and invasion 
(Zhang and Hochwald 2014).  
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1.3 – EPITHELIAL TO MESENCHYMAL TRANSITION 
 
EMT is the reversible process by which epithelial cells acquire mesenchymal properties, such as 
increased migration and invasion, that are leveraged by alterations in adhesion and cytoskeleton 
molecules and in microenvironment modulators. EMT is sometimes accompanied by changes in 
cell proliferation and survival.  
EMT is characterized by a gene expression landscape that reflects the phenotypic/morphological 
changes that cells undergo, depending on the cellular context. Some transcription factors, namely 
Snail, Slug, zinc finger E-box binding homeobox (Zeb) 1 and 2 and Twist, have a particularly 
prominent role as master coordinators of the gene expression changes that occur during EMT. 
They are induced upon the activation of several signaling pathways that occur in response to 
extracellular cues, such as the cytokines transforming growth factor (TGF)-β or tumor necrosis 
factor (TNF)-α, the growth factors HGF, EGF, or even nutrient and oxygen availability.  
EMT is an essential process in embryonic development and tissue repair and also contributes to 
progression of disease namely fibrosis and cancer. Each of these types of EMT will be explored 
in subsequent sections. 
 
1.3.1 - EMT phenotype 
The epithelial phenotype reflects the organization of a population of cells. Epithelial cells have 
three main features: (i) the cells are closely opposed to one another and, at the interface, present 
cell-to-cell adhesion molecules that form cell junctions; (ii) they exhibit functional and 
morphological apico-basal polarity and (iii) their basal surface is attached to a basement 
membrane (although in epithelioid tissues, cells lack the apical domain) (Pawlina and Ross 2015) 
(Fig 7).  
 
Fig. 7: Epithelial cell morphology, which is characterized by multiple cell-cell contacts, apico-
basal polarity and the presence of a basement membrane.  
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During EMT there is suppression of molecules that define the epithelial cell state and, at the same 
time, cells acquire mesenchymal properties. EMT was first described in the context of embryonic 
development, as a mechanism for tissue remodeling and a key event to diversify the structure of 
organisms. The mesenchyme is an embryonic precursor tissue with three dimensions, that 
generates a range of structures in vertebrates including cartilage, bone, muscle, kidney, and the 
erythropoietic system. During development, mesenchymal cells are characterized by its ability to 
invade the ECM and migrate great distances in the embryo, unlike epithelial cells (Hay 2005). 
For this to occur, they lose their apico-basal polarity, undergo a cytoskeleton reorganization and 
become bipolar (Hay 2005). As so, mesenchymal cells are loosely organized in a three-
dimensional extracellular matrix and integrate the connective tissues adjacent to epithelia (Fig. 
8).  
It is important to note that EMT is not always characterized by the transformation of an epithelial 
cell into a fibroblast (Nieto 2011). In some situations where EMT is thought to have occurred, 
namely in fibrosis, the tissue is mostly composed by activated fibroblastic and fibrogenic cells 
that lead to organ failure. However, EMT does not necessarily give rise to fully differentiated 
mesenchymal cells. Rather, EMT is a gradual process and so intermediate phenotypes occur (Fig. 
8). The concept of partial and “complete” EMT will be discussed in a further section. 
The major phenotypes related with EMT will be discussed in more detail in the next section. 
 
 
Fig. 8: Phenotypic changes that occur during epithelial to mesenchymal transition. 
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Cell adhesion and polarity 
Cell-to-cell adhesion and cell polarity are the two major and indissociable features of cell 
morphology, which reflect the specialized domains that compose the plasma membrane and their 
association with the networks in the cytoplasm.  
 
Cell adhesion  
The epithelial phenotype is defined at the level of a group of cells and the interactions established 
by the cells within the group. Cell adhesion is crucial for the assembly of individual cells into the 
three-dimensional tissues, allowing the proper physiological function of the organ. Epithelial cells 
display tight junctions, adherens (also called anchoring) junctions and gap junctions. Tight 
junctions are impermeable junctions that seal off the intercellular space, controlling epithelia 
permeability, and are formed by three major groups: occludins, claudins and junctional adhesion 
molecules. Gap junctions, which are formed by connexins, are important for the communication 
between cells since they allow the direct passage of signaling molecules. These will not be further 
detailed in this thesis. Finally, adherens junctions are composed of cadherins, integrins, selectins 
among others (Pawlina and Ross 2015).  Stability is a key feature of cellular junctions but they 
are not static and require active cellular processes. Another aspect required for maintaining tissue 
architecture is the association between adhesion proteins and the cytoskeleton of the cell 
(Vasioukhin et al. 2000). Furthermore, adhesion molecules participate in a large variety of signal 
transduction events that regulate cell adhesion and cell motility, cell growth, apoptosis, and 
specific gene regulation (Gumbiner 1996). 
 
Adherens junctions  
EMT is characterized by the disassembly of adherens junctions’ complexes and by the 
reorganization of the actin cytoskeleton. The main component of adherens junctions are the 
classical cadherins. Cadherins are, in fact, one of the most important and ubiquitous proteins 
involved in cell-to-cell interactions. Cadherins comprise a large superfamily of membrane-
associated proteins, characterized by the presence of multiple and highly conserved repeats of 
“extracellular cadherin domains”, β-sandwich domains that adopt a similar fold to 
immunoglobulin domains. Cadherins can be grouped into the classical cadherins, the non-
classical cadherins, which include desmosomal cadherins, and protocadherins (Paredes et al. 
2012) . Classical cadherins are calcium-dependent transmembrane glycoproteins that form 
homophilic bonds between adjacent cells (Brasch et al. 2012). Although most biological functions 
are associated with homophilic interactions, classical cadherins can, in some situations, form 
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heterophilic interactions too (Basu et al. 2017). The extracellular cadherins domains bind calcium 
ions that are critical to the adhesive transbinding. Specifically, these ions contribute for the 
ectodomain rigidification, for defining the structure of the X-dimer interface surfaces and for 
strand swapping (Brasch et al. 2012). The intracellular domain of the classical cadherins interacts 
with the cytoskeleton through linker molecules, called catenins, to form the cytoplasmic cell-
adhesion complex.  
 
E-cadherin and N-cadherin are among the best characterized classical cadherins that have 
implicated in EMT (Brasch et al. 2012). In the characterization of EMT, they are generally 
considered markers of epithelial and mesenchymal state, respectively. 
 
E-cadherin 
E-cadherin is a transmembrane receptor that, in normal epithelia, is typically localized in clusters 
at the adherens junctions between adjacent cells (Quang et al. 2013). E-cadherin (which initially 
was termed epithelial-cadherin) was originally associated with epithelial tissues (Hatta, Okada, 
and Takeichi 1985) and is expressed in most of the epithelial tissues across mammalians. The 
cytoplasmic domain of E-cadherin binds to β-catenin (or in some situations to its homologue γ-
catenin  [(McCrea, Turck, and Gumbiner 1991]) and to p120 catenin. β-catenin interacts with α-
catenin, which in turn anchors to the actin cytoskeleton, either directly or indirectly via actin-
binding proteins α-catenin, α-actinin and vinculin (Knudsen et al. 1995; Rimm et al. 1995; Weiss 
et al. 1998) while p120 regulates cadherin turnover and modulates actin assembly (Davis, Ireton, 
and Reynolds 2003; Xiao et al. 2003) (Fig. 9).  
 
 
Fig. 9: E-cadherin structure and the E-cadherin-catenin complex at the junction between two 
neighboring epithelial cells. 
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The importance of E-cadherin for tissue organization and dynamics is reflected on its regulation 
at multiple levels. E-cadherin is encoded by the CDH1 (cadherin 1) gene in humans and its 
transcription can be induced or repressed by several regulatory elements. In epithelial cells, for 
example, the transcription factor AP2 binds the CDH1 promoter inducing its expression, with the 
retinoblastoma protein (Rb) and c-Myc as co-activators (Batsché et al. 1998). On the other hand, 
transcription factors associated with the EMT transcriptional program such as Snail, Slug and 
Zeb1/2 (described later in section “EMT Transcription Factors”), are potent negative regulators 
of E-cadherin (Batlle et al. 2000; Cano et al. 2000; Comijn et al. 2001; Grooteclaes and Frisch 
2000; Hajra, Chen, and Fearon 2002). E-cadherin expression can also be downregulated through 
promoter hypermethylation, a mechanism observed in several cancer types and first described by 
Graff et al. (Graff et al. 1995). In addition to being regulated at the gene expression level, E-
cadherin sub-cellular localization is key for its function. E-cadherin trafficking to and from the 
cell membrane is done through the endocytic and the exocytic pathways and regulated by vesicle-
trafficking machinery. E-cadherin has also been shown to harbor post-translational modifications, 
such as phosphorylation and glycosylation. Activation of the Src tyrosine kinase, for instance, 
induces E-cadherin phosphorylation (presumably displacing p120) and this consequently leads to 
E-cadherin ubiquitination and endocytosis (Fujita et al. 2002). Furthermore, the ectodomain of E-
cadherin can be N- or O-glycosylated, a modification that plays an important role on the 
regulation of this protein (Pinho et al. 2011). This is exemplified by the fact that the cell surface 
transport of the newly synthesized E-cadherin can be blocked by O-glycosylation (Zhu, Leber, 
and Andrews 2001).  
The function of E-cadherin in several physiological processes has been investigated for a long 
time. E-cadherin has a central role in regulating the intercellular junction organization of 
keratinocytes as well as in epidermal morphogenesis (Wheelock and Jensen 1992); its crucial role 
was highlighted by in vivo experiments where CDH1 knock-out was shown to be embryonic 
lethal, due to failure to form a trophectoderm epithelium (Larue et al. 1994). Loss of E-cadherin 
is considered a key event of EMT that triggers a major cytoskeleton organization and several 
signaling cascades. The role of E-cadherin in developmental EMT was investigated regarding 
morphogenetic events, for example in mesoderm formation, where the loss of E-cadherin-
mediated cell contacts in vitro triggers a change in phenotype characteristic of the differentiation 
pathway of primitive streak mesoderm (Burdsal, Damsky, and Pedersen 1993). In cancers of 
epithelial origin, E-cadherin expression is frequently lost alongside tumor progression, due to 
several mechanisms, such as mutations, promoter methylation, transcriptional downregulation, 
increased endocytosis or degradation, and it is especially relevant in gastric (Corso et al. 2013; 
Oliveira et al. 2013) and breast tumors (Berx and Roy 2001; Corso et al. 2016). Indeed, hereditary 
diffuse gastric cancer is particularly associated with mutations or other alterations that lead to E-
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cadherin destabilization and loss-of-function, being the underlying genetic cause of this pathology 
(Simões-Correia et al. 2012). As mentioned before, loss of CDH1 expression is frequently 
associated with epigenetic events, such as promoter hypermethylation which have been 
considered a potential drug target, for example, in breast cancer (Huang, Ding, and Yang 2015). 
Moreover, transcriptional repression of CDH1 by the EMT-related transcription factors is 
associated with the signaling induced by several growth factors and cytokines. The impact of E-
cadherin in tumorigenesis is associated with the induction of migratory and invasive features, 
which are characteristics of EMT. Downregulation of E-cadherin in non-invasive Ras 
transformed cells results in a fibroblast-like phenotype and increased invasiveness when cultured 
in an embryonic chick heart (Navarro et al. 1991). Moreover, loss of E-cadherin-mediated cell 
adhesion is sufficient to promote tumor invasion in vivo and seems to be a rate-limiting step in 
the progression from adenoma to carcinoma in pancreatic carcinogenesis (Perl et al. 1998). 
Nonetheless, E-cadherin downregulation is not necessarily always associated with EMT. For 
example, when CDH1 is knocked-down in a non-transformed mammary epithelial cell line 
(MCF10A), there is a disruption of the organization of the actin and tubulin cytoskeletons, 
together with a decreased cell adhesion to a substrate, decreased migration and upregulation of 
some tight junctions’ proteins, but these changes were not accompanied by an EMT-associated 
gene expression profile, which suggests that E-cadherin downregulation is insufficient to induce 
an EMT (Chen et al. 2014). It is also debatable if E-cadherin can be considered an hallmark of 
EMT (Hollestelle et al. 2013), a controversy related to the partial EMT phenotype and cell 
plasticity concept that will be discussed later. The re-expression of E-cadherin in several cancer 
models has yielded contradictory results. On the one hand, CDH1 transfected into highly invasive 
epithelial tumor cell lines of dog kidney or mouse mammary gland origin, leads to decrease in 
invasiveness (Vleminckx et al. 1991) and transfection into squamous carcinoma cells results in a 
partial reversion of their tumorigenic phenotype (Navarro et al. 1991). On the other hand, simply 
expressing exogenous E-cadherin in spindle carcinoma cells, which show a fibroblast-like 
morphology in culture is not sufficient to change this phenotype or to significantly alter the 
tumorigenic behavior of spindle cells, regardless of the ability to confer calcium-dependent 
aggregation (Navarro, Lozano, and Cano 1993). This means that E-cadherin re-expression does 
not always revert EMT and tumorigenicity and the differences may reside on the genetic and 
signaling context of the cell and their ability to organize the exogenously expressed E-cadherin 
into functional adherens junctions.  
Other components of the adherens junction, such as α-catenin, when ablated have also been shown 
to be sufficient to promote precancerous hyperproliferation and sustained activation of the Ras- 
mitogen-activated protein kinase (MAPK) cascade in the skin (Vasioukhin et al. 2001). 
52 
 
Interestingly, E-cadherin plays an important role in coordinated collective migration of epithelial 
cells. Disruption of cell-cell junctions through β-catenin silencing leads to uncoordinated and 
random movement of single cells that delays the progression of the group of cells (Vedula et al. 
2012). In the Drosophila in vivo model of collective migration, E-cadherin has a key role in 
orchestrating the collective cell migration namely in the direction sensing mechanism (Cai et al. 
2014). Epithelial sheets can be rearranged through contractions of an actomyosin belt, 
constituting a form of collective migration that happens during zebrafish gastrulation (Behrndt 
and Salbreux et al. 2012). In this type of movement, cell adhesion is maintained and the 
expression landscape is not coordinated by the transcription factors (TFs) that characterize EMT. 
This collective migration can also happen during cancer progression (Labernadie et al. 2017). 
 
N-cadherin 
N-cadherin is a transmembrane calcium-binding protein usually associated with adherens 
junctions in the context of non-epithelial tissues and EMT. The sequence homology between N- 
and E-cadherin is high but N-cadherin forms homodimers with higher affinity (Katsamba and 
Carroll et al. 2009). Similarly to E-cadherin, N-cadherin intracellular domain also binds catenins, 
like p120 catenin, β-catenin and α-catenin, which regulate its activity, trafficking and downstream 
signaling (Derycke and Bracke 2004). The extracellular domain of N-cadherin forms cis and trans 
interactions, which are established within molecules emerging from the same membrane and with 
monomers on the surface of apposing cells, respectively (Bunse and Garg et al. 2013). N-cadherin 
is encoded by the CDH2 (cadherin 2) gene and some transcriptional regulators have already been 
described (Derycke and Bracke 2004). During gastrulation, the transcription of the CDH2 
homologue in Drosophila, is initiated by the transcription factor Twist, while Snail is also 
required for its complete upregulation (Oda, Tsukita, and Takeichi 1998). In a pathological 
context, Twist is necessary for N-cadherin expression in prostate cancer cells (Alexander et al. 
2006). Interestingly, this study also suggests that Twist-induced N-cadherin expression is 
dependent on integrin-β1–mediated cell adhesion to fibronectin (Alexander et al. 2006). On the 
other hand, much more is known concerning the regulation of N-cadherin and its associated 
molecules, through post-translational modifications. Like E-cadherin, N-cadherin is a 
glycoprotein and this post-translational modification confers a fine-tuning regulation of its 
functional role depending on the residue and the cell context. For example, inhibition or deletion 
of N-cadherin N-glycosylation leads to increased stabilization of cell-cell contacts, intracellular 
signaling mediated by cell-cell adhesion and reduced cell migration, with no impact on its 
expression at the membrane (Guo et al. 2009). In glioma cells, elimination of specific N-glycans 
promotes proteasomal degradation of N-cadherin and inhibits cadherin-mediated cell–cell 
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adhesion and promotes cell migration (Xu et al. 2017). Another post-translational modification 
important for regulating N-cadherin function is phosphorylation. For example, N-cadherin, which 
participates in neuron communication, as it undergoes a conformational change upon 
depolarization in the synaptic junctional adhesion in the central nervous system (Tanaka et al. 
2000), was shown to be phosphorylated by the serine/threonine kinase protein kinase D1 which 
increases its membrane localization and promotes functional synapse formation (Cen et al. 2017).  
N-cadherin-triggered homophilic adhesion of cells to a substrate is characterized by the induction 
of lamellipodia protrusions and a cytoskeleton reorganization. The organization of cadherin-
catenin complexes and actin filaments in cadherin adhesions is dependent on membrane 
recruitment of p120, which contributes for a Rac1-dependent extension and maturation of 
cadherin-mediated contacts (Gavard et al. 2004). In fact, cadherins are associated with several 
signaling pathways, such as Rho-family GTPases, through catenins. Rho-family GTPases, 
including RhoA, Rac1, and Cdc42, are molecular switches - cycling between an active GTP-
bound state, which allows association with an effector protein, and an inactive GDP-bound state 
- and have emerged as key regulators of cadherin-mediated cell-cell adhesion, being their 
differential activation determinant for the resulting cell phenotype (reviewed in Braga 2000). 
Furthermore, N-cadherin interacts with fibroblast growth factor (FGF) receptor, preventing its 
ligand-induced internalization, being this stabilization essential for FGF-2 sustained activation of 
the MAPK-ERK pathway, which leads to MMP-9 gene transcription and cellular invasion in 
cancer cells (Suyama et al. 2002). The formation of N-cadherin-induced lamellipodia is also 
associated with an activation of the PI3K pathway (Gavard et al. 2004), a pathway that also 
mediates cell survival (Li, Satyamoorthy, and Herlyn 2001; Tran et al. 2002; Zuo et al. 2013). N-
cadherin also mediates the expression of the anti-apoptotic cell survival protein Bcl-2 through the 
PI3K/Akt pathway in human prostate carcinoma cell lines (Tran et al. 2002). Finally, glial cell 
line-derived neurotrophic factor exerts a neuro-protective effect on dopaminergic neurons via N-
cadherin and the PI3K/Akt pathway (Zuo et al. 2013).  
N-cadherin was originally described in more detail in the nervous tissue - hence named as neural 
cadherin - and during development, where its expression is detected upon gastrulation (Hatta, 
Okada, and Takeichi 1985; Kohei Hatta and Takeichi 1986). In a cell biology perspective, N-
cadherin plays a major role in migration. Exogenous expression of N-cadherin in epithelial cells 
induces a change in their morphology and invasive properties. In model of squamous cell 
carcinoma, N-cadherin is associated with a scattered morphology in cultured cells and with 
invasion in tumor biopsies. Besides, when N-cadherin is expressed in squamous epithelial cells, 
it induces a more scattered and less adhesive phenotype, resembling features of EMT (Islam et 
al. 1996). Similar observations were made in breast cancer cell lines: N-cadherin promotes 
migration and invasion in vitro and metastasis in vivo (Hazan et al. 2000; Nieman et al. 1999). 
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Concerning metastasis, N-cadherin was shown to enhance metastatic potential to the lungs of 
mammary epithelial cells expressing the polyoma virus middle T antigen (Hulit et al. 2007).  
 
Cadherin switching 
Frequently during EMT, N-cadherin expression becomes upregulated while E-cadherin is 
downregulated, a phenomenon termed ‘cadherin switching’. It may also involve alterations in 
other cadherins, such as P-cadherin. This observation has been reported during development, for 
example in gastrulation (Oda, Tsukita, and Takeichi 1998) or in kidney morphogenesis (Dahl et 
al. 2002), as well as in several cancer types, like prostate cancer, breast cancer and pancreatic 
cancer (reviewed in Wheelock et al. 2008). In squamous cell carcinoma it has been reported an 
inverse correlation of the expression levels of N-cadherin and P-cadherin versus E-cadherin: in 
fact, when epithelial cells are transfected with N-cadherin, E-cadherin and P-cadherin become 
downregulated (Islam et al. 1996). This may suggest a reciprocal or coordinated regulation of 
both E-cadherin and N-cadherin. In fact, a collective downregulation of adherens junction 
components (E-cadherin, α-catenin, β-catenin and p120-catenin) has been observed in prostatic 
adenocarcinomas patients’ samples (Kallakury, Sheehan, and Ross 2001). During TGF-β-induced 
EMT in mammary cells, cadherin switching seems to be essential for increased cell motility, but 
not for changes in morphology (Maeda, Johnson, and Wheelock 2005).  
 
Tight junctions 
Other important structures that constitute the apical junctional complex, together with adherens 
junctions, and that regulates cell communication and cell polarity are tight junctions. In epithelial 
cells, tight junctions localize closest to the apical side and divide the cell surface into two 
functionally and biochemically distinct regions, which face either one of the two physiological 
compartments. Tight junctions work as selective permeability barriers that regulate the 
paracellular route for the movement of ions and solutes (Farquhar and Palade 1963; Gumbiner 
1987). They are composed of the transmembrane proteins claudin and occludin and cytoplasmic 
proteins that provide scaffolding, such as zonula occludens (ZO-) 1, 2 and 3 and several other 
cytoskeleton-associated proteins. Occludins have a major regulatory role for 
assembly/disassembly and function of tight junctions (Yu et al. 2005). These structures are very 
diverse and plastic since their permeability and signaling properties vary from tissue to tissue, 
their composition changes and they are subject to rapid regulation. For example, tight junctions’ 
stability can be regulated through post-translational modifications. Occludins can be 
phosphorylated in a process mediated by the Src-family tyrosine kinases c-Yes and c-Src, Rho 
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kinase, protein kinases C, casein kinase 1, VEGF or PDGF (Dörfel and Huber 2012). 
Phosphorylation by these kinases affects occludin half-life, localization and interaction with other 
tight junctions’ proteins (Dörfel and Huber 2012).  
As a key part of their communication role, tight junctions are intimately connected to the 
cytoskeleton and activate signaling cascades. One of the main components of the signaling 
pathways activated downstream of tight junctions are Rho family GTPases (Zihni, Balda, and 
Matter 2014), for example, the guanine nucleotide exchange factor (GEF) for RhoA, GEF-H1 
(also known as ARHGEF2) that regulates paracellular permeability (Benais-Pont et al. 2003). 
Moreover, GEF-H1 is recruited to tight junctions by binding to the junctional adaptor cingulin, 
which results in the inhibition of GEF-H1, with consequential inhibition of various RhoA-driven 
processes, such as cell cycle progression and gene expression. Interestingly, cingulin expression 
increases with increasing cell confluence and so, this mechanism may provide a link for the 
regulation of RhoA signaling and cell cycle by cell confluence (Aijaz et al. 2005; Benais-Pont et 
al. 2003). Furthermore, the Cdc42 effectors PAK4 and partitioning defective (Par) 6B are required 
for tight junction formation and junctional maturation (Wallace et al. 2010).  
Tight junctions’ dysregulation is associated with EMT. Using a luminescence-based approach to 
unravel the interactome for TGF-β signaling, occludin and Par6 were identified as binding to 
TGF-β receptors. Upon TGF-β treatment, TGF-β type II receptor was found to be recruited to 
tight junctions, phosphorylating Par6 and inducing RhoA degradation in a Smurf1-dependent 
manner. The phosphorylation of Par6 is required for TGF-β-induced EMT and interferes with the 
cortical actin cytoskeleton and ultimately contributes to tight junction disassembly (Barrios-
Rodiles et al. 2005; Ozdamar et al. 2005). In another EMT model, where Raf constitutively active 
expression induces transformation, cells lose their epithelial phenotype and E-cadherin expression 
at the membrane, while the tight junctions become disassembled, a phenotype that can be rescued 
by restoring occludin expression (Li and Mrsny 2000). Specifically, Raf1 induces the 
upregulation of the transcriptional factor Slug, which inhibits the expression of occludin (Wang 
et al. 2006). In fact, Snail and Slug, two transcription factors that play a major role in EMT, when 
overexpressed disrupt tight junctions and have been shown to repress the expression of claudins 
and occludin (Ikenouchi et al. 2003; Martínez-Estrada et al. 2006). The role of tight junctions on 
EMT is especially evident when cells are cultured under confluent conditions in vitro. ZO-1 is 
able to bind and regulate the intracellular localization of transcription factor named ZO‐1‐
associated nucleic acid‐binding protein (ZONAB). The binding of ZO-1 to ZONAB occurs in 
confluent culture conditions and sequesters the transcription factor within the tight junctions, 
preventing its nuclear translocation where it represses Erb2 expression, a tyrosine kinase co-
receptor important for epithelial differentiation (Balda and Matter 2000). ZONAB also regulates 
epithelial cell proliferation and cell density through binding and inhibition of the nuclear function 
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of cell division kinase-4 (CDK4) in confluent conditions (Balda, Garrett, and Matter 2003). Since 
ZO-1 loss of activity has been associated with EMT, ZO-1 has actually been considered an EMT 
marker (Huang, Guilford, and Thiery 2012; Zeisberg and Neilson 2009). 
The importance of tight junctions in EMT is dependent on the cell line, since there are cell lines 
that, under normal culture conditions, do not form tight junctions, as exemplified by MCF10A 
cells (used on chapter 3.2 of the “results” section) (Underwood et al. 2006). 
 
Cell polarity 
Cell polarity is a major entity in cell morphology that regulates cell behavior, namely cell 
communication, cell identity and cell movement. Cell polarity is a key determinant during cell 
cycle and for the establishment of the division plane. It also determines the direction of growth 
and the formation of cell protrusions.  
Polarized epithelial cells form a continuous cell layer, creating a barrier that define the shape of 
several organs. This confers protection and, at the same time, allows diverse polarized activities 
including absorption, secretion, transcellular transport and sensation.  
Cell polarity is initiated by the recognition of a spatial cue, such as cell-to-cell adhesion in the 
case of epithelial cells, which is decoded by membrane complexes and triggers downstream 
signaling events. This causes an assembly of the cytoskeleton, redistribution of the microtubules 
and of the secretory pathway components. Epithelial cell polarity requires both cell–cell and cell–
ECM adhesion, in order to establish structurally and functionally distinct apical and basal–lateral 
membrane domains (Drubin and Nelson 1996). Cell polarity is coordinated by three main protein 
complexes, the so called ‘polarity complexes’ - Crumbs, Par and Scribble complexes - and their 
interactions with cell-cell adhesion receptors, such as tight junctions and adherens junctions 
(forming the apical junctional complexes) and Rho family GTPases (Ngok, Lin, and Anastasiadis 
2014). E-cadherin and catenins play a role in cell polarity. For example, catenin downregulation 
leads to reduced cell polarity (Vasioukhin et al. 2001). However, the role of these adherens 
junctions’ proteins in cell polarity seems to be dependent on the signaling context, as exemplified 
by mammary epithelial cells, in which E-cadherin downregulated cells still retained cell polarity, 
based on the apical ZO-1 localization (Chen et al. 2014). The establishment, but not maintenance, 
of apical-basal polarity was also compromised in kidney epithelial cells after E-cadherin knock-
down (Capaldo and Macara 2007). 
Cell polarity has been shown to participate in tumorigenesis. For example, in human colorectal 
tumors, the decreased expression of DGL1 (discs large MAGUK scaffold protein 1) and SCRIB 
(scribbled planar cell polarity protein), two genes that have been considered tumor suppressors in 
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Drosophila and are commonly downregulated in cancer, is associated with the lack of epithelial 
cell polarity and a disorganized tissue architecture (Gardiol et al. 2006).  
EMT is frequently associated with changes in epithelial cell polarity and several polarity 
regulators have been linked with EMT. In particular, Zeb1, an EMT-associated transcription 
factor, is necessary for loss of basal-apical cell polarity during EMT by directly repressing the 
cell polarity genes Hugl2 (or Lgl2), Crumbs3, and Pals1-associated tight junction protein through 
binding to their promoters in colorectal and breast cancers (Aigner et al. 2007; Spaderna et al. 
2008). Conversely, Scribble, another polarity complex, mediates the expression of Zeb via 
MAPK-ERK signaling and Fra1 (Elsum, Martin, and Humbert 2013). Par3, a protein from the 
Par complex, is downregulated after TGF-β treatment together with other characteristic EMT 
features, which leads to the redistribution of the Par6–α protein kinase C and complex from the 
membrane to the cytoplasm and the subsequent disorganization of the Par complex, leading to a 
loss of polarity (Wang et al. 2008). 
 
Migration and invasion 
Increased migration is a key feature of EMT during development, wound healing response and 
fibrosis and in cancer. Cell motility that characterizes EMT in the embryo has been subject of 
study since the 80s (Hay 1989). For example, contractile actomyosin rings drive cell movements 
during zebrafish gastrulation (Behrndt and Salbreux et al. 2012). Besides, FAK was shown to 
regulate Snail1-dependent EMT in embryonic cells (Li et al. 2011).  
The study of cell migration and invasion is of particular interest in cancer research as it is a major 
determinant for metastatic progression. In this setting, EMT can be regarded as one of the ways 
by which cancer cells are capable of migrating and invading the adjacent tissue, the first step in 
cancer progression towards the production of metastasis. The interstitial migration and invasion 
program of mesenchymal cells in cancer is characterized by single cell movement, prominent 
protrusions and spindle-shaped morphology, strong adhesion to ECM and proteolytic tissue 
remodeling (Friedl and Wolf 2003).  Increased cell migration and invasion reflect several changes 
in the protein expression and signaling landscape that characterize EMT and so, several of the 
proteins that regulate mesenchymal migration are used as markers of EMT, including N-cadherin, 
fibronectin, MMPs and vimentin. 
Fibronectin is one of the most commonly used EMT markers. Fibronectin characterizes the breast 
cancer ECM (Helleman et al. 2008), while in mammary epithelial cells, the coating of cell culture 
plates with fibronectin not only induces an increased migratory behavior, but also the upregulation 
of fibronectin as well as the expression of several proteins associated with EMT such as N-
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cadherin, vimentin, MMP-2 and Snail (Park and Schwarzbauer 2014).  As previously mentioned, 
fibronectin can bind several integrin combinations, such as α5β1 (Humphries, Byron, and 
Humphries 2006), being the integrin binding domain on fibronectin sufficient to induce the 
previously mentioned effects on EMT protein expression (Park and Schwarzbauer 2014). 
Fibronectin was also shown to lead to a TGF-β pathway activation and endogenous production  
which is required for the EMT induction (Park and Schwarzbauer 2014). Moreover, using a 
computational model, it was shown that ECM density also promotes EMT by weakening of cell–
cell adhesions (Kumar, Das, and Sen 2014).  
MMPs are also commonly used as a marker of EMT although the expression of individual MMPs 
depends on the tissue type. The MMP-3 (or stromelysin-1), for example, changes the phenotype 
of mammary epithelial cells to invasive mesenchymal-like cells in a process mediated by E-
cadherin cleavage and β-catenin redistribution (Lochter et al. 1997; Sternlicht et al. 1999). 
Interestingly, MMPs from the microenvironment also seem to directly induce EMT in epithelial 
cells, as shown in a mouse mammary carcinoma model, where MMP-9 mediates the proteolytic 
activation of latent TGF-β, after docking to the hyaluronan receptor CD44 at the membrane. This 
promotes tumor invasion and angiogenesis (Yu and Stamenkovic 2000).  
Vimentin is an intermediate filament protein, generally expressed in mesenchymal cells, which 
forms a cytoskeleton network for the nucleus hedge to the membrane and provides mechanical 
resistance to cells (Chang and Goldman 2004). Importantly, vimentin is involved in cell 
migration, for example through interaction with filamin A and mediating integrin-β1-regulated 
cell spreading (Eckes et al. 1998; Kim et al. 2010). Vimentin filaments also interact with signaling 
proteins, such as phosphorylated ERK1/2 in a calcium dependent manner, protecting the kinase 
from dephosphorylation (Perlson et al. 2005, 2006). Vimentin expression is sufficient to induce 
the changes in cell shape and motility typical of the EMT (Mendez, Kojima, and Goldman 2010). 
Specifically, vimentin is necessary for invadopodia elongation (Schoumacher et al. 2010) and it 
is also required for focal adhesions formation, actin and microtubules cytoskeleton organization 
and directional migration in breast cancer cell lines. In fact, in a breast cancer cell line, vimentin 
expression results in Slug and integrin-β1 expression and E-cadherin downregulation (Liu et al. 
2015).  
Within a tissue, cell migration is dependent on a physicochemical balance between cell 
deformability and physical constraints. An interesting aspect of cancer cell migration, that is 
especially relevant when individual cells move through very tight interstitial spaces during 
metastasis formation, is the nucleus translocation and deformation. This process is regulated by 
the accumulation of non-muscle myosin IIB in the back of the nucleus (Thomas et al. 2015). 
Physical stress during migration can result in nuclear rupture and DNA damage. Laminins A/C 
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are important in protecting against nuclear envelope rupture and membrane remodeling proteins 
like ESCR-III (endosomal sorting complexes required for transport III) are involved in nuclear 
damage repair (Denais and Gilbert et al. 2016). Aggressive breast cancer cell lines show deformed 
nucleus architecture and have lower levels of laminin A/C and the downregulation of these 
proteins is also correlates with disease recurrence in colon cancer patients (Belt et al. 2011; 
Hutchison 2014; Matsumoto et al. 2015). These data raise an interesting question: does nuclear 
stress have an active role in cancer progression by promoting genomic instability? (Denais and 
Gilbert et al. 2016). 
It is important to reinforce that cancer cell movement can occur in the absence of EMT (Friedl 
and Alexander 2011). It was observed, using intravital imaging in live mice that breast cancer 
cells can switch from a collective type of movement to individual cell migration, in a process 
regulated by TGF-β signaling. Single cell movement allowed cells to enter the bloodstream, 
whereas collective invasion seems can mediate lymphatic dissemination (Giampieri et al. 2009).  
 
Proliferation and survival 
The relationship between EMT and proliferation rate has been subject of debate and it seems 
highly dependent on the signaling context of the cells. In general, EMT is associated with reduced 
proliferation, both in the context of development or cancer associated EMT.  
The coordination of cell cycle during development is crucial for morphogenesis and cell fate 
determination. The analysis of the cell cycle length in mesodermal and ectodermal cells of rat 
embryos during gastrulation showed that the cells of the primitive streak divided less often 
compared to epiblast cells before ingression (Mac Auley, Werb, and Mirkes 1993). In the 
Drosophila embryo, the cell cycle regulator Tribbles delays mitosis by downregulating String, a 
CDC25 mitotic activator, thus allowing gastrulation to be completed before cell division takes 
place (Mata et al. 2000). When a timed mitotic block is missing in cells undergoing EMT, there 
is a developmental failure of embryos (Mata et al. 2000).  
One of the most commonly used EMT inducers, TGF-β, has a dual role in proliferation in cancer: 
it can repress cell division or promote tumor growth, depending on the tissue (Derynck, Akhurst, 
and Balmain 2001; Massagué 2008). Specifically, in normal epithelial cells, TGF-β suppresses 
proliferation through Rb, causing an arrest at the G1 phase of the cell cycle and this suppression 
of proliferation can happen in the context of EMT (Laiho et al. 1990; Peinado, Quintanilla, and 
Cano 2003). Tumor cells can avoid growth inhibitory activities of TGF-β, through inactivation of 
certain components of the pathway due to genetic alterations or transcriptional silencing; 
however, they retain sensibility to other TGF-β responses due to different thresholds of signaling 
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(Derynck, Akhurst, and Balmain 2001; Massagué 2008). On the other hand, TGF-β can also 
trigger apoptosis (Derynck, Akhurst, and Balmain 2001; Massagué 2008) but in hepatocytes it 
has been shown that EMT confer resistance to the apoptotic effects of TGF-β (Valdés et al. 2002).  
An interesting study helped to clarify the compatibility (or lack of it) of cellular proliferation and 
EMT (Comaills et al. 2016). Cells that persist proliferating after EMT induction by TGF-β 
treatment present mitotic defects and genomic abnormalities. The defects in mitosis are due to 
failed cytokinesis and associated with suppression of nuclear envelope proteins implicated in 
mitotic regulation such as laminB1. Besides, EMT-induced mitotic defects are reversible, but the 
inherited genomic instability persists and promotes tumorigenic phenotypes (Comaills et al. 
2016).  
Using an inducible cell line model of EMT (non-small cell lung cancer cells with inducible Twist 
and Snail) to investigate how induction of the transition alters signaling networks and 
requirements for proliferation, Salt et al. reported that proliferation is affected during EMT, 
particularly in serum free conditions due to disruption of the neuregulin 1, Erb-B2 receptor 
tyrosine kinase 3 and PI3K-AKT pathway (Salt, Bandyopadhyay, and McCormick 2014). 
Mechanistically, Snail was shown to induce cell cycle arrest in G1, through several cell cycle 
regulators of the early to late G1 transition and of the G1/S checkpoint. Specifically, Snail 
represses cyclin D2 transcription leading to a maintenance of the low levels of cyclins D and 
blockage the G1/S transition by maintaining high levels of p21 (Vega et al. 2004). Moreover, 
Snail also promotes cell survival under serum depletion conditions through the MAPK and PI3K 
pathways (Vega et al. 2004). Like Snail, Slug activation also reduces the proliferation, 
concomitantly with decreased ERK activity and decreased Rb phosphorylation (Turner et al. 
2006). Besides, Zeb2 binds cyclin D1 gene, repressing its transcription which leads to 
accumulation of cells in the G1 phase of cell cycle (Mejlvang et al. 2007). Yet, Twist was shown 
to promote tumor cell proliferation (Ansieau et al. 2008; Qian et al. 2013; Shiota et al. 2008). In 
gastric cell lines, Twist induces FoxM1 expression, which plays a key role in cell cycle 
progression (Qian et al. 2013), while its downregulation induces G1 arrest and decreases cell 
proliferation (Shiota et al. 2008). Moreover, Twist1 and Twist 2 suppress oncogene-induced 
premature senescence in cancer cells, cooperating with Ras for malignant transformation and 
disrupting both p53 and Rb pathways (Ansieau et al. 2008). However, another study in an in vivo 
skin tumor model showed that induction of Twist1 is associated with EMT and reduced tumor 
cell proliferation and that turning off Twist1 at distant sites promoted metastatic growth (Tsai et 
al. 2012).  
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Concluding, EMT results from the alteration of multiple components of cellular phenotype, 
although the degree of these changes varies according to the cellular context. Specification of 
cells that will undergo EMT occurs through coordination of cell–cell, cell-ECM and soluble 
signals with intracellular mediators. 
 
1.3.2 - EMT regulation 
How is EMT induced? How are the changes in cellular phenotype coordinated? 
In adult tissues, EMT can be triggered by the composition, structure of the ECM components and 
its remodeling (Hay 1990; Masszi et al. 2004; Radisky et al. 2005), nutrient and oxygen conditions 
(Imai et al. 2003; Lv et al. 2011), as well as soluble growth factors or cytokines, including EGF, 
HGF, FGF, and TGF-β (Thiery et al. 2009).  
EMT is characterized by the activation of a transcriptional program that triggers and is responsible 
for changes in major cell structures and functions. Actually, EMT is a program regulated at 
different levels, namely chromatin changes, miRNAs, transcription, splicing, post-translationally 
(Nieto et al. 2016). For example, the miR200 family, highly expressed in epithelial tissues and 
involved in establishing epithelial lineages in early development, is one of the most studied 
mechanisms of regulation of EMT, being dysregulated in many epithelial cancers (Brabletz and 
Brabletz 2010). This family of microRNAs is induced by several EMT stimuli, targeting and 
downregulating EMT transcription factors such as Zeb 1 and Zeb2 (Korpal et al. 2008; Park et al. 
2008). Zeb is a particular target of miR200 since its gene sequence is highly enriched in binding 
sites for this specific family of miRs. Besides, Zeb also regulates the transcription of miR200 
family (Brabletz and Brabletz 2010). Polycomb repressive complexes (PRCs), which silence 
transcription by modifying histones and recruiting a variety of additional repressors also 
participate in the induction of EMT (Tam and Weinberg 2013). 
Nowadays, the transition is considered a dynamic process that reflects cellular plasticity. In many 
examples, either from studies in cell culture to in vivo and from cancer and fibrosis to wound 
healing and developmental processes, cells undergoing EMT exhibit several intermediate phases, 
sometimes called “stable and metastable states”, and do not reach a “fully mesenchymal” 
phenotype. These states are not characterized by a universal gene expression pattern (Nieto et al. 
2016). 
Next, I will introduce the inducers and effectors of the EMT program. Concerning the EMT 
effector molecules, I will be focusing on the regulation at the transcriptional levels by 
transcription factors.  
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Signals and pathways that induce EMT 
Many growth factors and cytokines have been described as EMT inducers including TGF-β, TNF-
α, BMP, EGF, FGF, PDGF, Wnt-β-catenin and Notch (Thiery et al. 2009). Among the cytokines 
that are capable of triggering EMT, TGF-β and TNF-α are the most commonly used for in vitro 
experiments. The specific roles of these molecules will be mentioned through-out the following 
sections of this thesis. Besides, the contact with the surrounding matrix can also trigger or be 
required for EMT. For example, the composition and structure of the ECM can regulate EMT in 
a process mediated by integrins (Hay 1990; Masszi et al. 2004; Radisky et al. 2005). The 
extracellular environment can also modulate the phenotype of cells through the availability of 
oxygen and nutrients, such as glucose (Lv et al. 2011). Hypoxia or HIF can induce the expression 
of EMT effectors such as Twist, Snail and Zeb (Evans et al. 2007; Yang et al. 2008). Moreover, 
metabolites namely succinate, fumarate and 2-HG have been shown to lead to EMT when 
accumulated intracellularly (Colvin et al. 2016; Sciacovelli et al. 2016; Tseng et al. 2018). These 
signals have been described as EMT inducers during embryonic development, fibrosis and cancer.  
Concerning cancer, besides the previously mentioned cues, common oncogenic pathways, such 
as those associated with HRas, ErbB2 or mutant p53, can promote EMT in association with other 
pathways (Adorno et al. 2009; Jenndahl, Isakson, and Baeckström 2005; Oft, Akhurst, and 
Balmain 2002; Peinado, Quintanilla, and Cano 2003). EMT-triggering signals often come from 
the tumor stroma, whose components, like fibroblasts, endothelial cells and immune cells, can 
secrete several types of cytokines, growth factors or proteins like MMPs, which can induce or 
mediate the acquisition of mesenchymal properties by cancer cells (Bussard et al. 2016). Besides, 
EMT inducers can work as paracrine and autocrine signals (Scheel et al. 2011).  
The signals that induce EMT can be very diverse, cell- or tissue-specific. Cells can indeed display 
different sensitivities to the same signals and their integration can be achieved differently, leading 
to distinct outcomes. Besides, many of these signals trigger a local response that is also highly 
dependent on the cell sensitivity. Finally, in response to these stimuli, several signaling pathways 
become activated, being EMT the result of a complex regulatory crosstalk inside the cell (Oft, 
Akhurst, and Balmain 2002). 
EMT stimuli converge in the activation of common transcription factors, which will be described 
in the next section. 
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EMT transcription factors  
The changes that epithelial cells undergo when becoming more mesenchymal are orchestrated by 
key factors that are commonly designated as EMT TFs. The idea of a master regulator that 
controls the migration machinery during EMT had already been put forward in the early days of 
EMT by E. Hay (Hay 1989). The role of these EMT TFs goes from gastrulation in flatworms, like 
planarians (Abnave et al., 2017) to roundworms like Caenorhabditis elegans (Manzanares, 
Locascio, and Nieto 2001), insects like Drosophila melanogaster (Grau, Carteret, and Simpson 
1984; Simpson 1983), vertebrates like Xenopus (Sargent and Bennett 1990), mouse (Smith, del 
Amo, and Gridley 1992) and human (Rhim et al. 1997). In fact, an interesting study using 
planarians showed that the EMT transcription factor homologues of Snail-1, Snail-2 and Zeb-1, 
together with a matrix metalloprotease and β-integrin, are essential for pluripotent adult stem cell 
and progeny migration in wound repair (Abnave et al., 2017). 
The contribution of these TFs to EMT is context-dependent. For example, when assessing the 
dependency of metastasis formation on EMT, different groups, using a pancreatic cancer mouse 
model, obtained distinct results depending on the EMT TFs used, suggesting functional 
differences of EMT TFs (Krebs et al. 2017; Zheng et al. 2015). This is matter of debate nowadays 
in the EMT field and further research is needed. Some of the genes regulated by the EMT TFs are 
shared and EMT TFs can regulate each other, creating a complex network. For example, E-
cadherin is a target of both Snail and Zeb1 (Batlle et al. 2000; Cano et al. 2000; Grooteclaes and 
Frisch 2000) and Snail can actually promote Zeb1 expression (Guaita et al. 2002). Finally, these 
TFs have pleiotropic functions and much is still unknown about the genetic programs that they 
regulate (Goossens et al. 2017). 
There are several TFs described as tightly associated with EMT (reviewed in Zheng and Kang 
2013). In this thesis, I will focus on the most studied EMT TFs that belong to the Snail, Twist and 
Zeb families and on their role in cancer-associated EMT.  
 
Snail family 
Snail family belongs to the larger Snail superfamily, which also includes the Scratch family 
(Manzanares, Locascio, and Nieto 2001). Snail is a family of zinc-finger transcription factors, 
characterized by a highly conserved carboxyl (C)-terminal containing 4 to 6 zinc-fingers and a 
much less conserved amino (N)-terminal where elements that modulate Snail transcriptional 
activity bind (Nieto 2002). In mouse and human, Snail encodes a four zinc-finger protein with 
85.5% homology between them (Paznekas et al. 1999). In vertebrates, Snail family contains 3 
members: Snai1 (Snail), Snai2 (Slug) and Snai3 (Smuc). Snail and Slug are key genes during 
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EMT in several cellular contexts, while the function of Smuc is less characterized (De Herreros 
et al. 2010) and therefore, it will not be described any further. Snail genes have been suggested 
to act primarily as survival factors and inducers of cell migration, rather than as inducers of EMT 
or cell fate (Barrallo-Gimeno and Nieto 2005). 
 
Snail 
Snail was first identified in Drosophila melanogaster as a gene necessary for proper mesoderm 
formation (Grau, Carteret, and Simpson 1984; Simpson 1983) and encodes a protein with five 
zinc-fingers suggesting, at that time, a DNA-binding function (Boulay, Dennefeld, and Alberga 
1987). It was later proposed that since Snail is expressed in multiple germ layers during 
development, its role is not limited to mesoderm formation (Alberga et al. 1991). Snail research 
was further expanded to vertebrates with the successful cloning of the Xenopus (Sargent and 
Bennett 1990) and the mouse Snail gene (Nieto et al. 1992; Smith, del Amo, and Gridley 1992), 
among others. In humans, SNAIL was mapped together with its pseudogene SNAI1P1 (Paznekas 
et al. 1999; Twigg and Wilkie 1999). In the early studies, Snail was described to be a 
transcriptional repressor of genes important for development (Gray, Szymanski, and Levine 1994; 
Ip et al. 1992; Kosman et al. 1991; Leptin 1991).  
Snail binds to a consensus sequence composed of 6 amino acids – CAGGTG -, a motif similar to 
the E box (Mauhin et al. 1993; Prokop et al. 2013). The most well-studied target of Snail is CDH1 
that encodes E-cadherin, an adhesion protein with a central role in EMT (see “E-cadherin” 
section). In 1998, it was first shown that Drosophila embryos mutant for Snail are associated with 
E-cadherin downregulation (Oda, Tsukita, and Takeichi 1998). It was later proven that Snail 
indeed binds to the CDH1 promoter E-boxes and represses its transcription, which results in the 
disassembly of adherens junctions (Batlle et al. 2000; Cano et al. 2000). In tumor cell lines, this 
repression was shown to be dependent on the PRC2, which is recruited by Snail to the CDH1 
promoter (Herranz et al. 2008). Recently, it has been shown that Snail binds the long non-coding 
RNA HOTAIR (for HOX transcript antisense intergenic RNA) recruiting EZH2 (enhancer of 
zeste homolog 2), member of the PRC2, to specific genomic sites (Battistelli et al. 2017). We 
now know that Snail family members can positively or negatively regulate transcription. In a 
breast cancer cell line, Snail expression was shown to lead to the differential expression of 7602 
genes, while an interactome analysis revealed Snail as an over-connected protein (Mezencev et 
al. 2016). Snail regulates tight junctions, for example by transcriptionally repressing claudins 
(claudin-3, claudin-4 and claudin7) and occludin (Ikenouchi et al. 2003), while in collaboration 
with EGR1 and SP1, it directly activates transcription of ZEB1 and MMP-9 induced by the tumor 
promoter 12-O-tetradecanoyl-phorbol 13-acetate (Wu et al. 2017). Snail also has been shown to 
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bind to target genes implicated in epithelial differentiation and signaling such as PTEN, FOXA 
family members, Rab25 and keratin 18 (De Craene et al. 2005; Jägle et al. 2017; Escrivà et al. 
2008). Snail regulates splicing, particularly repressing ESRP1 expression by binding directly to 
the E-box structure in the promoter of ESRP1, thus promoting CD44 isoform switching during 
EMT (Reinke, Xu, and Cheng 2012).  Importantly, Snail binds directly to the promoter and is 
able to regulate the expression of several metabolic enzymes such as PFKP, FBP1 and 
cytochrome c oxidase subunits (De Craene et al. 2005; Dong et al. 2013; Kim et al. 2017; Lee et 
al. 2012).  
From the description above, it becomes clear that Snail targets are related to EMT. In fact, Snail 
was first implicated in EMT through the work done with mutant forms of Snail in model 
organisms. Drosophila Snail mutants are characterized by defects in mesoderm formation, 
specifically the absence of mesenchymal cells (Leptin and Grunewald 1990). Similarly, mice 
embryos that express a mutated form of Snail show a retention of epithelial characteristics and 
maintenance of E-cadherin expression in mesoderm, pointing Snail as a key regulator of EMT 
during development. These mice die early in gestation due to defects in gastrulation and 
mesoderm formation (Carver et al. 2001).  
Cano et al. demonstrated that Snail overexpression in canine kidney epithelial cells results in a 
change to a fibroblast-like morphology, with long extensions, downregulation of E-cadherin and 
desmoplakins, upregulation of vimentin and fibronectin, increased migration and invasion (Cano 
et al. 2000). In colon cancer cells, the inducible Snail expression causes a change in cellular 
morphology, decreased aggregation, increased invasion, consistent with EMT (De Craene et al. 
2005). On the other hand, knock-down of SNAIL has been shown to reverse EMT, at least 
partially, and the invasiveness phenotype of tumor cells (Olmeda et al. 2006; Wang et al. 2013; 
Wu et al. 2009). Taken together, these results suggest that Snail expression is sufficient to induce 
EMT. 
Interestingly, Snail also regulates normal mesenchymal cell function, since in fibroblasts, Snail 
silencing impairs MMP-14-dependent invasive activity (Rowe et al. 2009). Snail can also have 
other functions, such as resistance to cell death (Kajita, McClinic, and Wade 2004), cell-cycle 
progression and survival (Vega et al. 2004), as well as the prevention from radiation-induced 
apoptosis, through regulation of PTEN and the Akt pathway (Escrivà et al. 2008).  
How is Snail induced and regulated? Snail-inducing stimuli and signaling pathways include TGF-
β, EGF, Notch, Wnt, ROS and hypoxia (Imai et al. 2003; Liu et al. 2014; Peinado, Quintanilla, 
and Cano 2003; Sahlgren et al. 2008; Yook et al. 2006). TGF-β was the first cytokine shown to 
induce Snail, in kidney epithelial cells, in a process mediated by the MAPK pathway (Peinado, 
Quintanilla, and Cano 2003). Later, it was shown that Smads, which are induced upon TGF-β 
66 
 
treatment, bind Snail promoter together with HMGA2 (high mobility group A2) leading to EMT 
(Thuault et al. 2008). Moreover, Snail and Smads form a transcriptional repressor complex that 
downregulates the expression of several epithelial-associated proteins such as E-cadherin and 
Coxsackie- and adenovirus receptor, a tight-junction-associated cell adhesion molecule (Vincent 
et al. 2009). Snail is also crucial for TNF-α mediated EMT (Wang et al. 2013) and other 
inflammatory cytokines, such as interleukine-1β, which have been shown to induce EMT and 
enhance Snail binding at the chromatin level (St. John et al. 2009). Another important pathway 
for development and is also activated under hypoxia conditions is the Notch pathway, which 
controls Snail expression through two distinct mechanisms: binding to the Snail promoter and 
through a HIF-1α mediated lysyl oxidase upregulation, that stabilizes the Snail protein (Sahlgren 
et al. 2008). Several growth factors trigger signaling cascades that upregulate Snail, for example 
the FGF receptor 1 (Ciruna and Rossant 2001) or EGF receptor (Lee et al. 2008; Lu et al. 2003). 
Oncogenic HRas signaling, through the MAPK and the PI3K pathways, and Akt signaling also 
induce Snail promoter (Grille et al. 2003; Peinado, Quintanilla, and Cano 2003). Interestingly, 
Snail seems to directly regulate itself by binding to its own promoter, creating a negative loop 
(Mauhin et al. 1993; Peiró et al. 2006). In several cases, Snail expression is increased by 
stabilization of its protein levels and cellular location, through GSK-3β-mediated phosphorylation 
(Zhou et al. 2004). In human embryonic kidney (HEK) 293 cells overexpressing Snail cells, the 
cytokine TNF-α promotes Snail stabilization via NF-kB (Wu et al. 2009), while in colorectal 
cancer cells it has been shown that the activation of AKT pathway and inhibition of the GSK-3β-
dependent ubiquitination are required to induce Snail stabilization upon TNF-α treatment (Wang 
et al. 2013). In human prostate and lung cancer cells, EGF induces EMT by promoting Snail 
stability in a process mediated by protein kinase C and the inhibition of GSK-3β activity (Liu et 
al. 2014). The Wnt pathway promotes an Axin2-dependent stabilization of Snail by acting as a 
nucleocytoplasmic chaperone for GSK-3β (Yook et al. 2006).  Data from a human kinome RNA 
interference screen pointed that Snail is also regulated post-transcriptionally by Lats2 kinase, that 
directly phosphorylates Snail in response to multiple signals, including TGF-β (Zhang et al. 
2012). Other microenvironmental cues such as hypoxia or matrix modulators (Imai et al. 2003; 
Radisky et al. 2005) can induce Snail. For example, MMPs through ROS can stimulate the 
expression of Snail (Radisky et al. 2005).  
Given the prominent role of Snail in inducing mesenchymal characteristics, it should be kept at a 
downregulated state in epithelial cells of adult tissues in order to maintain tissue homeostasis. In 
fact, during epithelial differentiation occurring in renal development, Snail is downregulated and 
its re-expression was shown to lead to kidney fibrosis (Boutet et al. 2006). 
 
67 
 
Slug  
Slug (or Snai2) is member of the Snail superfamily. Some authors suggest that a duplication event 
originated Snail and Slug genes (Sefton, Sanchez, and Nieto 1998). Slug was first isolated in chick 
embryos, where it is expressed in neural crest cells delaminating from the neural tube (Nieto et 
al. 1994). Its role in EMT was proposed upon its silencing which results in improper mesoderm 
formation related to defects in cell migration (Nieto et al. 1994). Besides, in vitro overexpression 
of Slug induced changes in morphology, loss of desmosomal cell-cell adhesion structures, looser 
cell contact phenotype while its silencing inhibits EMT induced by FGF or HGF (Savagner, 
Yamada, and Thiery 1997). In epithelial kidney cells, Slug overexpression also induces highly 
migratory behavior and slower proliferation rate (Bolós et al. 2003). Knock-out mice for Slug, 
although viable, exhibit post-natal growth deficiency (Jiang et al. 1998).  
Slug induces shared and specific gene expression patterns, when compared to Snail, upon their 
overexpression in epithelial cells (Moreno-Bueno et al. 2006). Similarly to Snail, Slug binds and 
represses E-cadherin expression (Bolós et al. 2003; Hajra, Chen, and Fearon 2002). The 
expression of other proteins is also directly affected by Slug, such as P-cadherin, that is 
preferentially expressed in the chick embryo epiblast, instead of E-cadherin, and similarly to E-
cadherin in the mouse, is downregulated in the mesoderm and in the neural plate (Acloque et al. 
2017). Slug has a key role in determining mammary cell identity, in a physiological or 
pathological setting, since its expression - together with Sox9 - is able to reprogram normal 
differentiated epithelial cells or non-metastatic cancer cells into stem cells or cancer cells with 
tumor-initiating and metastatic abilities, respectively (Guo et al. 2012). 
Slug is essential for EMT in the heart organogenesis and its expression can be induced by TGF-
β2 (Romano and Runyan 2000). Slug expression is also induced by FGF (Savagner, 1997), Notch 
(Leong et al. 2007), β-catenin, ERK (Conacci-Sorrell et al. 2003) and Wnt (Wu et al. 2012). So, 
Slug upregulation is mainly driven by signaling pathways commonly dysregulated in cancer, 
rather than genetic alterations on the gene itself, although, in humans, deletions of SLUG have 
been associated with Waardenberg syndrome (Sánchez-Martín et al. 2002). Moreover, several 
transcriptional factors and miRs can directly repress Slug expression (Zheng and Kang 2013). 
Slug protein stability is negatively regulated by GSK-3β and β-Trcp, which phosphorylate and 
ubiquitinate Slug, in a process regulated by Wnt signaling (Wu et al. 2012).  
The differential expression of Slug has been observed in several types of cancer such as 
esophageal squamous cell carcinoma (Uchikado et al. 2005). Slug is associated with 
aggressiveness of the tumors (Alves et al. 2009), for example in breast cancer (Chakrabarti et al. 
2012; Guo et al. 2012) and its overexpression leads to the development of mesenchymal cancers 
in mice (Pérez-Mancera et al. 2005). However, Slug expression is not always associated with E-
68 
 
cadherin lost (Alves et al. 2009). Slug role in carcinogenesis is also evident in skin carcinoma 
where it collaborates with Snail in promoting metastasis (Olmeda et al. 2008).  
 
Twist family 
Twist belongs to the helix-loop-helix transcription factor family that includes Twist1 (that will be 
referred as Twist) and Twist2 (Twist-related protein), which are encoded by two genes in 
vertebrates (Barnes and Firulli 2009). Twist is able to induce EMT (Yang et al. 2004) and, like 
Snail, it promotes the cadherin switching, because it not only represses E-cadherin (Vesuna et al. 
2008; Yang et al. 2004), acting in cooperation with the chromatin modifier Bmi1 (Yang et al. 
2010), but also activates N-cadherin (Alexander et al. 2006; Oda, Tsukita, and Takeichi 1998). 
Like the previously mentioned EMT TFs, Twist was first studied in the context of embryogenesis 
and was shown to be essential for mesoderm formation (Simpson 1983), although the phenotype 
of the mutated Drosophila was different than the one expressing mutated Snail (Alberga et al. 
1991). Mutations in TWIST1 are associated with the autosomal dominant Saethre–Chotzen 
syndrome and these patients have a higher predisposition to develop breast cancer (Sahlin et al. 
2007). Twist transcriptional role has, in fact, been highjacked by cancer cells and its expression 
seems to be required for intravasation and metastasis. Specifically, Twist is frequently 
overexpressed in human cancer (Ansieau et al. 2008) and Twist silencing has been shown to 
suppress the capacity of breast cancer cells to form lung metastasis (Yang et al. 2004).  
In mammary epithelial cells, Twist expression is upregulated in response to Wnt1 (Howe et al. 
2003), whereas in the cancer context, Twist expression can be triggered by TGF-β and the HRas 
pathway (Hong et al. 2011). Moreover, TNFα, through the NF-κB pathway, has been shown to 
upregulate Twist and conversely, Twist can regulate cytokine signaling thought a negative 
feedback loop that involves p65 (Šošić et al. 2003). MAPK pathway effectors p38, JNK and 
ERK1/2 can phosphorylate Twist, in this way stabilizing the protein by preventing its 
ubiquitination and consequent degradation (Hong et al. 2011). Not only cytokines and growth 
factors but also other microenvironment signals, such as oxygen availability, can regulate Twist 
expression. In fact, Twist promoter contains a functional HRE, which is the consensus DNA 
sequence for the binding of HIF; therefore, hypoxia can induce EMT through the binding of HIF-
1α in the Twist promoter (Yang et al. 2008). Indeed, Twist was shown to be essential for hypoxia-
induced EMT in hypopharyngeal cancer and breast cancer cell lines, despite the fact that Snail or 
lysyl oxidase are responsible for part of the migration and invasion activity not regulated by Twist 
(Yang et al. 2008).  
Twist also protects cells from Myc-dependent apoptosis, mediates survival after DNA damage-
induced stress, inhibits oncogene-induced senescence in cancer cells and was shown to be 
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important for tumor cell proliferation (Ansieau et al. 2008; Maestro et al. 1999; Qian et al. 2013; 
Shiota et al. 2008; Vichalkovski et al. 2010), although that is not always the case (Yang et al. 
2004). 
 
Zeb family 
Zeb1 and Zeb2 belong to the Zeb family of zinc finger/homeodomain transcription factors. In this 
thesis, I will use the name ZEB1 to refer to the gene that has also been called AREB6 (in humans), 
BZP (in hamster), or δEF1 (in chicken) (GenBankTM accession number U12170) and ZEB2 for 
the gene also known as SIP1 (GenBankTM accession number AB011141). 
Zeb TFs downregulate E-cadherin by direct repressing the transcription of its gene (Comijn et al. 
2001; Grooteclaes and Frisch 2000). Like Snail mutants, Zeb2 mutant embryos maintain E-
cadherin expression in the neural plate and the presumptive neural crest, causing several neural 
crest defects and die after neurulation (Van de Putte et al. 2003). In cancer cells, Zeb2 expression 
induces changes in morphology, invasion and loss of aggregation, together with alterations in the 
expression of several genes that encode adhesion proteins (Vandewalle et al. 2005). As an 
example, Zeb2 was shown to induce P-cadherin expression in the context of chick embryonic 
development and human cancer (Acloque et al. 2017; Vandewalle et al. 2005). Zeb proteins are 
part of the CtBP complex that recruits histone methyltransferases among others, being CtBP 
involved in repression of the CDH1 promoter (Furusawa et al. 1999; Postigo and Dean 1999, 
2000; Shi et al. 2003). Besides, the transcriptional repression by Zeb1 can also be mediated 
through recruitment of other histone modifiers, such as the SWI/SNF chromatin remodeling 
ATPase BRG1 (Sánchez-Tilló et al. 2010). One of the most well studied regulators of Zeb 
expression is the miR200 family, which has been considered a marker for epithelial cells and a 
regulator of EMT (Korpal et al. 2008; Park et al. 2008). 
The expression of Zeb proteins is activated by several signaling pathways like TGF-β (Comijn et 
al. 2001), HRas (Barberà et al. 2004; Shin and Dimitri et al. 2010) and Wnt (Sánchez-Tilló et al. 
2011). Zeb1/2 was found to mediate the transition to a mesenchymal phenotype driven by ERK2 
DEF motif signaling, downstream of Fra1 (Shin, Dimitri et al. 2010). Interestingly, Snail itself 
induces the expression of Zeb1 in cancer and non-transformed epithelial cells, through an increase 
in Zeb2 promoter activity (Guaita et al. 2002).   
Some of the main EMT inducers and effectors, as well as the described alterations in cellular 
phenotype are summarized on fig. 10. 
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Fig. 10: Epithelial to mesenchymal transition (EMT): some inducers, major EMT transcription 
factors and phenotypic alterations.  
 
1.3.3 - When does it occur? 
EMT mainly occurs in 3 different settings: during embryonic development, during the wound 
healing response and fibrosis and in cancer (Fig. 11). The EMT process was firstly studied and it 
is well-characterized in the developmental stages of the embryo and it was later expanded to other 
settings. 
 
Fig. 11: Processes where epithelial to mesenchymal transition has been described. 
 
Elizabeth Hay was one of the researchers who had a strong impact on the study of the “epithelial 
to mesenchymal transformation”, as it was first called. It was known that in the embryo (studies 
on chick embryo development), epithelial cells give rise to mesenchymal cells (Trelstad, Hay, 
and Revel 1967); however, the epithelial phenotype of cells was considered very stable. It was 
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then observed that epithelial cells from tissues explants, that normally do not form mesenchyme, 
when cultured in a gelatin solution of collagen, spread apart, loose their polarity and migrate 
(Greenburg and Hay 1982). Particularly, the heart development was one of the first in vitro 
experimental systems where EMT was studied. The detachment and invasion of myocardium by 
endothelial cells of the atrioventricular canal was studied in the 80s focusing on the role of 
extracellular matrix, having suggested the presence of factors that induce changes in endothelial 
cells (Krug, Mjaatvedt, and Markwald 1987; Runyan and Markwald 1983). Hay early studies also 
concern the mechanism for palate fusion, inspired by findings in the rat reproductive organs where 
EMT plays a role in the remodeling of embryonic tissues (Trelstad et al. 1982) and not only in 
the early embryo. In fact, they first showed that epithelial cells from the medial edge become 
elongated, form filipodia and pseudopodia, lose keratin expression and start expressing vimentin 
suggesting that epithelial to mesenchymal transformation underlies the mechanism of the 
disappearance of the midline epithelial stem (Fitchett and Hay 1989). 
 
EMT in embryonic development 
EMT is a key developmental process. It happens during numerous stages of development and it 
is a reversible process. EMT is essential for the formation of the embryo in several stages such as 
before implantation, during gastrulation and neural crest formation.  Moreover, the differentiation 
events that give rise to the heart and the palate were some of the first models where EMT was 
studied.  
Epithelia is the first tissue to be formed. For example, in amniote vertebrates, the embryo derives 
from an epithelial layer of cells called the epiblast. Then, a second tissue composed of cells with 
the ability to migrate appears as a result of EMT. Interestingly, amphioxus, a chordate ancestor, 
evolutionarily diverged before skeletal tissue was originated and only has epithelial tissue, 
suggesting that ontology repeats phylogeny. The appearance of the mesenchyme reflects the 
generation of motile cells, which are able to move into an extracellular matrix that provides organs 
with shape and strength, supporting the emergence of bigger structures (Hay 2005). 
 
Implantation and placenta formation 
During early embryogenesis, the cells from the outer trophectoderm, after blastocyst migration to 
the uterine cavity, adhere to the uterine wall. These cells undergo EMT enabling them to migrate 
and invade the endometrium, which facilitates the development of connections with the maternal 
blood supply and formation of the placenta (Kokkinos et al. 2010; Sutherland 2003). E-cadherin, 
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a key molecule in EMT regulation plays an important role in both the induction and orientation 
of polarity (Kokkinos et al. 2010). 
 
Gastrulation 
Gastrulation occurs after blastocyst formation and is the developmental stage when the body axes 
are defined and the three germ layers are produced. This occurs in result of the formation of a 
region where cells involute or ingress and of cell movements. In amniote vertebrates, the primitive 
streak forms upon the convergence of epiblast cells at the midline of the epiblast layer. The 
migration (ingression) of mesendodermal precursors through the primitive streak, which 
generates the mesoderm, involves EMT. Then, these mesenchymal cells migrate from the 
primitive streak, occupy different positions along the medio-lateral axis of the embryo and 
differentiate into the mesodermal and endodermal epithelia, presumably through mesenchymal to 
epithelial transition (MET) (Ferrer-vaquer, Viotti, and Hadjantonakis 2010). 
A second round of EMT, undergone by the epithelial mesoderm, is necessary to form the 
definitive mesenchyme that differentiates into specific cell types, such as the vertebras, 
hematopoietic cells, connective tissue of the muscle, palate, pancreatic endocrine cells and cells 
from the reproductive tract (Thiery et al. 2009). 
From invertebrates, like the sea urchin and flies, to Xenopus and mice, there is a sharing of various 
players involved in gastrulation (Thiery et al. 2009). Focusing on mammals, E-cadherin is 
expressed in the cells of the epiblast and then it becomes downregulated in the migrating 
mesoderm cells, where Snail is expressed (Damjanov, Damjanov, and Damsky 1986; Nieto et al. 
1992). Mice deficient in Snail die before birth, exhibiting defects in gastrulation and particularly, 
failing to downregulate E-cadherin (Carver et al. 2001). 
FGF is a key regulator of EMT in mammalian gastrulation. Using primitive streak explants and 
transgenic mice embryos, it was shown that FGF receptor 1 signaling is required for maintenance 
of Snail expression in the late primitive streak and for E-cadherin loss. Importantly, FGF signaling 
also regulates Wnt and β-catenin, two important developmental proteins (Ciruna and Rossant 
2001). On the other hand, FGF also plays a role in mesoderm cell fate determination (Ciruna and 
Rossant 2001).  
Besides being regulated at the transcription level, E-cadherin protein levels are also regulated 
during gastrulation. For example, p38-interacting protein, which binds and activates p38, is 
required for a proper downregulation of E-cadherin during mouse gastrulation, in a FGF receptor 
1/Snail independent way (Zohn et al. 2006). 
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Neural crest formation 
The ectoderm forms from the epiblast during gastrulation and it is the external germ layer in the 
embryo. It originates the nervous system and the epidermis. The neural crest is a group of 
stem/progenitor cells that appears after neurulation in between the surface ectoderm and the 
neuroepithelium of the central nervous system. In contrast to the epidermis, the emergence and 
migration of neural crest cells from the dorsal neural tube involves EMT. Neural crest cells 
originate cells of the peripheral nervous system, bone, cartilage, melanocytes, and also tissues of 
non-neural crest origin, like bone marrow, spleen or cardiac muscle (Zurkirchen and Sommer 
2017). 
During neural crest formation, a complex network of cooperating pathways is responsible for the 
regulation of cell polarity, adhesion and migration (Thiery et al. 2009). The differential expression 
of cadherins or “cadherin switching” is one of the key features in the formation of the neural crest. 
For example, cadherin 6B is required for EMT and mediates de-epithelization through BMP 
signaling (Park and Gumbiner 2010), which simultaneously inhibits N-cadherin expression in the 
dorsal neural tube (Shoval, Ludwig, and Kalcheim 2007). The Wnt pathway, specifically the non-
canonical arm, also plays an important role in neural crest migration (De Calisto et al. 2005; 
Dorsky, Moon, and Raible 1998).  
 
Heart formation 
The heart is the first functioning organ in the embryo and it that arises from multiple (three) 
rounds of EMT/MET. The first round occurs during gastrulation and originates the cardiac 
mesoderm. A secondary EMT happens when endocardial progenitors are formed. Finally, the 
atrioventricular canal and the outflow tract generate the cushion mesenchyme, which is the 
precursor of the cardiac valves, through a third round of EMT (Person, Klewer, and Runyan 
2005). Some authors suggest that this third transition should be designated as endothelial to 
mesenchymal transition (Nieto et al. 2016). Several pathways contribute to the morphogenetic 
program of EMT, particularly TGF-β, BMPs, Notch and ErbB (Brown et al. 1999; Camenisch, 
Molin, et al. 2002; Camenisch, Schroeder, et al. 2002; Luna-Zurita et al. 2010).  
 
Palatogenesis 
During palatal seam disintegration, the final stage of palate development, epithelial cells from the 
palate medial edges are replaced by mesenchymal cells. It has been proposed that this process, 
which happens during palate fusion, one of the critical phases of during palate development, 
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occurs through programmed cell death or EMT or both (Nawshad 2008). The two palate halves 
grow out from the internal surfaces of the maxillary processes and then elongate and ascend to a 
horizontal position above the tongue where they fuse, forming a medial epithelial seam. When a 
single layer of epithelial cells is created, the palatal epithelial seams disintegrates, a phenomenon 
mediated by TGF-β3, Smad4, Snail and Zeb2 signaling. E-cadherin promoter activity was shown 
to be repressed after TGF-β3 treatment, through Smad4 (activated by the Smad-dependent 
pathway), Snail and Zeb2 (activated by Smad-independent pathways) interaction with the CDH1 
promoter (Jalali et al. 2012). TGF-β3 signaling is also essential for other steps of palate fusion 
such as the filopodia formation by epithelial cells prior the contact of the opposing palatal shelves 
(Taya, O’Kane, and Ferguson 1999). 
The study of the role of EMT in palate formation can be of extreme value in a therapeutic 
perspective, since cleft palate (without cleft lip) is a birth defect affecting 6.35/ 10,000 live births 
in the United States of America (Parker et al. 2010). 
 
EMT in wound healing and fibrosis 
From physiology to disease setting, EMT is important during the process of tissue repair upon 
injury to the epithelium and during tissue fibrosis. These processes share several cellular and 
molecular features with EMT. Indeed, growth factors that have been linked to EMT induction in 
vitro are major inflammatory mediators, which are released after injury: TNF-α, TGF-β, nuclear 
factor kappa B subunit 1 (NF-κB), several interleukins are some examples (Suarez‐Carmona et 
al. 2017). 
 
Wound healing 
Upon injury to the epithelial tissue, the restoration of the epithelial layer involves the proliferation 
and migration of epithelial cells surrounding the wound. In the adult skin, after injury, clot 
formation and vasoconstriction to control the bleeding are followed by the inflammatory process, 
in which immune cells infiltrate the wound. Then, the proliferation stage starts, being is 
characterized by re-epithelization, angiogenesis, collagen synthesis and extracellular matrix 
formation. Finally, the tissue remodeling can last for years (Guo and DiPietro 2010). In the wound 
bed, during the proliferation stage, the stratified epithelium has to be regenerated to seal the 
wound; in this process, keratinocytes, which are the main constituent of the epidermis, have to 
undergo changes in their morphology and function. These cells migrate from the edges of the 
wound and this is accompanied by proliferation, stratification and redifferentiation to form an 
intact epithelium (Arnoux et al. 2005). 
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It was first proposed by Arnoux et al. that the alterations experienced by keratinocytes during re-
epithelization are reminiscent of EMT (Arnoux et al. 2005). Keratinocytes start expressing 
different keratins and integrins (Larjava et al. 1993; Paladini et al. 1996), which are molecular 
events described in other types of EMT. Adjacent to the wound, epithelial cells are arranged into 
two spatially different zones: a proliferative hub and a migrating leading edge. Migration and 
proliferation seem to be fairly mutually exclusive as the cells in the migratory front are not 
actively proliferating (Aragona et al. 2017), which is consistent with EMT. Epithelial cells show 
re-localization of E-cadherin (Arnoux et al. 2005) and its downregulation has been observed in 
the basal layer  (Kuwahara et al. 2001). Besides, epithelial cells express mesenchymal markers, 
such as fibroblast-specific protein-1 (FSP-1) and/or vimentin in acute and fibrotic wounds in 
human skin and TNF-α induces EMT in cultured primary human keratinocytes (Yan et al. 2010).  
Slug is a transcription factor that modulates wound re-epithelization. This molecule is expressed 
by migrating keratinocytes in the wound edge and is necessary for their outgrowth in skin explants 
(Savagner et al. 2005). It was also demonstrated that mice lacking Slug show a slower re-
epithelization in excisional wounds and develop non-healing cutaneous ulcers triggered by 
chronic exposure to ultraviolet radiation (Hudson et al. 2009). Moreover, EGFR through ERK5 
upregulates Slug expression in immortalized keratinocytes which is essential for EGF-induced 
re-epithelization (Valerie Arnoux et al. 2008). 
In the final stages of re-epithelialization, keratinocytes regain the epithelial phenotype, with the 
formation of stable intercellular and cell–substrate contacts (desmosome reassembly). For 
example, after the meeting of the epithelial tongue, when migration stops, E-cadherin expression 
is recovered (Kuwahara et al. 2001). 
 
Fibrosis 
I will mainly discuss fibrosis of the lung, liver and kidney, where the EMT hypothesis has been 
more extensively studied. However, since these tissues present distinct tissue architectures, their 
fibrosis program may show unique features. Fibrosis occurs during several chronic diseases and 
ultimately can lead to organ failure and destruction, being a major cause for morbidity and 
mortality. Fibrosis has also been shown to be important for tumorigenesis.  
Fibrosis is characterized by the excessive deposition of connective tissue and is the pathological 
end point in the response to inflammation. The myofibroblasts or activated fibroblasts that appear 
after tissue injury are responsible for the production of extracellular matrix. These cells are 
usually identified by the de novo expression of α-smooth muscle actin (α-SMA) (Hinz et al. 2007), 
although this is not universal (Okada et al. 2000). Depending on the tissue, myofibroblasts can 
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have several origins: they can be derived from quiescent fibroblasts or derived from other cell 
types of mesenchymal origin that reside in the tissue or that come from circulating bone-marrow-
derived progenitor cells. It has also been suggested that, in certain organs, activated fibroblasts 
can originate from the transformation of endothelial or epithelial cells, which undergo endothelial 
to mesenchymal transition or EMT, respectively. Concerning EMT, after the characterization of 
FSP-1 as a marker for fibroblasts allowing the analysis of their distribution in the fibrotic tissue 
and the study of the effects of FSP-1 overexpression in epithelial cells, it was hypothesized that 
fibroblasts in some cases arise, as needed, from the local conversion of epithelium (Strutz et al. 
1995).  
Indeed, part of the evidence that supports the role of EMT in fibrosis comes from the 
histopatological and immunohistochemistry analyses that revealed the presence of mesenchymal 
markers in fibrotic tissues (Díaz et al. 2008; Rastaldi et al. 2002; Xu-Dubois et al. 2014). 
Yamaguchi et al. proposed that fibroblastic foci in idiopathic pulmonary fibrosis, which are a 
hallmark of the disease, are derived from EMT since they are surrounded by alveolar epithelial 
cells and the latter express both epithelial and mesenchymal markers (Yamaguchi et al. 2017). 
TGF-β1 is thought to be a major regulator of fibrosis progression in several tissues. Strategies 
that target the pro-fibrotic roles of this pathways have been highly studied in the last years, with 
a few approaches in clinical trials (reviewed in Walton, Johnson, and Harrison 2017). In vitro 
studies showed that alveolar epithelial cells, hepatocytes and renal tubular epithelial cells undergo 
EMT upon TGF-β treatment (Humphreys et al. 2010; Nitta et al. 2008; Rastaldi et al. 2002; Willis 
et al. 2005; Yamaguchi et al. 2017). In the particular case of liver and lung, MAPK pathway 
seems to be an important mediator of this process (Godoy et al. 2009; Huang et al. 2016; Li et al. 
2017; Nitta et al. 2008). 
In vivo tracing studies emerged with the hope of shedding some light into the contribution of EMT 
to the formation of myofibroblatsts, however different studies have come to different conclusions. 
In the liver and upon inducing fibrosis with carbon tetrachloride, FSP1 positive fibroblasts 
contribute to the progression of liver fibrosis and can be derived from hepatocytes in vivo 
(Michael Zeisberg et al. 2007). On the other hand, a similar study showed that hepatocytes do not 
originate cells positive for type-I collagen nor do they acquire a mesenchymal morphology (Taura 
et al. 2010). The contribution of EMT for the formation of myofibroblasts present during fibrosis 
has also been assessed in the lung using genetic manipulation of mice. Tanjore et al. showed that 
a small subset of fibroblasts is originated from lung epithelium through EMT in bleomycin-
induced lung fibrosis (Tanjore et al. 2009). However, a study using a different lineage labeling 
system showed that epithelial cells originated from two progenitor populations do not generate 
myofibroblasts in the context of pulmonary fibrosis (Rock et al. 2011). In the kidney, Iwano et 
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al. has also shown that a percentage of cells expressing mesenchymal markers can have epithelial 
origin (Iwano et al. 2002), a study that was subsequently supported in more detail by other authors 
(LeBleu et al. 2013). Nevertheless, there is also evidence that pericytes, and not epithelial cells, 
are the main source of myofibroblasts after injuries that lead to interstitial fibrosis (Humphreys et 
al. 2010). 
As such, it is still debatable if EMT is indeed a contributor for the formation of activated 
fibroblasts in fibrosis of several organs (Kriz, Kaissling, and Le Hir 2011; Munker et al. 2017; 
Zeisberg and Duffield 2010). One of the most controversial questions is the necessity, or not, of 
epithelial cells acquiring a migratory potential in order to lead to fibrosis. This is one of the points 
where tissue architecture may be an important factor and may explain the weight of the EMT 
hypothesis in fibrosis of different tissues. 
Interestingly, the knock-out of EMT transcription factors revealed that EMT may play a more 
complex role in fibrosis. Snail, a transcription factor that induces the EMT program (as discussed 
previously) seems have an important role for the transition of renal cells from mesenchymal to 
epithelial during development, by regulating cadherin-16 through hepatocyte nuclear factor-1β 
(HNF-1β) and its reactivation is sufficient to induce fibrosis in vivo (Boutet et al. 2006). A study 
using transgenic mice where the expression of Snail could be traced in vivo and subjected to 
unilateral ureteral obstruction showed that Snail is actually required for the development of renal 
fibrosis by triggering a partial EMT in epithelial cells. However, these epithelial cells maintain 
the integrity of the tubular tissue and do not contribute directly for the myofibroblast pool but 
rather promote it by secreting of signals like TGF-β (Grande et al. 2015). This partial EMT is 
supported by a back-to-back study that also added that the EMT program is associated with a G2 
cell cycle arrest and with alterations in transporter proteins in tubular epithelial cells which require 
Snail and Twist (Lovisa et al. 2015).  
The non-concordant results about the contribution of EMT to the generation of activated 
fibroblasts can be explained by the stringency of the definition of EMT (complete EMT) and the 
possibility of partial EMT. However, in this case, if a “completely mesenchymal” fibroblast 
phenotype is not achieved, the functionality of a partial EMT is still lacking, some authors argue 
(Kriz, Kaissling, and Le Hir 2011). 
Many papers have shown that epithelial cells change their morphology and undergo 
dedifferentiation after injury but it has been very disputed if those changes can be termed EMT. 
The models used are heterogeneous and use a limited number of markers for in vivo tracing. One 
of the problems with in vivo tracing studies is the efficiency and specificity of the Cre expression 
system. The fibroblast markers used are also still debatable (α-SMA versus FSP-1) (Kriz, 
Kaissling, and Le Hir 2011). 
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EMT and cancer 
Carcinomas arise from epithelial cells, the latter being characterized by strong cell-to-cell contacts 
that limit their ability to move and invade, which are eventually lost during cancer progression. 
The EMT program can be reactivated during the metastasis process of carcinomas, especially in 
one of the first steps towards the colonization of the secondary tumor site, when tumor cells detach 
from the primary tumor, migrate and invade the adjacent tissue and intravasate into the vascular 
system. EMT confers tumor cells the ability to migrate and invade, having been proposed to be 
one of the cell-biological programs that enables dissemination (Thiery et al. 2009).  
Several lines of evidence implicate EMT in tumor progression. In 1989, Boyer et al. reported that 
epithelial bladder carcinoma cells cultured in matrixes undergo phenotypic changes characteristic 
of EMT, namely cellular morphology, adhesion and motility (Boyer et al. 1989). The presence of 
mesenchymal traits has been reported in several types of epithelial-derived tumors (Elloul et al. 
2005; Uchikado et al. 2005; Vasko et al. 2007; Yang et al. 2004). Particularly, the expression of 
mesenchymal-associated proteins is seen in cells located at the leading edge of the tumor 
(Brabletz et al. 2001; Prall 2007; Vasko et al. 2007). In transgenic in vivo models of mammary 
tumors, the expression of EMT makers linked to a reporter gene allowed the identification of 
Snail expressing cancer cells in the tumor, being these cells detached from the epithelial islands 
and exhibiting an elongated mesenchymal morphology (Ye et al. 2015). In fact, one of the first 
studies using transgenic mice showing the importance of EMT for metastasis was performed by 
Yang et al., who observed that Twist inhibition suppressed metastasis formation (Yang et al. 
2004). The development of fate tracing techniques was crucial in defining the presence of EMT 
in cancer cells in vivo (Tran et al. 2014; Trimboli et al. 2008). Additionally, the presence of EMT 
markers is associated with metastasis and poor prognosis in esophageal squamous cell carcinoma, 
ovarian, breast cancer, gastric cancer, among others (Elloul et al. 2005; Ryu et al. 2012; Uchikado 
et al. 2005). For example, after analyzing the expression of EMT markers in 1495 breast cancer 
biopsies, it was found that higher E-cadherin expression and lower expression of fibronectin is 
associated with longer survival (Bae et al. 2015). E-cadherin was one of the first proteins to be 
implicated in EMT during tumorigenesis, being associated with cell invasion and tumor 
progression (Frixen et al. 1991; Perl et al. 1998). Cadherins are, indeed, a family of adhesion 
proteins that have a primordial role in carcinoma progression (van Roy 2014). For example, the 
co-expression of E-cadherin and P-cadherin is associated with poor overall survival in breast 
carcinoma (Paredes et al. 2008). 
The tumor microenvironment has a primordial role in inducing EMT. Therefore, EMT is probably 
a focal rather a general event (Nieto et al. 2016). For example, mesenchymal cells generated 
spontaneously in vitro from immortalized human mammary epithelial cells actually arise and are 
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maintained by several factors that function in a paracrine and autocrine manner (Scheel et al. 
2011). Cells present in the tumor stroma, like macrophages, cancer-associated fibroblasts and 
adipocytes can produce signals that induce EMT (Bottai et al. 2016; Lee, Jung, and Koo 2015; 
Rupp et al. 2014; Vellinga et al. 2016; Wyckoff et al. 2004; Yu et al. 2013).  
When does EMT occur during tumorigenesis? The presence of EMT in pre-neoplastic lesions of 
breast and pancreatic cancer suggests that EMT is an early event during tumorigenesis (Harper et 
al. 2016; Hüsemann et al. 2018; Rhim et al. 2012). In breast cancer, a population of cells from 
tissues of early lesions that can be identified even before the detection of primary tumor masses, 
activate an EMT-like response, being characterized by a high expression of Twist and low E-
cadherin expression (Harper et al. 2016). 
 
EMT and metastasis: MET and partial EMT 
EMT was first described as an “epithelial to mesenchymal transformation”; however, with the 
discovery that EMT is a reversible process in development this denomination was changed into 
“epithelial to mesenchymal transition” to better reflect cell plasticity (Nieto et al. 2016).  
The fact that the cancer cells from the metastasis resemble histopathologically the ones from the 
primary tumor, in many cases presenting a well-differentiated, epithelial morphology, and not the 
migratory cells that are thought to be the ones initiating the metastasis process was an apparent 
paradox (Ng 2002; Rubin et al. 2000; Tan et al. 1999). Besides, the presence of cells expressing 
epithelial proteins in invasive or metastatic lesions suggested a lack of a complete transition or a 
reversion of the phenotype (Hashizume et al. 1996; Kartenbeck, Haselmann, and Gassler 2005; 
Mareel et al. 1991). For example, metastases of breast cancer are typically epithelial (Kowalski 
et al., 2003). 
Today we can explain these observations in several ways. One is that EMT is just a mechanism, 
among many others, associated with cancer cell dissemination and metastatic outgrowth 
(Lambert, Pattabiraman, and Weinberg 2017). On the other hand, a complete transition to a 
mesenchymal phenotype in not always required for tumor cell invasion. Perhaps most important 
is the finding that when circulating tumor cells arrive at their destination, they generally undergo 
the reverse process of EMT, denominated MET.  
In a study performed in an in vivo breast cancer model where mammary epithelial cancer cells 
were orthotopically implanted in the mammary fat pads of mice, which analyzed the expression 
of EMT markers in the cells from the primary tumor, the cancer cells in circulation and the cells 
from the metastasis showed that circulating tumor cells upregulate Twist, Snail and αSMA 
compared to the primary cancer cells. Moreover, the expression of these EMT-associated genes 
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was shown to be reversible since the cancer cells from the metastasis and the ones from primary 
tumor show similar levels of expression (LeBleu et al. 2014). 
Numerous in vivo experimental systems have shown that MET is required for actively 
proliferating metastases (Chaffer et al. 2006; Ocaña et al. 2012; Tsai et al. 2012). Ocaña et al. 
demonstrated that Prrx1 (paired-related homeobox transcription factor 1), an EMT inducer in 
embryos and cancer cells that cooperates with Twist, must be downregulated for metastasis to 
occur (Ocaña et al. 2012). Using an inducible reporter system in vivo, Tran et al. showed that 
Snail is expressed in primary breast tumors but then lost in tumor cells that disseminated to the 
bone-marrow and in lung metastases (Tran et al. 2014). The downregulation of Twist is also 
essential for the establishment of macrometastases (Tsai et al. 2012). Moreover, it was also shown 
in a in vivo breast cancer model that forced and prolonged activation of TGF-β signaling impairs 
the formation of lung metastasis showing the importance of a cell being able to downregulate 
TGF-β signaling at certain phases of tumor progression (Giampieri et al. 2009). A prolonged EMT 
signal may indeed be detrimental for the cells. A transient Twist activation in human mammary 
epithelial cells, rather than constitutive, primes a subset of cells for stem-cell-like traits that 
emerge as stable traits after Twist1 deactivation (Schmidt et al. 2015). Interestingly, this short-
term Twist activation permanently alters cell state (Schmidt et al. 2015). Interestingly, some 
evidence points to the fact that when cells undergo MET, they do not return to their original 
epithelial cell state, rather remaining in an intermediate state (Schmidt et al. 2015).  
 
Another interesting concept that may unify the field of EMT is that EMT reflects cell plasticity. 
Some authors propose that a complete transition to a mesenchymal phenotype is not required for 
invasion and metastasis and a graded range of intermediate states may exist (Christiansen and 
Rajasekaran 2006; Kalluri and Weinberg 2009; Nieto 2013).  
In some of the cases where EMT occurs, a “complete” mesenchymal end point is not observed 
but rather a mix of epithelial and mesenchymal markers. This has been reported not only in the 
context of cancer but also wound healing and fibrosis (Valerie Arnoux et al. 2008; Harper et al. 
2016; Pinkas and Leder 2002; Yamaguchi et al. 2017). Cells from early lesions originated in a 
breast cancer transgenic model, besides EMT features, still expressed cytokeratins 8 and 18, 
suggesting that a partial EMT is sufficient for early dissemination, dormancy and metastasis 
formation (Harper et al. 2016). Another aspect that supports the existence of a partial EMT in 
cancer cells is the presence of epithelial and mesenchymal markers in circulating tumor cells (Yu 
et al. 2013). This also reinforces the active role of EMT for dissemination of cancer cells from 
the primary tumor site and intravasation. The retention of epithelial features may bring advantages 
during dissemination, since clusters of tumor cells in circulation exhibit increased metastatic 
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propensity compared to single cells (Aceto et al. 2014). Besides, partial EMT may also be 
advantageous for collective migration of cancer cells during the delamination form the primary 
tumor (Campbell and Casanova 2016).  
 
In 2015, two back-to-back studies analyzed the contribution of EMT to metastasis formation, 
bringing a new insight on the role of EMT in chemoresistance. Fischer et al., built an in vivo 
system where the reporter activation caused by expression of the mesenchymal markers Fsp-1 
and vimentin is irreversible, allowing to monitor EMT by color change, even if cells reversed. 
They showed that primary breast tumors and derived lung metastasis of transgenic or orthotopic 
mouse models are mainly composed of cells that did not activate the expression of Fsp-1 or 
vimentin (Fischer et al. 2015). It was also shown that the number of cells in the metastasis that 
had undergone EMT increased after the mice were treated with cyclophosphamide, a 
chemotherapeutic agent, indicating these cells are more resistant to chemotherapy (Fischer et al. 
2015). Similarly, Zheng et al. showed that loss of Snail or Twist does not block metastasis 
formation in a mice PDAC model, but increases chemotherapy sensitivity (Zheng et al. 2015). 
The authors of both studies concluded that EMT does not significantly contribute to the 
development of lung metastasis. However, different interpretations have been suggested by 
others, who also have pointed some limitations of these studies, especially concerning the markers 
used to trace EMT (Nieto et al. 2016).  
In fact, pathways that regulate EMT are not universal and we still need to further understand 
which EMT effectors are activated in the different cellular contexts. For example, in breast 
tumors, the expression of Snail and Zeb1 rather than Slug is associated with the invasive cells 
(Ye et al. 2015).  
Importantly, some cancers may metastasize without the need for an EMT program, as EMT is not 
the only phenomenon that has been associated with metastasis. Cancer cells can invade and enter 
the vascular system through collective epithelial-cell migration (Giampieri et al. 2009). For 
example, the formation of heterodimers composed of E-cadherin and N-cadherin between  cancer-
associated fibroblasts and cancer cells can mediate the cancer cell invasion (Labernadie et al. 
2017).  
Concluding, although not being a guiding principle for all cancers, evidence supports an important 
contribution of EMT for the formation of metastasis especially in the first steps of the metastatic 
cascade in carcinomas. 
 
EMT and stemness 
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The role of EMT in the acquisition of stem cell properties has become a research area of particular 
interest. Some authors propose that certain epithelial cells that undergo EMT acquire the self-
renewing trait associated with normal tissue stem cells and cancer stem cells (Polyak and 
Weinberg 2009). For example, EMT induced by the overexpression of Twist or Snail or activation 
of the Ras/MAPK signaling pathway is associated with a CD44high/CD24low expression pattern 
that characterizes mammary tumor stem cells and the capability of forming mammospheres, 
which are stem cell-enriched structures (Mani et al. 2008; Morel et al. 2008). In breast cancer, the 
CD44high/CD24low cell population exhibits the expression of epithelial and mesenchymal proteins 
(Goel et al. 2014).  
However, in some instances, stemness and EMT can be uncoupled. In a benign skin tumor model, 
low levels of Twist are required for tumor cell proliferation and tumor stemness through a yet 
unknown mechanism, whereas high levels of Twist1 switch cells into a migratory mode with 
reduced proliferation to promote metastasis (Beck et al. 2015). This suggests that it is not the 
EMT program per se that confers cancer stem cell properties, but these can be attributed to the 
pleiotropic functions of EMT TFs. 
 
Targeting EMT in cancer 
EMT in cancer is associated with progression and drug resistance, two of the greatest challenges 
in oncology. Therefore, EMT has gained increasing interest as a potential therapeutic target, 
especially to overcome cancer drug resistance (Fischer et al. 2015; Zheng et al. 2015). This 
complex process offers several targeting strategies, for example by blocking extracellular 
signaling molecules or EMT signal transduction pathways, such as EMT TFs. Some authors have 
suggested targeting the players in EMT, for example, the cadherin switching, which can be 
achieved by 5-aza-2′-deoxycytidine to restore normal CDH1 promoter methylation patters and E-
cadherin expression (Graff et al. 1995). Alternatively, in lung cancer inflammation-associated 
factors like TGF-β and interleukine-6 contribute to primary and acquired erlotinib (a receptor 
tyrosine kinase inhibitor that acts on EGF receptor) resistance (Yao et al. 2010). However, many 
of the molecules involved in EMT have important roles in physiological processes such as wound 
healing. Moreover, although in the recent years a significant number of studies examining the 
role of EMT in cancer has emerged, the interplay between different signaling pathways that drive 
EMT is more complex than we initially thought. Importantly, targeting cancer cells EMT may be 
a double-edged sword, since inhibiting EMT may promote the colonization of secondary tumor 
sites when they are already disseminated cancer cells. Despite these challenges, there may be 
potential benefits in tempering cancer EMT in combination with existing chemotherapeutic 
agents.  
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2 - GENERAL AIMS AND OBJECTIVES 
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The reprogramming of cellular metabolism is emerging as a key feature of cancer cells after the 
pioneer work of Otto Warburg, who showed that cancer cells display increased aerobic glycolysis. 
Warburg proposed that this metabolic phenotype was due to an impaired mitochondrial 
respiration, although the causes and the tumorigenic effects resulting from the “Warburg effect” 
are still unclear. Therefore, in the first part of this thesis, we set out to understand if a defective 
OXPHOS due to mtDNA mutations impacts cancer cell metabolism - consistent with the 
“Warburg effect”? - and what are the consequences on cancer cell behavior.  
In the second part, we aimed at revealing the metabolic requirements of EMT, taking into 
consideration that EMT and the presence of mesenchymal markers in human tumors are 
associated with increased migration and invasive properties, the latter being key for cancer cell 
dissemination (Fig. 12). The relevance of this part of the thesis is to put forward new, metabolic-
linked mechanisms that control EMT and to deliver metabolic players that are crucial for EMT 
pathways. These players may be candidate targets for cancer therapy, particularly for aggressive 
tumors that often display mesenchymal markers. This metabolic reprogramming can confer 
selective advantage for tumor progression and, therefore, be a source of vulnerability and 
therapeutic opportunity. 
Below, we describe our specific objectives for each part of this work. 
 
PART 1: Metabolic and oncogenic properties of OXPHOS-deficient cells associated with 
mtDNA alterations 
1) Establish cybrid cell lines with defects in OXPHOS caused by a mtDNA mutation (Paper I); 
2) Evaluate the metabolic changes induced by the OXPHOS dysfunction (Paper I); 
3) Assess the consequences of OXPHOS dysfunction on the behavior of cancer cells in vitro and 
in vivo (Paper I); 
 
PART 2: The metabolic requirements of cancer-associated EMT  
1) Investigate the metabolic alterations associated with an in vitro ERK2-driven model of EMT 
(Paper II); 
2) Determine to what extent EMT induction is dependent on such metabolic alterations (Paper 
II); 
3) Characterize the networking between activated metabolic pathways and EMT signaling 
pathways (Paper II). 
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Fig. 12: Aim of part 2 of this thesis: to understand the metabolic requirements of cancer-associated 
EMT. 
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3.1 – PAPER I: OXPHOS Dysfunction Regulates 
Integrin-β1 Modifications and Enhances Cell Motility 
and Migration 
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Abstract
Mitochondria are central organelles for cellularmetabolism. In cancer cells,mitochondrial oxidative phosphorylation (OXPHOS)
dysfunction has been shown to promote migration, invasion, metastization and apoptosis resistance. With the purpose of
analysing the effects of OXPHOS dysfunction in cancer cells and the molecular players involved, we generated cybrid cell lines
harbouring either wild-type (WT) or mutant mitochondrial DNA (mtDNA) [tRNAmut cybrids, which harbour the pathogenic
A3243T mutation in the leucine transfer RNA gene (tRNAleu)]. tRNAmut cybrids exhibited lower oxygen consumption and
higher glucose consumption and lactate production than WT cybrids. tRNAmut cybrids displayed increased motility and
migration capacities, which were associated with altered integrin-β1 N-glycosylation, in particular with higher levels of β-1,6-
N-acetylglucosamine (GlcNAc) branched N-glycans. This integrin-β1 N-glycosylation pattern was correlated with higher levels
of membrane-bound integrin-β1 and also with increased binding to ﬁbronectin. When cultured in vitro, tRNAmut cybrids
presented lower growth rate thanWT cybrids, however, when injected in nudemice, tRNAmut cybrids produced larger tumours
and showed higher metastatic potential than WT cybrids. We conclude that mtDNA-driven OXPHOS dysfunction correlates
with increased motility and migration capacities, through a mechanism that may involve the cross talk between cancer cell
mitochondria and the extracellular matrix.
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Introduction
Metabolic re-wiring, or the ability to adapt cellularmetabolism to
growth, migration and invasion, has gained considerable atten-
tion in the cancer research ﬁeld over the past decade. A cancer,
by deﬁnition a proliferating and ultimately invading and metas-
tasizing cell mass, has different nutritional demands than those
of most adult tissues, which aremainly in a quiescent state (1). A
key feature of the metabolic re-wiring of cancer cells is the high
rate of glucose uptake to meet their increased energetic and bio-
synthetic needs andproduce a full-blown tumour (2). Cancer cells
often display the so-called ‘Warburg effect’, i.e. they convertmost
of the glucose to lactate, rather than metabolizing it through
mitochondrial oxidative phosphorylation (OXPHOS), even in the
presence of oxygen (3,4). This phenomenon sets mitochondrial
activity, in particular OXPHOS, as a central metabolic function
for tumour cells. In fact, OXPHOS activity in tumour cells is still
controversial, as there are arguments supporting a deﬁcient OX-
PHOS in tumourigenesis, and others agreeing with an effective
utilization of OXPHOS by tumour cells (5). An increasingly ac-
cepted notion is that multiple types of tumour bioenergetic sig-
natures occur, ranging from mainly oxidative to exclusively
glycolytic, in which OXPHOS activity is signiﬁcantly reduced (6).
Several mechanisms are able to induce OXPHOS downregula-
tion in cancer, including those associatedwith themicroenviron-
ment (low oxygen tension) and oncogenic pathway activation
[where hypoxia inducible factor-1alpha (HIF-1α) appears as a
key molecule], as well as those related to genetic alterations in
OXPHOS-related genes encoded by thenuclear DNAormitochon-
drial DNA (mtDNA). mtDNA mutations have been detected in a
wide variety of human tumours and, in some instances, asso-
ciated with poor prognosis (7–9). Such mutations are often dele-
terious and result in OXPHOS impairment, thereby altering
mitochondrial bioenergetics and biosynthesis (10). There is com-
pelling evidence thatmtDNAmutations not only lead to OXPHOS
deﬁciency, but also empower cancer cells with enhanced tu-
mourigenic properties, namely increased capacity to migrate,
invade and metastasize (11,12). Nonetheless, there is scant
information about the molecular mechanisms and signalling
pathways that connect mtDNA mutations/OXPHOS deﬁciency
with migration, invasion and metastization. In the process of
migration and invasion, cancer cells bind to molecules of the
extracellular matrix (ECM) through the integrin family of trans-
membrane glycoprotein receptors (13). Integrins are heterodi-
mers composed of α and β subunits and mediate anchorage
and migration of cancer cells over a variety of ECM molecules,
such as collagen, ﬁbronectin, laminin and vitronectin (13).
In this study, we have generated cybrid cancer cell lines
that recapitulate the setting of OXPHOS deﬁciency (caused
by a mtDNA tRNAleu mutation) and normal OXPHOS [with
wild-type (WT) mtDNA]. In comparison with control cells,
OXPHOS-deﬁcient cells displayed increased motility and migra-
tion properties, which were associated with differential glycosy-
lation and membrane localization of integrin-β1, together with
increased expression of ﬁbronectin.
Results
Generation of cybrid cell lines
Cybrid (cytoplasmic hybrid) cell lines are hybrid cells where
the nuclear and mitochondrial genomes are from different
sources (14). Cybrids are a valuable in vitro cellular system for
the study of mitochondrial gene function, because they allow
the comparison of different mtDNA genomes (either WT or mu-
tant) against the same nuclear background.
To create cybrids with OXPHOS dysfunction (hereafter named
tRNAmut cybrids), we fusedmtDNA-depleted cells (143Bρ0 cells),
which were derived from the osteosarcoma cell line 143B, with
platelets harbouring themtDNAA3243Tmutation in the tRNAleu
(UUR) gene, previously described as pathogenic (15). The platelets
were obtained from a patient who was diagnosed with encepha-
lomyopathy and harboured the aforementioned mutation. As
controls, we used cybrids that were generated from the fusion
of 143Bρ0 cells with WT mtDNA platelets, obtained from a
healthy blood donor (hereafter named WT cybrids). The restor-
ation of the expression of the mtDNA-encoded protein cyto-
chrome c oxidase II (COXII) conﬁrms that both WT and tRNAmut
cybrids were successfully generated (Fig. 1A). On the other hand,
143Bρo cells, which lack mtDNA, do not express COXII (Fig. 1A),
but do show expression of the nuclear-encoded mitochondrial
protein succinate dehydrogenase subunit A (SDHA) (Fig. 1B).
As each cell has multiple mtDNA copies, we sequenced the
mtDNA to analyse the proportion of mtDNA-mutant molecules,
also designated as the degree of heteroplasmy. We determined
that tRNAmut cybrids display the A3243T mutation in ∼50% of
mtDNA molecules (Fig. 1C).
CompletemtDNA sequencing of the 143B cell line and the two
cybrids conﬁrmed the absence of mtDNAmutations in 143B and
WT cybrids and that the tRNAmut cybrids only harbour the
A3243T mutation in the tRNAleu (UUR) (data not shown).
tRNAmut cybrids display decreased oxygen consumption
and increased glycolytic rate
than WT cybrids
After generating theWT and tRNAmut cybrids, we evaluated the
metabolic changes induced by the mtDNA mutation, namely at
the level of oxygen consumption (as a measure of OXPHOS func-
tion), aswell as glucose consumption and lactate production (as a
measure of glycolysis). As expected, 143Bρo cells showed almost
no oxygen consumption, while tRNAmut cybrids presented a sig-
niﬁcant decrease in basal oxygen consumption when compared
with WT cybrids (Fig. 2A), conﬁrming that the tRNA mutation
leads to decreased OXPHOS function. Treatment with the com-
plex V inhibitor oligomycin signiﬁcantly decreased oxygen con-
sumption in 143B and WT cybrids, but had no effect in 143Bρ0
(Fig. 2B). tRNAmut cybridswere less sensitive to oligomycin, indi-
cating that these cellsmight have complex V impairment (Fig. 2B).
The treatment with carbonyl cyanide 3 chlorophenylhydrazone
(CCCP), which forces the mitochondria to work at its maximum
respiratory capacity, increased oxygen consumption in 143B, WT
cybrids and tRNAmut cybrids but not in 143Bρ0 (Fig. 2B).
The aforementioned differences in oxygen consumptionwere
mirrored by the glycolytic rate of the cell lines. Glucose and lac-
tate levels were quantiﬁed in the medium at 0 h and after 96 h
of cell culture. Glucose consumption was signiﬁcantly increased
in 143Bρ0 and tRNAmut cybrids when compared with 143B and
WT cybrids, respectively (Fig. 3A). Additionally, we observed
that 143Bρ0 and tRNAmut cybrids produced more lactate when
compared with 143B and WT cybrids, respectively (Fig. 3B).
The combined results of oxygen consumption, glucose con-
sumption and lactate production suggest that themtDNA tRNAmu-
tation leads to OXPHOS dysfunction and a concomitant increase in
glycolytic rate, a phenotype that recapitulates the Warburg effect.
It has been shown that there is a threshold for the positive tu-
mourigenic effects of mtDNA mutations; above this threshold,
there is energetic impairment that prevents tumour growth
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(16). We thus decided to focus our analysis in the tumourigenic
effects of OXPHOS dysfunction using the tRNAmut cybrids that
present 50% of mutation load and compare them with 143B and
WT cybrids that have normal mtDNA. Considering that complete
lack of mtDNA does not occur in human tumours, 143Bρ0 cells
were not further analysed.
Cellular growth and apoptosis are decreased in tRNAmut
cybrids
To address the consequences of OXPHOS dysfunction at the level
of cellular growth,we counted cells over a period of 5 days and ob-
served that tRNAmut cybrids had signiﬁcantly lower growth rates
than WT cybrids and 143B cells (Fig. 4A). This result indicates
that, under optimal growth conditions, cells with OXPHOS deﬁ-
ciency have a decreased growth capacity in comparison with
cells with normal OXPHOS.
Apoptosis was evaluated in the cybrid cell lines after treat-
ment with 50 n staurosporine (STS) [the concentration that
most reﬂected the differences between cell lines (data not
shown)]. By determining the geometric mean of the histogram,
we conﬁrmed that STS induced apoptosis in all cell lines,
although this effect was only statistically signiﬁcant in 143B
(2-fold increase compared with untreated cells). WT cybrids
showed a 1.7-fold increase compared with untreated cells,
while tRNAmut cybrids were the least sensitive to STS (1.15-
fold increase compared with untreated cells) (Fig. 4B and C).
Motility and migration are increased in tRNAmut cybrids
Upon observation of the cell lines under bright ﬁeld microscopy,
there were evident morphological differences between the cell
lines: tRNAmut cybrids presented amore spindle-like phenotype
and reduced cell–cell contacts, when compared with 143B and
WT cybrids (Fig. 5).
Because such morphological differences can denote different
cellular migration and motility capabilities, we assessed the dis-
tance covered by single cells in the plate (motility) and the rate of
closure over time in the wound-healing assay (migration) of
the three cell lines, using time-lapsemicroscopy. In a 14 h period,
tRNAmut cybrids showed signiﬁcantly more individual cell
motility than 143B and WT cybrids: tRNAmut cells, on average,
covered ∼3.3 times the distance of 143B and WT cybrids (Fig. 6A
and B). In addition, the wound-healing assay showed that tRNA-
mut cells had the highest migratory capacity, covering 87% of the
wound in 8 h, comparing with WT cybrids (43% of wound cover-
age) and 143B (35% of wound coverage) (Fig. 6C and D).
tRNAmut cybrids display increased expression
and binding to ﬁbronectin
A fundamental step in cancer cell motility and migration is
the interaction with the surrounding stroma. Cancer cells often
secrete ECM proteins and reshape the surface expression of
cell-matrix interacting molecules, such as integrins, to promote
their capacity to migrate and invade the adjacent tissues (17).
Figure 1. (A) Western blot showing that the mtDNA-encoded protein COXII is present in 143B, WT cybrids and tRNAmut cybrids, but absent in 143Bρ0; (B) the nuclear-
encoded mitochondrial protein SDHA is present in all cell lines. (C) Electropherogram showing a stretch of the leucine tRNA gene in WT (top panel) and tRNAmut
cybrids (lower panel) and highlighting the A3243T point mutation in the tRNAmut cybrids (arrow; electropherogram shows the reverse sequence of leucine transfer
RNA gene).
Figure 2. (A) Basal oxygen consumption in the four cell lines showing that 143Bρ0 has virtually nomitochondrial respiration and that tRNAmut cybrids have signiﬁcantly
lessmitochondrial respiration thanWTcybrids. (B) Sensitivity to respirationmodulators: oligomycin signiﬁcantly decreased oxygen consumption in 143B andWTcybrids
but not in 143Bρ0 or tRNAmut cybrids. Results are representative of at least three independent experiments; error bars are SEM; *P < 0.05; **P < 0.01; ***P < 0.001.
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To test the binding capacity todifferent ECMsubstrates,weper-
formed an adhesion assay by culturing cells in wells coated with
collagen type I, collagen type IV,ﬁbronectin or poly-lysine (positive
control). We observed that tRNAmut cybrids adhered more efﬁ-
ciently to ﬁbronectin than 143B and WT cybrids (Fig. 7A), while
the binding to collagen type I or IV was not signiﬁcantly altered
(Fig. 7B andC, respectively). Furthermore, inwestern-blot (WB) ana-
lysis, tRNAmut cells showed signiﬁcantly increased levels of ﬁbro-
nectin when compared with WT cybrids and 143B (Fig. 8A and B).
tRNAmut cybrids display increased modiﬁcation of
integrin-β1 with β-1,6 GlcNAc branched N-glycans
structures
Considering that tRNAmut cybrids show higher motility, migra-
tion and binding capacity to ﬁbronectin than 143B and WT cy-
brids, we addressed the status of integrin-β1 in the three cell
lines. Integrins are known to play a crucial role in adhesion to
the ECM, thereby contributing to migration, invasion andmetas-
tization of tumour cells (18). Integrin-β1 is one of the major
players in these processes and is known to preferentially bind
to ﬁbronectin after dimerization with integrin-α5 (19).
In theWB analysis, integrin-β1 showed two distinct bands: an
upper bandwith ∼130 kDa and a lower band of ∼115 kDa (Fig. 8A).
Although the overall expression of integrin-β1 did not differ be-
tween the three cell lines (Fig. 8C), there was a clear difference
in the relative intensity of the upper and lower band: while the
parental 143B displayed similar intensity of both bands, the WT
cybrids have more expression of 115 kDa integrin-β1 and tRNA-
mut cybrids were enriched in the 130 kDa band (Fig. 8D). In add-
ition, the integrin-β1 130 kDa band of tRNAmut cybrids also
showed less mobility in the gel than the same band of 143B and
WT cybrids (Fig. 8A).
Figure 3. (A) Glucose consumption and (B) lactate productionwere assessed by quantifying glucose and lactate, respectively, in themediumof cells cultured for 96 h. Both
glucose consumption and lactate production were signiﬁcantly elevated in 143Bρ0 and tRNAmut cybrids when compared with 143B andWT cybrids, respectively. Results
are representative of at least three independent experiments; error bars are SEM; *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 4. (A) Assessment of cell growth and (B and C) apoptosis in vitro. (A) In a period of 96 h, tRNAmut cells showed a slower growth rate than 143B andWT cybrids. (B)
Flow cytometry analysis after incubationwith 50 n STS using terminal deoxynucleotidyl transferase dUTPnick end labeling (TUNEL). Each histogram is representative of
three independent experiments. (C) Quantiﬁcation of TUNEL ﬂuorescence in untreated cells and after STS treatment: tRNAmut cybrids show the lowest response to STS.
Results are representative of at least three independent experiments; error bars are SEM; *P < 0.05; **P < 0.01; ***P < 0.001.
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Glycosylation modiﬁcations have been described to be a key
regulatory mechanism of several cell biology processes, includ-
ing cell adhesion and cell-matrix interaction, particularly affect-
ing the integrin-mediated cellular migration (20,21). Taking into
account that integrin-β1 is modiﬁed by N-glycosylation and
that glycosylation affects the protein mobility in sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, we
characterized the integrin-β1 N-glycosylation proﬁle in each cy-
brid cancer cell lines using twodifferentN-glycosidases: endogly-
cosidase H (Endo H), which is an endoglycosidase that cleaves
within the chitobiose core of high mannose and some hybrid
oligosaccharides from N-linked glycoproteins, and peptide-
N-glycosidase F (PNGase F), which is an amidase that cleaves
between the innermost GlcNAc and asparagine residues of
high mannose, hybrid and complex oligosaccharides from
N-linked glycoproteins. In 143B andWTcybrids, EndoHdigestion
completely converted the 115 kDa band to an 85 kDa band (corre-
sponding to the size of integrin-β1 core protein), while in tRNA-
mut cybrids, Endo H only yielded a faint digestion product
(Fig. 9A). On the other hand, PNGase F digestion converted the
130 and 115 kDa bands to the 85 kDa-sized integrin-β1 in 143B,
WT cybrids and tRNAmut cybrids (Fig. 9A). These results indicate
that, in 143B andWTcells, integrin-β1 ismodiﬁedwith highman-
nose, hybrid and complex type N-glycans, whereas in tRNAmut
cybrids, integrin-β1 is mainly modiﬁed with complex type N-gly-
cans. To determine whether integrin-β1 from tRNAmut cells are
modiﬁed with the β-1,6 GlcNAc branched structures catalysed by
beta1,6 N-acetylglucosaminyltransferase V (GnT-V) enzyme, we
performed integrin-β1 immunoprecipitation followed by β-1,6
GlcNAc branchedN-glycans recognition using the phaseolus vul-
garis leucoagglutinin lectin (L-PHA). The increased L-PHA re-
activity in tRNAmut cybrids, in comparison with 143B and WT
Figure 5. Light microscopy images of 143B (A), WT cybrids (B) and tRNAmut cybrids (C). The tRNAmut cybrids display reduced cell–cell contacts, showing a more
spindle-like morphology than 143B and WT cybrids. Pictures were taken using the 20× objective.
Figure 6. Time-lapse microscopy was used to evaluate motility (distance covered by single cells in a 14 h period; A and B) and migration (wound-healing assay in a 14 h
period; C and D). In (A), the lines show the distance covered by single cells. In (C) the top panel represents the wound at baseline and the bottom panel represents the
wound after 14hrs. tRNAmut cybrids showed signiﬁcantly increased motility and migration when compared with 143B and WT cybrids. Each image is representative
of three independent experiments. Results are representative of at least three independent experiments; error bars are SEM; *P < 0.05; **P < 0.01; ***P < 0.001.
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cells (Fig. 9B and C), demonstrates that tRNAmut cybrids are en-
riched in GnT-V-mediated β-1,6 GlcNAc branched structures
(∼3.5-fold higher than WT cybrids).
tRNAmut cybrids show predominantly integrin-β1
and integrin-α5β1 membrane localization
Wenext assessed whether the differences in integrin-β1 glycosy-
lation had an impact on its sub-cellular localization, as it had
been previously shown (22). Using immunoﬂuorescence staining,
tRNAmut cybrids showed predominantly membrane-localized
integrin-β1, in structures that resembled focal adhesions
(Fig. 10A, upper-right picture). On the other hand, 143B and WT
cybrids (Fig. 10A, upper-left and upper-middle pictures, respect-
ively) showedmostly cytoplasmic staining. To quantify the levels
of membrane-bound integrin-β1, we have used imaging ﬂow
cytometry that enables the quantiﬁcation of proteins in different
cellular compartments. Applying a setting that speciﬁcally quan-
tiﬁes the levels of membrane-localized integrin-β1, we saw
that the tRNAmut cybrids displayed higher levels of mem-
brane-bound integrin-β1 than 143B and WT cybrids (Fig. 11A).
In addition, after categorizing the expression levels of mem-
brane-bound integrin-β1 as low or high (Fig. 11E), we observed
that, in the tRNAmut cybrids, the percentage of cells displaying
strong expression ofmembrane-bound integrin-β1was increased
in comparison with 143B or WT cybrids (Fig. 11B). Conversely,
143B or WT cybrids had a higher percentage of cells displaying
low expression of membrane-bound integrin-β1 than tRNAmut
cybrids (Fig. 11B).
Because integrin-β1 requires dimerization with α subunits for
proper function, we have used the same imaging ﬂow cytometry
analysis to quantify the levels of membrane-bound integrin-
α5β1, the dimer that preferentially binds ﬁbronectin. Similarly
to what we observed for integrin-β1, the levels of membrane-
bound integrin-α5β1 were elevated in tRNAmut cybrids, when
compared with 143B andWT cybrids (Fig. 11C). tRNAmut cybrids
also showed a higher percentage of cells with a higher expression
of membrane-bound integrin-α5β1 and lower percentage of cells
with low expression, when compared with 143B and WT cybrids
(Fig. 11D).
Phenformin, a complex I inhibitor, mimics the effects
of the tRNA mutation
Phenformin is a selective OXPHOS complex I inhibitor (23). We
have tested the effects of phenformin in WT cybrids and
found that it inhibited O2 consumption to a degree similar to
that of oligomycin (Fig. 10C). To evaluate whether phenfor-
min-induced OXPHOS dysfunction in 143B and WT cybrids
had an impact on integrin-β1 localization, we treated cells
with 5 m of phenformin for 1 h and evaluated the effects by
confocal microscopy and imaging ﬂow cytometry. Using
Figure 7. Quantiﬁcation of cell adhesion to ﬁbronectin (A), collagen type I (B) or collagen type IV (C), shown as percentage of adhesion to poly-lysine (positive control).
tRNAmut cybrids adhere more efﬁciently to ﬁbronectin than 143B or WT cybrids, while no differences were observed concerning collagen type I or type IV. Results are
representative of at least three independent experiments; error bars are SEM; *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 8. Western blots showing the expression of ﬁbronectin and integrin-β1. (A) Representative WB showing increased ﬁbronectin expression and enrichment of the
integrin-β1 130 kDa in tRNAmut cybrids. The quantiﬁcation of ﬁbronectin (B), total integrin-β1 (C) and the ratio 130 : 115 kDa bands of integrin-β1 (D) is shown. Results
are representative of at least three independent experiments; error bars are SEM; *P < 0.05; **P < 0.01; ***P < 0.001.
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confocal microscopy, 143B andWT cybrids showedmembrane
re-localization of integrin-β1 with a pattern that closely re-
sembled that of tRNAmut cybrids, whereas phenformin had
little effect on integrin-β1 localization in tRNAmut cybrids
(Fig. 10A, bottom panels). After quantiﬁcation by imaging
ﬂow cytometry, we conﬁrmed that phenformin increased the
levels of membrane-localized integrin-β1 in all cell lines,
although only reaching the level of statistical signiﬁcance
in WT cybrids (Fig. 10B). Such effect was less evident in the
tRNAmut cybrids that intrinsically have OXPHOS dysfunction
and present higher levels of membrane-bound integrin-β1
(Fig. 10B).
tRNAmut cybrids have higher tumourigenic potential
in nude mice than WT cybrids
Taking into consideration that a metabolic defect might have
considerably different effects depending on the microenvi-
ronment, we assessed the tumour-forming capacity of WT and
tRNAmut cybrids in vivo. One million cells were injected in the
Figure 9. (A) Sensitivity to the glycan-cleaving enzymes Endo H (cleaving only high-mannose type glycans) and PNGase F (cleaves all N-linked glycans). 143B andWT, but
not tRNAmut cybridswere sensitive to treatmentwith EndoH,while all cell lineswere sensitive to PNGase F. (B) Integrin-β1 immunoprecipitation followed by β-1,6 GlcNAc
branched N-glycans recognition (using L-PHA lectin). tRNAmut cybrids show signiﬁcantly increased levels of β-1,6 GlcNAc branched N-glycan structures in integrin-β1 in
comparison to WT cybrids (C). Results are representative of at least three independent experiments; error bars are SEM; *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 10. (A) Confocal microscopy using anti-integrin-β1 antibody (red). Untreated 143B andWT cells displayed integrin-β1 expressionmainly localized in the cytoplasm,
while tRNAmut cybrids showed integrin-β1mainly inmembrane protrusions, in structures that resembled focal adhesions (arrow). Further, 5 m phenformin treatment in 143B
andWT cybrids induced an integrin-β1 expression pattern thatmimicked that found in untreated tRNAmut cybrids. Nuclei are stained in blue [4',6-diamidino-2-phenylindole].
Pictures were taken using the 63× objective. (B) Quantiﬁcation of membrane-bound integrin-β1 by imaging ﬂow cytometry in cells treated with 5m phenformin, showing that
the levels of membrane-bound integrin-β1 increase in all cell lines, although only signiﬁcantly in WT cybrids. (C) Phenformin treatment signiﬁcantly reduces oxygen
consumption in WT cybrids. Results are representative of at least three independent experiments; error bars are SEM; *P< 0.05; **P< 0.01; ***P< 0.001.
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dorsal ﬂank of nude mice and tumour growth was monitored for
∼36 days. While tumour formation was observed in all mice in-
jected either with WT or with tRNAmut cybrid cells (except one
mouse injected with the WT cybrid), the tumours derived from
tRNAmut cybrids were signiﬁcantly larger in volume than tu-
mours derived from WT cybrids (Fig. 12A). In addition, we ob-
served metastatic foci in the lungs of 3 of the 14 mice injected
with tRNAmut cybrids, while no animal injectedwithWT cybrids
had lung metastases (data not shown). To further assess the
metastatic potential of WT and tRNAmut cybrids, we repeated
the in vivo tumour-forming capacity experiment, but instead of
sacriﬁcing the animals by Day 36, the tumours were removed
and the mice were kept alive until Day 49 (13 days after tumour
removal) to allow the formation of metastases. After collecting
the lungs of the animals, we performed immunohistochemistry
against vimentin (a marker expressed by WT and tRNAmut cy-
brids) and found that 67% ofmice injected with tRNAmut cybrids
displayed lung metastases, whereas only 33% of mice injected
with WT cybrids had lung metastases (Fig. 12B and C).
Discussion
In his seminal works, Warburg postulated that deﬁcient OXPHOS
was on the origin of tumourigenesis, owing to his consistent ob-
servations of lack of respiration and increased lactate production
in human tumours (3). Because this phenotype persisted even in
the presence of oxygen,Warburg designated it as aerobic glycoly-
sis. Several lines of evidence have conﬁrmed that OXPHOS deﬁ-
ciency is common to many human tumours, although its
functional role in tumour development remains under study.
The consequences of mitochondrial OXPHOS dysfunction in
cancer cells have been addressed by various approaches, namely
chemical inhibition (using OXPHOS-targeted drugs, such as oli-
gomycin, rotenone or phenformin) or genetic manipulation, via
Figure 11. Imaging ﬂow cytometry quantiﬁcation of the membrane-bound integrin-β1 and membrane-bound integrin-α5β1. Graphics (A) and (C) illustrate the mean
expression level of membrane-bound integrin-β1 and membrane-bound integrin-α5β1, which are increased in tRNAmut cybrids when compared with 143B and WT
cybrids. In graphics (B) and (D), we sub-divided the cell population into those with low or those with high expression of membrane-bound integrin-β1 or integrin-α5β1.
tRNAmut cybrids have an increased proportion of cells with high expression levels of membrane-bound integrin-β1 (B) and integrin-α5β1 (D); conversely, 143B and WT
cybrids have increased percentage of cells with low levels of membrane-bound integrin-β1 (B) and integrin-α5β1 (D). Results are representative of at least three
independent experiments; error bars are SEM. For the three cell lines, representative bright-ﬁeld images and the corresponding ﬂuorescent image from the low or
high expression membrane-bound integrin-β1 or integrin-α5β1 cell populations acquired with the imaging ﬂow cytometer are shown in (E). Scale bar 10 μm.
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the introduction of mtDNA mutations (cybrid cell lines). mtDNA
mutations are found in awide variety of cancers, such as colorec-
tal, thyroid, gastric, breast, leukaemia, glioblastoma and prostate
(10,24–28). Manyof suchmutations are deleterious and able to in-
hibit OXPHOS, implying that alterations in mitochondrial bio-
energetics and metabolism have a role in supporting neoplastic
transformation. An interesting ﬁnding is that there is no muta-
tional hotspot within mtDNA; instead, mtDNA mutations are
scattered across themitochondrial genome, spanning all the OX-
PHOS-encoding genes, suggesting that the key target is OXPHOS
function, rather than a speciﬁc gene.
Following the genetic-based strategy, we created a cybrid cell
model, where we engineered cells to have WT mtDNA (WT cy-
brids) or a pathogenic mtDNA mutation (tRNAmut cybrids).
Given the diversity of mtDNA mutations found in human can-
cers, we chose to use a deleterious mutation (A3243T in the leu-
cine tRNA) that clearly induces OXPHOS dysfunction (15). In this
way, our model is well ﬁtted to address the converging outcome
of mtDNA mutations, i.e. OXPHOS dysfunction. In addition, this
mutation occurs in the same nucleotide as the A3243G, which
has already been detected in human cancers (29,30). Our results
showed that tRNAmut cybrids exhibited OXPHOS dysfunction,
because they display loweroxygen consumptionwhen compared
with WT cybrids. This is in line with a previous report showing
that the same germline mutation caused decreased activity of
complexes I, III and IV in the muscle ﬁbres of an encephalomyo-
pathy patient (15). Furthermore, tRNAmut cybrids showed a
metabolic shift towards aerobic glycolysis, as evidenced by the
increased glucose consumption and lactate production. This
cybridmodel thus constitutes a valuable tool to study the pheno-
typic effects of OXPHOS dysfunction.
The inﬂuence of the microenvironment over tumour cell
behaviour is an important aspect for studying the relevance of
altered metabolism in tumourigenesis. When we compared
growth capacity in vitro, tRNAmut cybrids showed slower growth
rate thanWT cybrids. However, when injected in the dorsal ﬂank
of nude mice, tRNAmut cybrids produced larger and faster-
growing tumours. These results are in accordance with previous
studies using cybrid cells (31–33) andﬁt with numerous examples
where the in vivo results diverge from the results obtained in vitro.
It is possible that, within the microenvironment where the cells
are injected, the nutrient availability, presence of ﬁbroblasts
and immune cells may provide growth advantage to OXPHOS-
deﬁcient cells, while optimal in vitro growth conditions beneﬁt
OXPHOS-proﬁcient cells. Moreover, tRNAmut cybrids seem to
be more resistant to the apoptosis inducer STS, a ﬁnding
that could also explain the increased size of the tumours pro-
duced by tRNAmut cybrids in nudemice. Several studies showed
that mtDNA mutations suppress apoptosis in cultured cybrids
(32,33), which is in accordance to the crucial role played by mito-
chondria and the respiratory chain in apoptosis (34).
WT and tRNAmut cybrids showed marked differences con-
cerningmotilityandmigration: tRNAmut cybrids displayedhigher
individual cellmotility (whenplated in lowdensity) andmigration
(wound healing) than WT cybrids. These differences were asso-
ciated with distinct cell morphology: WT cybrids formed colonies
with clear cell–cell interactions, whereas tRNAmut cybrids ap-
peared as individualized (dispersed) cells with few cell–cell
Figure 12. In vivo tumour growth andmetastatic capacity ofWTand tRNAmut cybrids. After injecting in the dorsal ﬂank of nudemice, tRNAmut cybrids gave rise to larger
tumours thanWT cybrids (A). Metastatic potential (B) was assessed by injecting cells in the dorsal ﬂank of nude mice, removing the tumours (∼Day 36) and euthanizing
mice byDay 49. The analysis of thewhole lungs revealed that 67% of the animals injectedwith tRNAmut cells presented lungmetastases, while only 33% of those injected
withWT cybrids showed lungmetastases. (C) Illustration of a lungmetastasis in an animal injectedwith tRNAmut cybrids. Pictureswere takenusing the 10× objective (top
image) and the 40× objective (bottom image).
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contacts. Noteworthily, when injected in nude mice, tRNAmut
cybrids producedmore lungmetastases thanWTcybrids, suggest-
ing that the in vitromigratory capacities of tRNAmut cybrids were
associated with an increased metastatic ability in vivo.
Our results ﬁt with previous ﬁndings suggesting that OXPHOS
dysfunction increases the migratory and metastatic potential
of cancer cells (11,12,33). In some of these studies, reactive oxy-
gen species (ROS) were pointed out as important mediators of
the enhanced migration and metastization of OXPHOS-deﬁcient
tumour cells (12), although the underlying effector molecules
remain to be clariﬁed.
OXPHOS dysfunction has been advanced to modulate the
ECM in a way that promotes cell invasion andmetastatic proper-
ties (35,36). Crucial for migration and invasion, the crosstalk can-
cer cell-stroma ismediated byadhesion proteins,where integrins
play a central role by regulating a diverse array of cellular func-
tions necessary to the initiation, progression and metastization
of solid tumours (18). Surface integrin-β1 promotes cell migration
and invasion by binding to ﬁbronectin in the ECM. In our experi-
ments, tRNAmut cybrids showed both an increased expression
and binding to ﬁbronectin compared with 143B and WT cybrids.
Interestingly, while no signiﬁcant changes were observed in the
total levels of integrin-β1, tRNAmut cybrids consistently exhib-
ited higher levels of the 130 kDa integrin-β1 isoform than 143B
and WT cells.
Integrins are glycoproteins and therefore major carriers
ofN-glycans (sequences of carbohydrates attached to asparagine
residues of the protein). Glycosylation has been described
as a fundamental molecular mechanism affecting the folding,
expression, intracellular trafﬁcking, localization, activity and
half-life of several proteins, both in normal and pathological con-
ditions (37,38). Integrin-β1 is tightly regulated by N-glycosylation.
Indeed, deglycosylation mutants of integrin-β1, or treatment
with the N-glycosylation inhibitor tunicamycin, abolish integ-
rin-β1 transport to the cell surface and its binding to ECM sub-
strates (21). Moreover, aberrant N-glycosylation with increased
expression of β-1,6 GlcNAc branched N-glycans (catalysed by
GnTV enzyme) directsmore integrin-β1 delivery to plasmamem-
brane and promotes ﬁbronectin-based cell migration and inva-
sion (39). Such β-1,6 GlcNAc branched glycans in integrin-α5β1
have been shown to be associated with increased cell spreading
on ﬁbronectin in a context of oncogenic signalling driven by
mutant Ras (40).
Our results show that integrin-β1 N-glycosylation pattern dif-
fers between WT and tRNAmut cybrids, speciﬁcally in the levels
of integrin-β1modiﬁedwith the β-1,6 GlcNAc branchedN-glycans
that were signiﬁcantly elevated in tRNAmut cybrids. In line with
previous reports (39,40), such integrin-β1 N-glycan modiﬁcation
in tRNAmut cybrids may account for their increased binding
to ﬁbronectin, as well as for enhanced motility and migration
capabilities.
Our observation of differential integrin-β1 N-glycosylation
levels between tRNAmut and WT cybrids may be associated
with (i) increased expression or enzymatic activity of GnT-V or
(ii) increased availability of the substrates for N-glycosylation
such as UDP-N-acetylglucosamine (UDP-GlcNAc), promoting an
increased N-glycosylation biosynthetic pathway. The production
of UDP-GlcNAc for N-glycosylation is achieved by the hexosa-
mine biosynthetic pathway, which requires the coordination of
both glucose and glutamine metabolism. Indeed, UDP-GlcNAc
levels have been shown to be critical factors in the production
of β-1,6-branched N-glycans, as they increase the production of
these sugar chains without an increase in GnT-V activity (41).
While our data associate OXPHOS deﬁciency to increased glucose
uptake, it has also been observed that glutamine metabolism is
essential for cancer cells harbouringmtDNAmutations (42). Tak-
ing all this together, we speculate that OXPHOS deﬁciency may
remodel glucose and glutamine metabolism, thereby affecting
the intracellular pool of N-glycosylation substrates and leading
to the modiﬁcation of the N-linked glycosylation of membrane
proteins like integrin-β1. Interestingly, Wellen et al. (43) demon-
strated that glucose availability to the hexosamine pathway reg-
ulates interleukin-3 receptor alpha (IL-3Rα) surface expression in
a N-linked glycosylation-dependent manner. Our ﬁnding on the
association between carbohydratematuration on integrin-β1 and
the glycolytic shift caused by OXPHOS deﬁciency thus support
and extend the results of Wellen et al. (43), strengthening the no-
tion that cellular metabolism can affect signal transduction
through regulation of glycosylation.
Hung et al. (44) had advanced a connection between OXPHOS
deﬁciency and integrin signalling in a model of gastric cancer
cells. Hung et al. (44) used amodel of chemically inducedOXPHOS
dysfunction (using the mitochondrial inhibitors oligomycin
and antimycin A) and proposed that mitochondrial dysfunction
enhances migration through mitochondria-generated ROS-
mediated integrin-β5 expression. We focussed mainly on the ef-
fects elicited by genetically induced OXPHOS dysfunction, but we
also observed that treatment with the mitochondrial complex I
inhibitor phenformin resulted in increased surface expression
of integrin-β1. Our results, combined with those of Hung et al.
(44), suggest that mitochondrial dysfunction is associated with
integrin-mediated cell motility, migration and invasion.
In conclusion, we have built an in vitro cybrid cell model that
recapitulates OXPHOS dysfunction of tumour cells induced by
mtDNAmutations. In this study, we show that OXPHOS dysfunc-
tion has a major impact in the migratory phenotype of cancer
cells in vitro, and that the adhesion glycoprotein integrin-β1
may be behind the mechanism by which the defect in OXPHOS
leads to an increased motility and migration capacity. In add-
ition, when transplanted in nude mice, tRNAmut cybrids display
increased tumourigenic/metastatic potential than WT cybrids.
Materials and Methods
Cell lines
Cell lines were cultured in Dulbecco’s modiﬁed Eagle’s medium
high-glucose supplemented with 10% (v/v) inactivated foetal bo-
vine serum (FBS), 100 units/ml penicillin, 100 µg/ml streptomycin
(all fromGIBCO, Life Technologies, NY, USA) and 50 µg/ml uridine
(Sigma-Aldrich, St. Louis, USA). Cellsweremaintained at 37°C, 5%
CO2 in a humidiﬁed incubator and cultured as a monolayer.
The 143Bρ0 is anmtDNA-depleted cell line, derived from 143B
osteosarcoma cells after transient expression of UL12.5 Herpes
simplex protein (45). Compared with the alternative method of
generating ρ0 cells—long-term exposure to ethidium bromide—
this method of mtDNA depletion has the advantage of selective
degradation, assuring that no alterations are induced in the
nuclear DNA.
Cybrid cell lines were obtained after fusion of 143Bρ0 cells
with human platelets harbouring either WT or mutant mtDNA.
Platelets were isolated from peripheral blood collected in ethyle-
nediaminetetraacetic acid (EDTA) tubes. Whole blood wasmixed
with one-tenth (v/v) of a 10× warm salt solution of citrate (0.15 
NaCl and 0.1  trisodium citrate dehydrated, pH 7.0), and cen-
trifuged for 20 min at 200g. To pellet the platelets, the top
three-fourths of the platelet-rich plasma (supernatant) were cen-
trifuged for 20 min at 1500g. Platelets were resuspended in
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physiological saline (0.15  NaCl, 15 m Tris–HCl, pH 7.4) as pre-
viously described (46).
After isolation, the platelet suspension was centrifuged for
15 min at 1500g and the supernatant discharged. One million
143Bρ0 cells were carefully added to the platelets’ pellet, which
was then centrifuged for 10 min at 180g. The cellular fusion
was achieved when the pellet was resuspended in 0.1 ml of PEG
45% (v/v) and incubated for 1 min. The fusion mixture was then
plated in Petri dishes in different dilutions (1 : 1, 1 : 10 and 1 : 100)
and selection began 48 h later, by removing uridine from the
culture medium. Only the clones that survive and proliferate
after uridine removal were selected.
Western blot analysis
Cells were detached with Versene dissociation solution (GIBCO)
and lysed in RIPA buffer (50 m Tris–HCl, 1% NP-40, 15 m NaCl
and 2 m EDTA, pH 7.5) supplemented with protease (Roche Ap-
plied Science, Penzberg, Germany) and phosphatase inhibitors
(Sigma-Aldrich). Protein extracts (25–100 μg) were denatured, re-
solved in SDS-PAGE gels and then electrotransferred onto a nitro-
cellulose membrane (GE Healthcare, Piscataway, USA) for 2 h at
100 V and 4°C, or alternatively overnight at 30 V and 4°C.
Membranes were blocked for 1 h at room temperature
[in phosphate buffered saline (PBS) containing 0.5% Tween-20
and 5% low-fat dry milk] and incubated with primary antibodies
diluted in blocking solution, according to the manufacturer’s
instructions. The primary antibodies used were the following:
α-tubulin (Sigma-Aldrich); COXII (Mitosciences, Abcam, Cam-
bridge, UK); SDHA (Mitosciences); ﬁbronectin (Santa Cruz, Dallas,
USA); integrin-β1 (BD Transduction Laboratories, San Jose, USA).
Membranes were then washed with PBS-T and incubated with
the suitable horseradish peroxidase conjugated secondary anti-
body. Protein bands were detected by chemiluminescense and
X-ray ﬁlm exposure (GE Healthcare).
Measurement of oxygen consumption
Cells were trypsinized and resuspended in FBS-containing
culture medium. Cells were counted and aliquots containing
5 × 106 cells were further pelleted, resuspended in Krebs buffer
containing 132 mNaCl, 4 mKCl, 1 mCaCl2, 1.2 mNaH2PO4,
1.4 mMgCl2, 6 m glucose and 10 m 4-(2-hydroxyethyl)-1-pi-
perazineethanesulfonic acid and allowed to equilibrate for 5 min
in an oxygen electrode chamber (DW1, Clark electrode, Hansa-
tech, Norfolk, UK), after calibration for dissolved oxygen. After re-
cording the basal rate of oxygen consumption (in nmol/ml/min),
maximum respiration was assessed by adding 2.5 μ CCCP plus
2 μg/ml oligomycin to the reaction medium. Potassium cyanide
(700 μ) was added at the end of the experiment to conﬁrm O2
consumption by mitochondria.
Glucose and lactate quantiﬁcation
Identical cell numbers (104) were plated in 6-well plates and the
medium was collected at 0 h and after 96 h in culture. Glucose
levels present in the conditioned medium after 96 h in culture
were quantiﬁed using the Glucose GOD/PAP Kit (Roche Applied
Science) and subtracted to the initial levels (0 h). Lactate was
quantiﬁed in a similar manner, using the lactic oxidase-peroxid-
ase (LO-POD) enzymatic colorimetric assay (Spinreact, Sant
Esteve de Bas, Spain).
Cell population growth and apoptosis
For cell population growth studies, identical cell numbers (104)
were plated in 6-well plates and cells were counted in 24 h inter-
vals, for 96 h, using a Z Series Particle Count and Size Analyser
(Beckman Coulter, Brea, USA).
The terminal deoxynucleotidyl transferase dUTP nick end la-
beling (TUNEL) assay [‘In situ cell death detection kit, ﬂuorescein’
(RocheApplied Science)] was used to evaluate andquantify apop-
tosis induced by STS. Cellswere treated for 4 hwith three concen-
trations—25, 50 and 100 n—of STS in dimethyl sulfoxide and
the assay was performed according to the manufacturer’s proto-
col. The ﬂuorescencewas detected in the range of 515–565 nm by
ﬂow cytometry (Beckman Coulter). Analysis of the results was
performed in FlowJo software (Tree Star) and the geometric
mean of the curves was calculated. Whenever necessary, a gate
was drawn to exclude unspeciﬁc ﬂuorescence.
Motility and migration
For individual motility assays, cells were plated in low density
(104 cells) in a 12-well plate. After seeding for 24 h, cells were
monitored for 14 h using a Leica DMI 6000B time-lapse micro-
scope (Leica Microsystems, Wetzlar, Germany). The movement
covered by a single cell was quantiﬁed only if the cell was clearly
individualized, remained in the ﬁeld and did not enter division or
apoptosis. For migration (wound healing) assays, cells were pla-
ted in high density (5 × 105 cells), to reach conﬂuence. After seed-
ing for 8 h, the cell monolayer was scratched with a pipette tip,
cell debris was removed by replacing the culture medium and
cells weremonitored in a Leica DMI 6000B time-lapsemicroscope
(Leica Microsystems) using the 10× objective. Migration was de-
ﬁned as the capacity to migrate into the wound and measured
as the percentage of wound coverage through time. For both
assays, images were automatically collected in each ﬁeld every
5 min using LAS AF software (Leica Microsystems) and further
processed using the same software. Appropriate groups of
images corresponding to the same ﬁeld were joined to make
the ﬁlm.
PNGase F and Endo H digestion
Total cell lysates (30 µg) were combined with denaturing buffer
and incubated at 100°C for 10 min. Samples were then digested
with 1 unit of PNGase F or Endo H (New England Biolabs, Ipswich,
USA) overnight at 37°C. The deglycosylated proteins were loaded
in SDS-PAGE gels and immunoblotted with anti-integrin-β1 anti-
body (BD Transduction Laboratories). For controls, samples were
incubated without the enzymes.
Integrin-β1 immunoprecipitation and lectin blot analysis
Equal amounts of total protein (1500 µg) from each cell lysate
were pre-clearedwith protein G-sepharose beads (GE Healthcare)
for 1 h and the supernatant was incubated overnight with 5 µg of
monoclonal antibody against integrin-β1 (BD Transduction La-
boratories). After that, incubation with protein G-sepharose for
2 h was performed and the immune complexes were released
by boiling for 5 min at 95°C in Laemmli buffer. Protein extracts
were resolved in SDS-PAGE gels, electrotransferred onto a nitro-
cellulose membrane (GE Healthcare) for 2 h at 100 V and then
probed with the primary antibody against integrin-β1 (BD Trans-
duction Laboratories). For β-1,6 GlcNAc branched structure ana-
lysis on integrin-β1 immuno-precipitated, membranes were
probed with biotinylated Phaseolus vulgaris leucoagglutinin lectin
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(L-PHA), a lectin that speciﬁcally recognizes the β-1,6 GlcNAc
branched N-glycan structure catalysed byN-acetylglucosaminyl-
transferase V (Vector Laboratories, Burlingame, USA). Protein
bands were detected by chemiluminescense and X-ray ﬁlm ex-
posure (GE Healthcare).
Confocal microscopy
Cells were seeded on top of glass coverslips, ﬁxed with 4% paraf-
ormaldehyde, permeabilized with 0.1% Triton X-100, blocked
with 5% bovine serum albumin (BSA) and incubated 1 h at room
temperature with integrin-β1 antibody (Abcam). Alexa ﬂuor 488
(Invitrogen, Life Technologies, NY, USA) was used as secondary
antibody. Images were acquired on a Leica TCS SP5II confocal
microscope (Leica Microsystems) using a Plan-Apochromat 63×
oil objective. Images were processed using the LAS AF software
(Leica Microsystems). Background noise wasminimal when opti-
mal gain/offset settings for the detectors were used. Digital
images were optimized for contrast and brightness using Adobe
Photoshop (Adobe Systems, San Jose, USA).
Adhesion assay
Cell adhesion assay was performed in 96-well plates, previously
coated with ﬁbronectin, type-I or type-IV collagen (all from
Sigma-Aldrich) (5 µg/ml) overnight at 4°C. Plates were washed
three times in PBS and non-speciﬁc-binding sites were blocked
by adding 0.5% BSA (w/v) in PBS containing Pen/Strep for 2 h at
37°C. A total volume of 100 µl serum-free medium, containing
106 cells/ml, was plated in coated wells for 30 min, after which
plates were washed with PBS to remove non-adherent cells,
and the attached cells were ﬁxed with acetone :methanol (1 : 1)
for 10 min at 4°C. Cell adhesion was determined following the
colorimetric method described by Busk et al. (47). The absorbance
was measured at 570 nm with a microplate reader. The attach-
ment of cells to wells coated with 1 mg/ml of poly--Lys and
ﬁxed with 4% paraformaldehyde before aspiration was deﬁned
as 100% of adhesion.
Imaging ﬂow cytometry
To characterize the integrin-β1 and integrin-α5β1 distribution by
imaging ﬂow cytometry, 106 cells were seeded for 24 h, detached
with Versene (GIBCO) and processed as live cells in suspension.
Cells were incubated with integrin-β1 (Abcam) and integrin-
α5β1 (Merck Millipore, Billerica, USA) antibodies for 1 h at room
temperature. Alexaﬂuor 488 (Invitrogen) was used as the second-
ary antibody. Samples were analysed in the imaging ﬂow cyt-
ometer (ImageStream®, Amnis, EDM Millipore), using a 488 nm
excitation laser. All images were captured with the 40× objective
(image pixel 0.5 μm2) using the INSPIRE software (Amnis, EDM
Millipore), acquiring at least 10 000 events.
Data were analysed using the IDEAS® software (Amnis, EDM
Millipore, version 6.0.348) using only the single cell events. For
the quantiﬁcation of the ﬂuorescence intensity of the labelled
integrin-β1/integrin-α5β1 in the plasma membrane, a mask ﬁt-
ting the plasma membrane was built using the corresponding
bright-ﬁeld image, and ﬂuorescence intensity was quantiﬁed
within this region of interest.
Phenformin treatments
The effect of phenformin (Sigma-Aldrich) over respiration was
evaluated by adding 5 m phenformin before CCCP or oligomy-
cin in oxygen consumption experiments described above. For
confocal microscopy or imaging ﬂow cytometry, 5 m phenfor-
minwas added 1 h before ﬁxation or cell harvesting, respectively.
Xenografts
All the procedures were carried out in accordancewith the Guide-
lines for the Care and Use of Laboratory Animals, directive 86/609/
EEC. N:NIH(s)II:nu/nu nude mice were subcutaneously injec-
ted in the dorsal ﬂanks with 106 cells of WT or tRNAmut cybrids.
Mouse weight and tumour width and length were measured
with callipers every week. Excised tumours and lungs (to assess
the presence of metastases) were ﬁxed with 4% neutral buffered
formalin and parafﬁn-embedded. The presence of lung metasta-
seswas evaluated by immunohistochemistry using anti-vimentin
monoclonal antibody (DAKO, Glostrup, USA), and the streptavi-
din–biotin–horseradish peroxidase technique.
Statistical analysis
Statistical analysis was performed using GraphPad software
(GraphPad Software Inc., La Jolla, USA), using Student’s t-test or
two-way ANOVA with Tukey post hoc test. Differences were con-
sidered statistically signiﬁcant when P < 0.05 (*P < 0.05; **P < 0.01;
***P < 0.001).
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Abstract 
Most cancer-associated deaths are associated with metastasis. In epithelial cell-derived cancers, 
the formation of metastasis has been associated with transdifferentiation towards a mesenchymal 
phenotype, i.e. epithelial to mesenchymal transition (EMT). It is therefore crucial to have a 
detailed picture of the processes that govern EMT. Our interest has been directed to studying the 
metabolic reprogramming that occurs during EMT, a topic that is still widely unknown. To be 
able to perform a temporal characterization of the EMT process, we have created an inducible 
system where a non-tumorigenic mammary epithelial cell line (MCF10A) expresses a mutated 
form of ERK2 (D319N mutation), which was previously shown by our group to shift the ERK 
substrate preference and promote EMT. We have characterized the metabolism of these cells 
primed for EMT using metabolomics, revealing that, during EMT, cells undergo metabolic 
reprogramming, showing significant differences when compared with epithelial cells. Among 
these, cells undergoing EMT showed increasing levels of a metabolite, UDP-glucose, which 
comes from a non-classical and less explored glucose metabolic pathway. Moreover, these cells 
showed upregulation of the enzyme that catalyzes UDP-glucose production, UGP2, not only in 
the ERK2-driven system but also in other EMT models such as those driven by Ras, and TGF-β 
alone or plus TNF-α. Subsequent analyses showed that the expression of UGP2 is required for 
the EMT process in ERK2-driven system. UDP-glucose can integrate several pathways such as 
the production of UDP-glucuronate. This product of UDP-glucose, along with UDP-N-
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acetylglucosamine (UDP-GlcNAc), the end-product of the hexosamine biosynthetic pathway, are 
also increased in cells undergoing EMT. Both UDP-glucuronate and UDP-GlcNAc are precursors 
of key molecules in migration and invasion of cells, including hyaluronan, which may be a key 
modulator of EMT. Taken together, our results show that UGP2 and the UDP-glucose pathway 
are associated with a EMT in a ERK2-D319N mammary model. 
 
Introduction  
Cancer cells undergo a metabolic reprogramming (Hanahan and Weinberg 2011). Metabolic re-
wiring, which is considered today as a hallmark of cancer, was first explored by Warburg almost 
a century ago (Otto Warburg 1925) and arises from genetic alterations and from changes in 
oncogenic signaling, having an important role in tumorigenesis. Recent breakthroughs in cancer 
metabolism have shown that cancer cells have increased uptake of not only of glucose, but also 
amino acids such as glutamine, serine and glycine, while showing changes in the TCA cycle, 
oxidative phosphorylation and lipid metabolism, just to name a few (DeBerardinis and Thompson 
2012; Vander Heiden, Cantley, and Thompson 2009). These studies revealed a robust picture of 
the metabolic needs of cell proliferation. However, less in known about the metabolic alterations 
associated with the formation of metastasis. Therefore, a key challenge is to understand the 
metabolic reprogramming of cancer cells during the acquisition of migratory and invasive 
features. 
Epithelial to mesenchymal transition (EMT) is a process that occurs during development, in which 
epithelial cells lose their apico-basal polarity, reduce cell-cell contacts and acquire mesenchymal 
characteristics, namely fibroblast-like morphology and increased motility and invasion (M 
Angela Nieto 2013). This process has been shown to be recapitulated in some pathological 
conditions such as tissue fibrosis and cancer. In the latter, epithelial cell plasticity has also been 
associated with the acquisition of migratory and invasive properties and chemoresistance  (Fischer 
et al. 2015; Nieto 2013). This cell plasticity is orchestrated by several transcription factors, like 
Snail, Slug, Zeb1 or Twist, that are responsible for the downregulation of epithelial proteins, such 
as E-cadherin, a key cell-cell adhesion protein, and upregulation of mesenchymal proteins (Thiery 
et al. 2009). One of the key features of EMT is the acquisition of migratory and invasive 
properties. It reflects changes in the expression of several cytoskeleton proteins such as vimentin, 
adhesion proteins such as E-cadherin and N-cadherin and secreted or shed proteins that modulate 
the extracellular microenvironment like fibronectin, collagen and metalloproteinases. Many of 
these molecules are glycosylated, a post-translation modification that regulates the localization 
and activity of proteins. Hyaluronan (or hyaluronic acid; HA) is one of the most abundant 
glycosaminoglycans of the extracellular matrix, organizing and maintaining its structural 
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integrity, that has been associated with tumor progression and aggressiveness (Toole 2004). This 
polymer is formed from products of the uridine diphosphate (UDP)-glucose and hexosamine 
biosynthesis pathways. By interacting with other proteins, such as cell membrane receptors, it can 
also function as a signaling molecule (Toole 2004). However, the role of HA in tumor progression 
is not clear because of the several functions of HA which depend on several factors such as its 
length, localization and its physical properties (Evanko and Wight 1999; Stern, Asari, and 
Sugahara 2006). On the other hand, the amount of HA and its length are also result of the balance 
of the enzymes that synthesize and degrade the molecule.  
EMT can be triggered by several extracellular cues, such as TGF-β (Transforming Growth Factor-
β), HGF (Hepatocyte Growth Factor), EGF (Epidermal Growth Factor), FGF (Fibroblast Growth 
factor), Notch/Jagged or phenomena like hypoxia (Thiery et al. 2009). ERK (Extracellular-signal 
Regulated Kinase), a Ras/MAPK (Mitogen-Activated Protein Kinase) pathway effector, has been 
shown to be at the cross-roads of several EMT inducers including TGF-β, HGF, EFG and FGF 
(Buonato and Lazzara 2014; Gonzalez and Medici 2014; Xie et al. 2004; Zhang et al. 2012). 
Previously, our group contributed with key findings on the ERK signaling that regulates EMT. 
We demonstrated that the D319N mutation in the CD (common docking) motif of active ERK2 
promotes EMT (Shin, Dimitri et al. 2010) (Fig. 1). This point mutation does not affect the overall 
kinase activity but shifts the ERK substrate preference to DEF motif-containing substrates. 
 
                         
Fig. 1: ERK2 induces epithelial to mesenchymal transition via DEF motif-dependent signaling 
events (based on Shin and Blenis 2010). 
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In the current study, focused on understanding the metabolic requirements of EMT using our 
previously characterized ERK2-driven EMT model. Our goal was to define the metabolic 
landscape of the ERK2-DN cells as they undergo EMT, and then determine how metabolic 
pathways contribute to EMT. Our hypothesis is that cells reprogram their metabolism when they 
undergo EMT to support their migratory and invasive phenotype. 
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Material and Methods 
 
Materials 
All the materials used in this study are listed in the supplementary tables 1 to 9.  
 
Cell lines and cell culture 
MCF10A cells were acquired from ATCC. These cells and its derivatives were maintained in 
Dulbecco's Modification of Eagle's Medium (DMEM) / Ham's F-12 50/50 Mix containing L-
glutamine and 15 mM HEPES (Corning) supplemented with 5% horse serum, 20ng/mL EGF, 
100ng/mL cholera toxin, 0.5µg /mL hydrocortisone and 10μg/mL insulin in a humidified 
incubator at 37ºC and 5% CO2 and cultured according to Debnath et al. (Debnath, Muthuswamy, 
and Brugge 2003).   
Stable cell lines overexpressing ERK2 were made by infecting MCF10A cells with tetracyclin 
(Tet) ON -inducible lentiviral plasmids either with a selectable marker for neomycin or 
puromycin. In the majority of the experiments, we used a construct containing a neomycin 
resistance gene, pINDUCER plasmid, containing the sequence for GFP (control) or for the rat 
HA-tagged ERK2 – wild-type (WT) or with an Y261A or D319N mutation. The rat HA-tagged 
ERK2 with a Y261A or D319N mutation was also cloned to an pTRIPZ plasmid (contains a 
puromycin resistance gene). These cell lines were named GFP (pINDUCER control), empty 
vector (pTRIPZ control), ERK2-WT, ERK2-YA and ERK2-DN cells.  
Stable cell lines with UGP2 knock-down were obtained by infecting GFP control or ERK2-DN 
cells with the pRRL-Lenti-miRE-Ren713 plasmid containing shRNAmir against UGP2, 
according to the protocol on the “shRNAmir system” section. The expression was induced with 
0.5µg/mL of doxycycline (DOX) (Calbiochem).  
Cell lines overexpressing UGP2 isoforms were made by infecting MCF10A cells with the 
pCW57.1 plasmid containing the sequences of UGP2 isoform 1 or UGP2 isoform 2 (see 
“Gateway cloning” section for the details on the plasmids production). The expression was 
induced with 0.5µg/mL of DOX. 
Cell lines expressing shRNA sequences against the HAS2 gene were made by infecting GFP 
control or ERK2-DN cells with the pLKO.1 plasmid with the shRNA sequences. 
Cells containing the pINDUCER construct (ERK2 and RasV12 expression) were maintained in 
media with 300µg/mL G418 (the selection agent in eukaryotic cells containing the neomycin 
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phosphotransferase gene). On the other hand, the cells containing pTRIPZ (ERK2 expression), 
pRRL-Lenti-miRE-Ren713 (shRNAmir), pCW57.1 (UGP2 expression) or pLKO.1 (shHAS2) 
constructs were cultured in media with 2µg/mL puromycin. 
Assay media used in the migration and invasion assays using transwells is the same media used 
for MCF10A cells but without EGF or insulin and with only 2% horse serum.  
HEK-293T, used to generate virus, were obtained from GenHunter (Q401) and cultured in 
DMEM, high glucose (Gibco) supplemented with 10% fetal bovine serum (FBS) (Sigma-
Aldrich).  
All the cells lines were not kept in culture for more than 3 weeks.  
 
AZD6244 treatment 
GFP control, ERK2 WT and DN cells were treated with DOX for 7 days and on day 5 were plated 
on 6-well plates. On day 7, cells were treated with 1µM or 2µM of AZD6244 or the vehicle 
control dimethyl sulfoxide (DMSO) for 4h. After the incubation period, lysates were collected 
and run as described in the “Western Blotting” section. 
 
shRNAmir system 
shRNAmir technology was used to knock-down the UGP2 gene (Dickins et al. 2005; Stegmeier 
et al. 2005; Zeng, Cai, and Cullen 2005; Zeng, Wagner, and Cullen 2002). We used the protocol 
established by Dow, Premsrirut and Zuberet et al. (Dow et al. 2012)(Dow, Premsrirut and Zuberet 
et al. 2012) and the pRRL-Lenti-miRE-Ren713 plasmid (Fellmann et al. 2013). 
The 97mer were designed using splashRNA.mskcc.org and ordered through Invitrogen (table 9). 
We designed 10 oligonucleotides for the UGP2 gene. The PCR cloning of the shRNAs was 
performed using the high-fidelity polymerase “Platinum™ Pfx DNA Polymerase” (Invitrogen) 
and the PCR product was run on an agarose gel. After confirming the presence of a band in the 
expected size (131 base pairs), the remaining product was isolated using the “E.Z.N.A.® Cycle 
Pure Kit (V-spin)” (Omega). The ligation reaction was performed using “T4 DNA Ligase” (New 
England BioLabs) and each previously digested fragment was ligated to the Tet-ON inducible 
plasmid (similarly digested) pRRL-Lenti-miRE-Ren713 (Fellmann et al. 2013). After bacterial 
transformation, 4 colonies per ligation reaction product were purified using “PureLink™ Quick 
Plasmid Miniprep Kit” (Invitrogen) and sequenced. A product with a correct sequence was 
selected per sequence of shRNA and transfected into HEK-293T cells to produce virus to 
subsequently infect MCF10A + ERK2 DN and control cells. The knock-down efficiency of each 
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shRNA was assessed by Western blotting and from the total of 10 sequences tested, the 2 
constructs that achieved higher knock-down were selected. Cells infected with the plasmid pRRL-
Lenti-miRE-Ren713 targeting Renilla luciferase 713 (shRen) were used as control. 
 
shRNA 
A total of 8 sequences were tested and the 3 constructs that achieved higher knock-down were 
selected. shRNA constructs were from the RNAi Consortium (TRC) at the Broad Institute: shGFP 
(TRCN0000072181), shHAS2 #1 (TRCN0000045393, targeting CDS) shHAS2 #6 
(TRCN0000045396, targeting CDS) and shHAS2 #8 (TRCN0000418983, targeting CDS) in a 
pLKO.1 backbone. 
 
Gateway cloning 
The Gateway technology (Hartley, Temple, and Brasch 2000) was used to produce the expression 
plasmids of both isoforms of UGP2 with the goal of overexpressing them in MCF10A cells. Two 
constructs containing the sequence of the open reading frame of both UGP2 isoforms was 
commercially available: the attB expression clone pOTB7 that has the sequence for UGP2 
isoform 2 and the entry clone pENTR223 that contains the sequence for the isoform 1 of UGP2. 
First, the entry clone for pOTB7 UGP2 was generated by performing the BP recombination 
reaction (attB × attP recombination, where “attB” stands for recombination attachment sites in 
bacteria and “attP” stands for such sites in phage) using the “Gateway™ BP Clonase™ II Enzyme 
mix” (Invitrogen) and the pDONR vector (containing attP sites). A positive control vector was 
used to monitor the efficiency of the reaction. The products of this reaction were amplified by 
transforming competent E. coli bacteria with 2µL of each product. Independent colonies for each 
clone were isolated and the plasmid DNA was purified using “PureLink™ Quick Plasmid 
Miniprep Kit” (Invitrogen) according to product’s manual. To confirm the sequence, the 
expression clones were sequenced. Subsequently, both entry clones, the one originated from 
pOTB.7 and the pENTR223 – together with the control pENTRY-GFP (Addgene; 15301) were 
transferred into the pCW57.1 lentiviral TetON-inducible puromycin-resistant destination vector 
(Addgene; 41393) by LR recombination reaction (attL × attR recombination, where “L” = “left” 
and “R” = “right”). This was achieved using the “Gateway™ LR Clonase™ II Enzyme mix” (Life 
Technologies; 11791-100). The products of this reaction – the expression clones - were amplified 
by transforming competent E. coli bacteria with 2µL of each product. Independent colonies for 
each construct were isolated and the plasmid DNA was purified using the same miniprep kit, 
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according to product’s manual. To confirm the sequence, the expression clones were sequenced. 
Virus containing the expression plasmids were produced and used to infect MCF10A cells. 
 
Plasmids and generation of stable cells 
HEK-293T cells were used to generate lentivirus. Cells were plated in 6-well plates coated with 
a solution of 0.2% gelatin (in 1x phosphate-buffered saline [PBS]) in order to reach approximately 
70-80% density on the day of the transfection. Then, plasmids were transfected into HEK-293T 
cells using Lipofectamine® 2000 Transfection Reagent (Invitrogen by ThermoFisher Scientific; 
11668019) with the lentiviral expression plasmids for packaging (Δ8.9) and envelope (VSV-G), 
and medium was changed the next day, using media with 20% FBS. When producing virus 
carrying the shRNAmir, a shRNA targeting Pasha was co-transfected to enhance virus titer 
(Chang et al. 2013). After 48h, virus-containing supernatants were collected and new medium 
with 20% FBS was added. Additional virus-containing supernatants were collected after another 
48h and the total supernatant was filtered using 0.45µm filters. 
Cells were plated in order to reach about 50% density on the following day. Cells were infected 
with virus-containing supernatants in the presence of a serum-containing medium (ratio 1:1) 
supplemented with 8 µg/mL polybrene. Virus-containing medium was removed after 24h and 
cells were grown in serum-containing medium for another day. Cells were then treated with 
puromycin (2µg/mL) or G418 (300µg/mL) for selection. A “kill plate” with non-infected cells 
was used to monitor the antibiotic efficacy (the selection was only considered completed when 
there are no live cells in the “kill plate”). The knockdown efficiency was confirmed by 
immunoblot analysis. 
 
EMT models 
MCF10A cells infected with the TetON inducible lentiviral pINDUCER ERK2-WT, ERK2-YA 
and ERK2-DN constructs or infected with the TetON inducible lentiviral pTRIPZ ERK2-YA and 
ERK2-DN constructs were plated at a cell density of approximately 1.7 x 104 cells/cm2 on day -
1. After 24h (on day 0), the cell media was replenished and treatment with DOX at a final 
concentration of 0.5µg/mL was started and performed every 24h. The morphology of cells was 
monitored every day using a bright field microscope. Cells were trypsinized and re-plated every 
other day (days 1, 3, 5 and 7) and media was replenished (containing fresh DOX) on the day in 
between. On days 0, 1, 3, 5, 7 and 9 cells were at an approximate density of 80% and data was 
collected. The same protocol was used for MCF10A expressing pINDUCER HRAS G12V.  
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MCF10A cells were plated at a cell density of 1.7 x 104 cells/cm2 and treated with 5ng/mL TGF-
β (PeproTech) or 5ng/mL TGF-β and 5ng/mL TNF-α (Tumor Necrosis Factor-α) (PeproTech) on 
day 0. The morphology of cells was monitored every day using a bright field microscope. Cells 
were trypsinized and re-plated every other day (days 2, 4, 6, 8 and 10) and media was replenished 
(containing TGF-β or TGF-β and TNF-α) on the day in between. On days 0, 2, 4, 6, 8 and 10 cells 
were at an approximate density of 80% and data was collected. 
 
Migration and invasion 
Migration - wound healing assay 
Cells were plated in 12-well plates in order to reach a confluent monolayer after 48h, on timepoint 
day. The cell monolayer of each well was scraped in a straight line to create a “scratch” with a 
p200 pipet tip. It was important that each scratch has a similar width. In In order to remove the 
debris and smooth the edge of the scratch, cells were washed once with growth medium and then 
fresh media was added. The time-lapse microscopy was performed using a Nikon Eclipse Ti-E 
microscope (Nikon) that has the NIS-Elements software (Nikon). The tissue plate was placed in 
the pre-heated cell incubator at 37°C and the fields to be monitored over time selected. Pictures 
were acquired every 5min. for 12h with an amplification of 10x. The area of the wound in (µm2) 
was measured in several timepoints. The biological replicates were averaged and normalized to 
the area of the wound on t=0 of each condition. Migration was defined as the capacity to migrate 
into the wound and measured as the percentage of wound closure through time. 
Migration assay using transwells 
Before plating the cells, the transwells “Transparent PEM Membrane 24-well 8.0 µm pore size” 
(VWR) were placed on the wells of a 24-well plate and the top of the membrane was blocked for 
1h at 37ºC using assay media. Cells (5 × 104 in 250μL of assay media) were added to the top 
chamber of the transwells and 600 µL of Assay media + 5ng/mL EGF was added to the bottom 
chamber of the well. The cells were allowed to migrate through the membrane for 6h or 12h 
(shUGP2 and shHAS2). After the desired time, the viability of cells was confirmed using a 
microscope, the cells from the top side of the membrane were removed and the cells that migrated 
the lower surface of the membrane were fixed using 100% ethanol for 10min at room temperature 
(RT). Cells were then stained using a solution of 0.2% crystal violet (in 2% ethanol) for 10min at 
RT. Migration was accessed using an inverted microscope and pictures with a 4x objective were 
taken.  
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Invasion assay using transwells 
The invasion assay using transwells was performed as described in the migration assay but using 
transwells coated with Basement Membrane Extract (BME) prepared from “Cultrex® 5x BME 
Solution” (Trevigen) in filtered ddH20 or available commercially precoated transwells “Matrigel® 
Invasion Chamber 24-well Plate 8.0 Micron” (Corning). The transwells either coated with BME 
or Matrigel® were rehydrated before use for 2h at 37ºC with assay media. In the bottom chamber 
of the well, 600µL of Assay media + 20ng/mL EGF was added and the cells were allowed to 
invade for 22h or 24h (shUGP2). 
 
Immunofluorescence 
Cells were plated in coverslips placed into 6-well plates. On the day of the timepoint, cells were 
washed with 1x PBS, fixed using 4% formaldehyde (in 1xPBS) for 10min at RT. Cells were rinsed 
four times in 1x PBS and blocked for 10min with a solution of 3% bovine serum albumin (in 1x 
PBS). The primary antibody for E-cadherin (BD Transduction Laboratories, 610181) was diluted 
1:50 in the blocking solution and incubated for 2h at RT. Negative controls, where the primary 
antibody was not added, were included in the experiment in order to control for non-specific 
staining of the secondary antibody. After rinsing the coverslips four times in 1x PBS, the cells 
were incubated with the secondary antibody conjugated to a fluorochrome “Alexa Fluor 488 goat 
anti-mouse IgG (H+L)” (Thermo Fisher Scientific) diluted 1:1000 in blocking solution for 2h at 
RT. After rinsing the cells three times with 1x PBS, the nucleus was counterstained using 
“Hoechst 33258, Pentahydrate (bis-Benzimide)” (Thermo Fisher Scientific) and then washed 
again once. Cells were imaged in a Nikon Eclipse Ti-E microscope (Nikon).  
 
HA binding protein staining 
After treatment of MCF10A cells with TFG-β for 4 days, cells were washed once with 1x PBS 
and fixed in a solution of 4% formaldehyde (in 1x PBS) for 10min at RT. Then, cells were rinsed 
twice with 1x PBS and blocked with 1% BSA (in 1x PBS) for 1h. The incubation with 
“Hyaluronic Acid Binding Protein-Biotin bovine” (Sigma) was done using a final concentration 
of 10µg/mL o/n at 4ºC. After the incubation, cells were rinsed three times with 1x PBS and 
incubated with the secondary antibody “Alexa Fluor® 568 streptavidin” at a dilution of 1:1000 (in 
blocking solution) for 1h at RT. After rinsing the cells three times with 1x PBS, the nucleus was 
counterstained using “Hoechst 33258, Pentahydrate (bis-Benzimide)” (Thermo Fisher Scientific) 
and then washed again once. Cells were imaged in a Nikon Eclipse Ti-E microscope (Nikon). 
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Glucose uptake 
Glucose uptake was measured using the “Glucose Uptake Colorimetric Assay Kit” (Biovision; 
K676), according to the manufacturer’s instructions. This assay uses an analogue of glucose, 2-
deoxy-D-glucose (2-DG) that is taken up by cells, through glucose transporters and metabolized 
to 2-DG-6-phosphate (2-DG6P). The latter cannot be further metabolized and thus accumulates 
in the cells. The accumulated 2-DG6P is directly proportional to 2-DG uptake by cells. After 
some enzymatic reactions, the end-product is measured by absorbance. Briefly, cells were washed 
with 1x PBS and then starved for 1h with DMEM media without glucose and pyruvate + 10% 
dialyzed FBS, that proceeded the incubation with 2-DG for 40min. (except in control cells which 
were incubated with media with normal glucose). After washing the cells to remove the remaining 
extracellular 2-DG, cells were lysed and added to the plate, diluted in the reaction mix. A standard 
with known glucose concentrations was added to the plate to extrapolate the glucose uptake from 
the samples. The absorbance at 412nm was measured in the plate reader Envision 2014 
Multimode Plate Reader (PerkinElmer) after 30min at 37ºC. Glucose uptake was calculated using 
the standard curve and normalized to cell number. 
 
Lactate secretion  
Lactate concentration in the cell media was measured using a BioProfile FLEX Analyzer (Nova 
Biomedical). Lactate secretion was determined by subtracting the values for lactate in the 
experimental conditions from the values in the respective control media (no cells) and normalized 
to protein concentration - µg/µL of protein – (see “Western Blotting” section). The average and 
standard deviation were calculated for 3 biological replicates.  
 
Metabolites’ extraction and LC-MS/MS 
Polar metabolites were extracted using a solution of 80% methanol (for HPLC gradient grade 
≥99.9%) according to Yuan et al. (Yuan et al. 2012). Briefly, cells seeded in 15cm plates were 
washed once with 1x PBS and cell culture media was replenished 2h before metabolite extraction. 
The cell culture media from each cell plate was aspirated completely and cells were washed once 
with 1x PBS. The plates were put on dry ice and a cooled to -80ºC solution of 80% methanol 
(vol/vol, in ddH2O) was added to the plate. Cells were incubated for 15min at -80ºC and scraped 
off the plate on dry ice using a cell lifter. The cell lysate/methanol mixture was centrifuged at 
14000g for 5min at 4ºC. The metabolites-containing supernatant was transferred to a new tube 
and the pellet was washed with 80% methanol and pellet. The metabolites-containing supernatant 
was dried using a SpeedVac (no heat) and the metabolites were stored at -80ºC until further use. 
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Before the liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, the dried 
pellets were resuspended in 20µL of LS/MS-grade water, centrifuged for 2min. at 1000rpm and 
the supernatant was transferred to LS-MS/MS system tubes. The quantitative steady-state 
metabolomics profiling was performed using LC-MS/MS by the Beth Israel Deaconess Medical 
Center Mass Spectrometry Core Facility (Boston, USA) headed by John M. Asara, according to 
Yuan et al. (Yuan et al. 2012).  
 
Metabolomics data analysis 
The metabolomics data obtained was the peak area integrated total ion chromatogram (TIC) 
values. Samples were normalized to protein concentration – µg/µL - (see “Western Blotting” 
section) on a duplicate set of cells treated identically to the experimental cells and the average of 
3 biological replicates was calculated.  
The heatmap was created using MeV Multi Experiment 4.9 data analysis and visualization 
software. Metabolomics data (treated as mentioned previously) was input and the following 
analysis was performed: hierarchical clustering, using the average linkage as linkage method and 
the distance metric the Pearson correlation. 
 
Gene expression analysis using real-time PCR (qPCR) 
RNA was isolated using RNeasy Mini Kit (QIAGEN) or “PureLink™ RNA Mini Kit” (Ambion) 
according to the product’s manual. One µg of total RNA was treated with “DNase I Amplification 
Grade” (Sigma Aldrich) and was reverse transcribed by using “iScript™ cDNA Synthesis Kit” 
(Bio Rad)  according to the manufacturer’s guidelines. The resulting cDNA was diluted in 
nuclease-free water (1:5). qPCR was performed with gene specific primers at 50ºC for 2min. and 
95°C for 10 sec (hold stage), 40 cycles at 95ºC for 15sec and 60°C for 1min. (PCR stage) and 
95ºC for 15sec, 60ºC for 1min. and 95ºC 15sec ((melt curve stage) in 10μl reaction mix containing 
2μl cDNA (20ng), 1μl mix of primers reverse and forward and 5μl of “SYBR™ Green PCR 
Master Mix” (Life Technologies) using a “Applied Biosystems™ QuantStudio™ 6 Flex Real-
Time PCR System” (ThermoFisher Scientific) thermocycler. Actin and TATA box binding 
protein (TBP) were used as an endogenous control. After assuring that the efficiency of the 
amplification between the target gene and endogenous control were similar, the quantification 
was performed using the ΔΔCt method (Schmittgen and Livak 2008). See Table 8 for the primer 
sequences used for qPCR analysis. 
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Luciferase promoter activity assay 
The construct of the Renilla luciferase gene under the promoter of UGP2 and the Cypridina TK 
control promoter construct were purchased to SwitchGear Genomics. Cells plated on a 6-well 
plate were co-transfected with 2μg of the construct containing the Renilla luciferase gene under 
the promoter of UGP2 (or the empty vector control under a minimal promoter) and 1µg of control 
Cypridina construct – the co-transfection control- using “X-tremeGENE™ HP DNA Transfection 
Reagent” (Roche). 48h after transfection, the activity of luciferase was measured using the 
“LightSwitch™ Dual Assay Kit” (Active Motif), according to the manufacturer’s protocol. The 
absorbance was measured and the Renilla luciferase activity was normalized by Cypridina 
luciferase activity. 
 
Lambda Phosphatase treatment 
Protein (30μg) was resuspended in a mixture of 20 units of phosphatase “Lambda Protein 
Phosphatase (Lambda PP)” (New England BioLabs) per µg of protein, in the phosphatase buffer 
and MnCl2 provided with the enzyme. The tubes were vortexed and incubated for 1h at 30ºC in a 
water bath. Control samples were treated identically and simultaneously, but without any 
phosphatase. According to the manufacture, 100 units of Lambda PP remove ~ 100% of 
phosphates (0.5nmol) in phosphorylated myelin basic protein (18.5 kDa) in 30min. in a 50μL 
reaction. The concentration of phosphorylated myelin basic protein is 10μM with respect to 
phosphate, as described by the manufacturers. After the incubation, the Western blotting loading 
buffer (see “Western Blotting” section) was added to the lysates, followed by boiling at 95ºC and 
the Western blotting protocol was continued according to the “Western Blotting” section. 
 
Western Blotting 
Cells cultured in plates were washed once with 1x PBS before lysis. Cells were lysed and protein 
precipitated in a solution of 10% trichloroacetic acid (in 10mM Tris-HCL pH8.0, 25mM NH4OAc 
and 1mM Na2EDTA) and by scrapping cells off the plate using a cell lifter. Cell lysates were 
centrifuged at 13200 rpm for 10min. The supernatant was aspirated and the pellet was 
resuspended in 3% SDS buffer (in 0.1M Tris-HCL, pH 11.0) and boiled at 95ºC for 10 min.  
Cell lysates were quantified using an adapted Lowry method provided by the DCTM Protein Assay 
(Bio-Rad). Samples were normalized to 2.5µg/µL in a 2% SDS, 10% glycerol, bromophenol blue, 
0.1% β-mercaptoethanol (in 0.2M Tris-Cl, pH 6.8) loading buffer and boiled for 5 min. A total of 
25µg of protein were loaded into each well and electrophoresed by SDS-PAGE using 10% 
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acrylamide gels. Proteins were transferred from the gel to a nitrocellulose membrane – 
“Amersham Protran 0.45 NC” (GE Healthcare) - in a 10% methanol glycine-based transfer buffer.  
Immunoblotting with the primary antibody (see table 1) diluted in 1x Tris-buffered saline with 
Tween (TBS-T) (25mM Tris-HCl, pH 7.5, 150mM NaCl, 0.5% Tween® 20) was performed after 
blocking the membrane in “Odyssey® Blocking Buffer (TBS)” (LI-COR) (in 1x TBS) in a rocking 
shaker o/n at 4ºC. “IRDye® 800CW” or “IRDye® 680RD” secondary antibodies (LI-COR 
Biosystems) were incubated at a 1:20000 dilution in TBS-T for 1h at RT. Membranes were 
washed after the primary and secondary antibodies with TBS-T. Immunoblot signals were 
detected by Odyssey® CLx Imaging System (LI-COR Biosciences).  
Slug antibody and the corresponding secondary antibody - “ECL anti-Rabbit IgG, HRP-linked, 
whole molecule, from donkey” (GE Healthcare - Life Sciences) - were diluted 1:5000 in a solution 
of 5% nonfat dried milk (in TBS-T). Slug was developed using enhanced chemiluminescence 
(ECL). Immunoblot images are representative of at least two independent experiments. 
In the case of the detection of glycoproteins using lectins, the Western blot was performed 
according the above described, except 5 µg of protein was loaded in an 8% acrylamide gel. 
Besides, the membranes were blocked with 4% BSA (in PBS with 0.05% -Tween® [PBS-T]). The 
lectins were diluted in a solution of 1% BSA (in PBS-T) and incubated for 45min at RT. After 
washing the membranes three times for 10min, they were incubated with the avidin/biotin 
technology reagents from the “Vectastain® Elite® ABC-HRP Kit” (Vector Laboratories) for 
45min at RT. After washing the membranes three times for 10min, they were developed using 
ECL. 
Vinculin and actin expression were used as loading controls. 
 
Glycogen – PAS staining  
Detects polysaccharides (such as glycogen) and glycoconjugates. Based upon the reactivity of 
free aldehyde groups within carbohydrates with the Schiff reagent to form a bright red magenta 
end product. 
The protocol adapted from Shen et al. (Shen et al. 2010) and the reagents used were part of the 
“Periodic Acid-Schiff (PAS) Kit” (Sigma). Briefly, cells were plated in coverslips placed into 6-
well plates. On the timepoint day, medium was removed, cells washed with 1x PBS and fixed 
with Carnoy's fixative (3 parts ethanol and 1 part glacial acetic acid) for 1h at RT. The cells were 
rinsed with absolute alcohol and 66% alcohol once for 2 min, followed by rinsing with deionized 
water three times for 30sec. The cells were treated with periodic acid solution for 10 min and then 
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rinsed with deionized water three times for 30sec. Then the cells were treated with Shiff reagent 
for 20min in the hood, followed by 5min. with running tap water. After air-drying, the stained 
cells were covered with a glass slides using pure glycerol as mounting medium.  
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Results 
Establishment of the doxycycline-induced ERK2-D319N EMT model 
In order to study the metabolic requirements of EMT, we generated a doxycycline (DOX)-
inducible ERK2-driven EMT model. In this model, the non-tumorigenic mammary epithelial cell 
line MCF10A expresses a mutated form of ERK2, ERK2-D319N (ERK2-DN cells). This 
mutation – an aspartic acid (D) to asparagine (N) – is located in the CD motif of ERK2, shifting 
the ERK substrate preference to DEF motif-containing substrates and had previously been 
described by our group as capable of inducing EMT (Shin and Dimitri et al. 2010). On the other 
hand, the ERK2-Y261A mutation affects the DEF-motif binding pocket, resulting in ERK2 
preferentially signaling to D-motif substrates. Cells expressing the ERK2-DBP mutant (ERK2-
YA cells) do not exhibit morphological changes and will be used as a control in the first part of 
this paper. The overexpression of the WT form of ERK2 (ERK2-WT cells) results in a milder 
EMT phenotype (Shin, Dimitri et al. 2010).  As a control, we used MCF10A cells infected with 
an empty or GFP vector (vector or GFP cells). We optimized a DOX-inducible system (3rd 
generation tet-HA-ERK2) that provides a temporal characterization of EMT (Fig. 2). All the 
ERK2 constructs - ERK2-WT, ERK2-YA and ERK2-DN - are HA-tagged. Compared to control 
vector cells and ERK2-YA cells, within a few days after DOX treatment, ERK2-DN cells changed 
their epithelial cellular morphology, became more elongated and fibroblast-like and exhibited 
alterations in the expression of epithelial (E-cadherin) and mesenchymal-associated proteins 
(fibronectin, N-cadherin and Zeb1) (Fig. 3). Specifically, ERK2-DN cells downregulate E-
cadherin and upregulate fibronectin, N-cadherin and Zeb1 over time (Fig. 3 and Shin, Dimitri et 
al. 2010). The downregulation of E-cadherin is also evident by immunofluorescence staining, 
while in vector and ERK2-YA cells, E-cadherin is localized at the membrane (Fig. 3 and Shin, 
Dimitri et al. 2010).  
 
 
Fig. 2: ERK2-driven EMT model (A) and cell systems used (B). 
A 
B 
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Fig. 3: Morphology after 11 days of DOX treatment (A), expression of the EMT markers during 
the time-course DOX treatment (B) and immunofluorescence staining for E-cadherin (green) after 
9 days of DOX treatment (C) in ERK2 -YA and -DN mutants compared to the vector control. The 
phase contrast images were taken with a 10x objective. The immunofluorescence images were 
taken with a 20x objective and the nucleus was counterstained with Hoechst (blue). The 
experiment was repeated at least 3 times. 
 
One of the most important features of EMT is increased migration. Consequently, we performed 
a wound healing assay in order to assess the ability of cells to migrate and close a “scratch” or 
wound in the cell monolayer.  We also analyzed the migratory and invasive capacity of the cells 
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through a porous membrane in non-coated transwells (migration) or in transwells coated with 
basement membrane extract (BME), a commercially available matrix (invasion). As expected, 
ERK2-DN cells displayed enhanced migratory and invasive capacities when compared to control 
cells or ERK2-YA, as measured by the percentage of wound closure over time (Fig. 4A) and by 
staining the cells that have migrated through the porous membrane (Fig. 4B).  
 
   
Fig. 4: Wound healing assay (A) and migration and invasion of cells in non-coated or BME-
coated transwells (B) in ERK2 YA and DN mutants compared to the vector control during the 
time-course DOX treatment (wound-healing) or after 7 days of DOX treatment (migration and 
invasion in transwells). Both experiments were repeated at least 3 times. Data from the graph are 
represented as mean ± SD. 
 
Glucose consumption and lactate secretion of ERK2-driven EMT 
Having established a suitable model, our goal was to identify the metabolic alterations associated 
with ERK2-driven EMT. Firstly, we measured the glucose consumption using a 2-DG assay in 
cells undergoing EMT.  This assay uses an analogue of glucose, 2-DG, that is taken up by cells, 
through glucose transporters and quantifies an intracellular product that accumulates in the cells. 
After 9 days of DOX treatment, ERK2-DN cells consume less glucose than vector control and 
ERK2-YA cells (Fig. 5). Accordingly, after analyzing the protein expression of one of the glucose 
transporters, we saw that GLUT1 is downregulated in ERK2-DN after DOX treatment (Fig. 6). 
Moreover, we assessed lactate production by quantifying this metabolite in the cell media. We 
concluded that ERK2-DN cells secrete less lactate to the cell media (Fig. 5).  
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Fig 5: Glucose uptake and lactate secretion in ERK2 -YA and -DN mutants compared to the 
vector control. The glucose uptake was measured using 2-DG assay after 9 days of DOX treatment 
and the lactate production was determined in the cell media using a BioProfile FLEX Analyzer 
(Nova Biomedical) during the time-course DOX treatment. Data of lactate production are 
represented as mean ± SD. 
 
 
Fig. 6: Protein expression of GLUT1 in ERK2-DN cells compared to vector control after 1, 7 and 
9 days of DOX treatment. 
 
Metabolic reprogramming and increased UDP-glucose levels during EMT 
In order to define the metabolic effectors that regulate EMT in this model, we utilized liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) to perform a quantitative 
metabolomics profiling analysis and determine the metabolic program associated with the 
transition. During the experiment, the endogenous polar metabolites were extracted from ERK2 
-DN and -YA cells (in addition to the empty vector control cells) in several time-points during a 
9-day experiment. The data was normalized to protein concentration. By analyzing the relative 
abundance of the metabolites of DN cells and YA cells (normalized to vector control) over time, 
we concluded that there is dramatic metabolic reprogramming in these cells during the EMT (Fig. 
7A). Notwithstanding the low glucose consumption, we were intrigued by the reduced lactate 
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production during EMT and questioned the fate of glucose in ERK2-DN cells. Interestingly, one 
of the metabolites whose levels were markedly increased over time in DN cells (and not in YA 
or vector control cells) was UDP-glucose (Fig. 7B). UDP-glucose is an intermediate metabolite 
in several pathways of the carbohydrate metabolism that can be synthetized from glucose after its 
conversion into glucose 6-phophate and glucose-1-phosphate. 
 
      
Fig. 7: Metabolic profiling (A) and UDP-glucose levels (B) in ERK2 -YA and -DN mutants 
compared to the vector control during the time-course DOX treatment. The graphic represents the 
quantification of integrated peak areas TIC values. The experiment was repeated 3 times. Data 
are represented as mean ± SD.  
 
UGP2 is upregulated during EMT 
To identify the molecular mechanism behind the increased UDP-glucose levels during EMT, we 
analyzed the expression level of the enzyme responsible for UDP-glucose production, UDP-
glucose pyrophosphorylase 2 (UGP2). This enzyme uses glucose-1-phosphate and UTP as 
substrate to produce UDP-glucose, in a reversible reaction (Fuhring et al. 2015). Consistent with 
the increased UDP-glucose production, UGP2 expression was upregulated at both the mRNA and 
protein level in DN cells (Fig. 8). Additionally, ERK2-WT overexpressing cells also upregulate 
UGP2, although to a lesser extent in accordance with their mild EMT (Fig. 8B). 
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Fig. 8: Expression of UGP2 at the mRNA (A) and protein (B) level in ERK2 WT and DN cells 
compared to the vector control during the time-course experiment. Both experiments were 
repeated at least 3 times. mRNA data are represented as mean ± SD. 
 
Expression of UGP2 is increased in different EMT models 
Since UGP2 is the enzyme responsible for the production of UDP-glucose, we further explored 
the expression of this enzyme during EMT, questioning whether UGP2 is also upregulated in 
other EMT models. We analyzed the expression of UGP2 in MCF10A either treated with TGF-β 
or TGF-β plus TNF-α, or with DOX-inducible overexpression of HRAS-G12V (Thiery et al. 
2009). Consistent with the results from our ERK2-driven EMT model, UGP2 was upregulated in 
the mesenchymal cells from these systems (Fig. 9). 
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Fig. 9: Protein expression of UGP2 in MCF10A+Ras-V12 cells during the time-course DOX 
treatment (A) and in MCF10A cells treated with TGF-β or TGF-β and TNF-α for 10 days (B). 
Both experiments were repeated twice. 
 
The immunoblotting for UGP2 after running the proteins in a SDS-PAGE gel consistently shows 
the presence of two specific bands. In order to assess if the bands represent phosphorylated forms 
of UGP2, we treated the lysates with lambda phosphatase and we concluded that the two bands 
are not caused by the addition of phosphate groups to the UGP2 protein (Fig. 10). Later, we 
determined that the two bands are actually caused by the two main isoforms of the human UGP2 
(Uniprot Q16851; UniProt: the universal protein knowledgebase 2017), after selectively 
overexpressing the cDNA of one or the other in MCF10A cells (Fig. 11). These isoforms differ 
in the first 11 amino acids of the protein (presence or absence), with isoform 1 being the longer 
isoform and isoform 2 shorter at the N-terminus (Fig. 12). Interestingly, in the EMT models 
tested, ERK2-, Ras-V12-, TGF-β and TGF-β plus TNF-α, only the longer UGP2 isoform 
(isoform 1) was increased in the cells undergoing EMT (Figs. 8 and 9).   
 
 
Fig. 10: UGP2 expression after treatment with lambda phosphatase in ERK2 WT and DN mutant 
cells compared to the vector control after 7 days of DOX treatment. The experiment was repeated 
twice. 
B A 
129 
 
 
Fig. 11: Overexpression of the two UGP2 isoforms in MCF10A cells.  
 
 
Fig. 12: Schematics for the transcripts of the isoform 1 (NM_006759.3) and isoform 2 
(NM_001001521.1) of the human UGP2. The grey boxes represent the promoter and the color 
boxes represent the exons. The empty boxes represent non-translated exons. The 5’ untranslated 
region (UTR) locations and the ATG site are also indicated.  
 
UGP2 is necessary for ERK2-driven EMT 
In order to assess the dependence of the ERK2-driven EMT on the UDP-glucose pathway, more 
specifically on the expression of UGP2, and to discriminate the events that are essential for the 
phenotypic transition from those that are just bystander effects, we established a model to knock-
down UGP2 protein. We choose to use shRNA in order to have a stable silencing. Taking in 
consideration the fact that MCF10A are not easily transfectable, we used a lentivirus system to 
deliver the plasmids. After testing multiple constructs in different systems, we were able to knock-
down UGP2 using an DOX-inducible system based on the shRNAmir technology (Dickins et al. 
2005; Stegmeier et al. 2005; Zeng, Cai, and Cullen 2005; Zeng, Wagner, and Cullen 2002) with 
different efficiencies.  
The UGP2 knock-down in cells overexpressing ERK2-DN resulted in lower levels of 
mesenchymal markers such as fibronectin and Slug and higher expression of E-cadherin, 
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compared to ERK2-DN overexpressing cells where UGP2 was not silenced (ERK2-DN + shRen) 
(Fig. 13). Additionally, after UGP2 silencing, ERK2-DN cells display reduced fibroblast-like 
morphology, more closely resembling the control epithelial cells (Fig. 14). Importantly, the 
increased migration and invasion capacities of ERK2-DN cells were reduced upon UGP2 knock-
down (Fig. 15 and 16).  Collectively, these data suggest that UGP2 plays an important role in 
EMT upstream of the EMT markers fibronectin and E-cadherin, as well as the EMT transcription 
factor Slug, consistent with its important role in EMT. 
 
 
Fig. 13: Protein expression of UGP2 and select EMT markers in ERK2 DN cells infected with 
shRNAmir targeting UGP2 or Renilla (control), compared to GFP control, after 5 days of DOX 
treatment. The lanes on each condition correspond to 3 biological replicates. 
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Fig. 14: Morphology of ERK2 DN cells infected with shRNAmir targeting UGP2 or Renilla 
(control), compared to GFP control, after 5 days of DOX treatment. The bright field images were 
taken with a 10x objective. The experiment was repeated 3 times.  
 
 
Fig. 15: Migration of ERK2 DN cells infected with shRNAmir targeting UGP2 or Renilla 
(control), compared to GFP control, after 5 days of DOX treatment. The experiment was repeated 
3 times. 
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Fig. 16: Invasion in Matrigel® of ERK2 DN cells infected with shRNAmir targeting UGP2 or 
Renilla (control), compared to GFP control, after 5 days of DOX treatment. The experiment was 
repeated 3 times. 
 
Taking in consideration the results from the knock-down of UGP2, we wanted to understand if 
the effects of the silencing constructs are specific by performing the “add-back” experiment. After 
knocking-down the endogenous UGP2 using shRNA, we overexpressed it using a plasmid with 
its cDNA, generated through gateway cloning. This experiment would allow us to assess if the 
blockage of EMT after infection with shUGP2 could be “rescued” after the enzyme re-expression, 
and thus be specifically due to UGP2 expression. Unfortunately, we were not able to overexpress 
the enzyme at the desired levels due to technical problems. 
 
UDP-glucuronate is increased and UGDH is upregulated during EMT 
UDP-glucose is a key intermediate in carbohydrate metabolism and it can have several fates inside 
cells (Führing et al. 2015) (Fig. 17).  For example, UDP-glucose can serve as a precursor for 
glycogen. Thus, we analyzed the glycogen content of control and ERK2-DN cells throughout the 
time-course DOX treatment, using Periodic Acid–Schiff (PAS) staining, which detects 
polysaccharides (such as glycogen) and glycoconjugates. Although ERK2-DN cells appear to 
have slightly higher glycogen content on day 5 of DOX treatment, in the remaining timepoints 
this increase is not as evident (Fig. 18). Since the results from this assay were not conclusive, we 
explored other pathways associated with UDP-glucose.  
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Fig. 17: Schematics with the 2 more relevant products of UDP-glucose.   
 
 
Fig. 18: Glycogen content assessment using PAS staining in ERK2-WT, -YA and -DN cells 
compared to the vector control, during the time-course DOX treatment. 
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UDP-glucose can also be converted into UDP-glucuronate through UDP-glucose 6-
dehydrogenase (UGDH). From the metabolomics data, ERK2-DN cells on day 7 of DOX 
treatment exhibited higher levels of UDP-glucuronate compared to the controls (Fig. 19).  
 
 
Fig. 19: UDP-glucuronate levels in ERK2 YA and DN cells compared to the vector control during 
the time-course DOX treatment. Quantification of integrated peak areas TIC values. The 
experiment was repeated 3 times. Data are represented as mean ± SD. 
 
The analysis of the mRNA and protein levels of UGDH shows that this enzyme was also 
upregulated in cells undergoing EMT (Fig. 20). This may be of particular relevance to 
mesenchymal cells because UDP-glucunorate is a precursor for proteoglycans and 
glycosaminoglycans, such as hyaluronan, which compose the extracellular matrix and are 
important for migration and invasion of cancer cells (Nikitovic et al. 2014). 
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Fig. 20: Expression of UGDH at the mRNA (A) and protein (B) level in ERK2 WT and DN cells 
compared to the vector control during the time-course DOX treatment. Both experiments were 
repeated at least 3 times. mRNA data are represented as mean ± SD. 
 
Hyaluronan may be mediating the effects of UDP-glucose and hexosamine biosynthetic 
pathway in EMT 
From the previous results, we concluded that mesenchymal cells that overexpress the DN 
mutation in ERK2 have increased levels of UDP-glucose and show upregulation of the enzyme 
that catalyzes its production, UGP2. Moreover, UDP-glucuronate, a metabolite produced from 
UDP-glucose and the enzyme responsible for its production, UGDH, are also increased. As such, 
we explored how the UDP-glucose pathway may impact the mesenchymal phenotype, especially 
the enhanced migration and invasion. One possible link is through the generation of hyaluronan 
(HA), a polysaccharide synthetized by HA synthases (HAS) using cytosolic UDP-glucuronate 
and UDP-N-acetylglucosamine (UDP-GlcNAc) as precursors (Weissmann et al. 1954). Indeed, 
MCF10A cells that are undergoing EMT also showed increased levels of UDP-GlcNAc, the end-
product of the hexosamine biosynthetic pathway (Fig. 21). Because this metabolite can also be 
used in the glycosylation of proteins (both N- and O-glycosylation) and in the formation of 
glycosaminoglycans (Pinho and Reis 2015), we analyzed the glycosylation pattern of the global 
cellular proteome using an O-GlcNAc antibody for O-glycosylation and probing total cellular 
extracts with lectins, which are carbohydrate-binding proteins that bind to specific forms of 
glycans (Cummings and Etzler 2009). We did not find global differences in the pattern of 
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glycosylated proteins when comparing ERK2-DN with control cells, although minor changes may 
exist for PHA-E and O-glycosylation (Fig. 22).    
 
 
Fig. 21: UDP-GlcNAc levels in ERK2 YA and DN mutants compared to the vector control during 
the time-course DOX treatment. Quantification of integrated peak areas TIC values. The 
experiment was repeated 3 times. Data are represented as mean ± SD. 
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Fig 22: Expression of proteins with the N-glycan and O-glycans epitopes in ERK2-DN cells 
compared to the vector control after 1, 7 and 9 days of DOX treatment, using lectins and an O-
GlcNAc antibody. The lectins Phaseolus vulgaris erythroagglutinin (PHA-E) detects bisecting 
GlcNAc N-glycan structures (A), Phaseolus vulgaris leucoagglutinin (PHA-L) detects β1,6 
GlcNAc-branched N-glycan structures (B) and Sambucus nigra lectin recognizes α2,6; α2,3 
linked sialic acid (C). O-Glycans were recognized using an O-GlcNAc antibody (D). 
 
In accordance with the increased UDP-GlcNAc levels, we identified UDP-N-acetylglucosamine 
pyrophosphorylase 1 (UAP1) - the enzyme that catalyzes the production of UDP-GlcNAc – as 
being upregulated in ERK2-DN cells at the mRNA and protein level after DOX treatment (Fig. 
23). In ERK2-WT cells after DOX treatment, UAP1 protein is also increased (Fig. 23B). 
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Fig. 23: Expression of UAP1 at the mRNA (A) and protein (B) level in ERK2 -WT and -DN cells 
compared to the vector control during the time-course DOX treatment. Both experiments were 
repeated at least 3 times. mRNA data are represented as mean ± SD. 
 
We decided to focus our attention in HA, which can be produced by 3 HA synthases localized at 
the plasma membrane. One of these - hyaluronan synthase 2 (HAS2) – was found to have 
increased mRNA levels in ERK2-DN cells (Fig. 24). Unfortunately, the protein levels were not 
measured because after troubleshooting the conditions, neither of the several antibodies tested did 
not work for immunoblotting.  
 
 
Fig. 24: mRNA expression of HAS2 in ERK2-DN mutant cells compared to the vector control 
during the time-course DOX treatment. The experiment was repeated twice. Data are represented 
as mean ± SD. 
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Since our findings suggest an enrichment of the metabolic intermediates that lead to HA 
production, we next determined if the knock-down of HAS2 impacts the mesenchymal 
phenotype. We were able to identify 3 shRNAs that efficiently silence at least 50% of HAS2 in 
ERK2-DN overexpressing cells (Fig. 25). We then looked for the impact of HAS2 silencing on 
HA levels, using HA binding protein (HABP), due to the lack of consistent Western blotting 
results. Our result show that HAS2 silencing in MCF10A cells treated with TGF-β (4 days of 
treatment) results in decreased levels of HA (Fig. 26).  
 
 
Fig. 25: mRNA expression of HAS2 in ERK2-DN cells infected with shRNAs targeting HAS2 
or control, compared to GFP control, after 5 days of DOX treatment. The experiment was repeated 
3 times. Data are represented as mean ± SD. 
 
 
Fig. 26: HABP staining (red) on MCF10A cells infected with shRNAs targeting HAS2 or control 
treated with TGF-β for 4 days, compared to control cells. The nucleus was counterstained with 
Hoechst (blue) for better perception of the cell number and localization. The immunofluorescence 
images were taken with a 20x objective and were digitally zoomed 3 times.  
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When inducing ERK2-DN overexpression for 5 days in cells silenced for shHAS2, we observed 
that the levels of E-cadherin are not as decreased nor the levels of fibronectin as increased as in 
ERK2-DN cells that express HAS2 (Fig. 27). Besides, with HAS2 knock-down, ERK2-DN cells 
look less like fibroblasts and migrate less that the cells infected with the shRNA control (Figs. 28 
and 29), confirming that HAS2 expression has a role in the maintenance of EMT.  
 
 
Fig. 27: Protein expression of selected EMT markers in ERK2 DN cells infected with shRNAs 
targeting HAS2 or GFP, compared to GFP control, after 5 days of DOX treatment. The lanes on 
each condition correspond to 3 biological replicates. 
 
 
Fig. 28: Morphology of ERK2 DN cells infected with shRNAs targeting HAS2 or GFP, compared 
to GFP control, after 5 days of DOX treatment. The bright field images were taken with a 10x 
objective. The experiment was repeated 3 times. 
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Fig. 29: Migration of ERK2 DN cells infected with shRNAs targeting HAS2 or GFP, compared 
to GFP control, after 5 days of DOX treatment. The experiment was repeated 3 times. 
 
Promoter activity does not explain the upregulation of UGP2 
UGP2 is overexpressed in cells undergoing EMT after expression of a mutated form of ERK2. 
However, it is unclear how ERK2 signaling leads to altered expression of the metabolic enzyme. 
As shown earlier by qPCR, the mRNA levels of UGP2 are increased in ERK2-DN cells (Fig. 8), 
so, since the most-well studied ERK substrates are TFs, a possible explanation for this a higher 
activity of the UGP2 promoter in these cells. So, we performed a luciferase promoter assay, by 
transfecting ERK2 -WT and -DN cells with a plasmid that contains the gene encoding luciferase 
under the UGP2 promoter: in this assay, the more active the promoter is, the more luminescent 
the cells become. Surprisingly, the promoter for UGP2 used in this assay seems to be less active 
in DN cells than in control and ERK2-WT cells (Fig. 30), suggesting that the increased mRNA 
and protein levels of UGP2 in ERK2 WT and DN cells are not due to increased promoter activity. 
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Fig 30: Promoter activity analysis of ERK2 WT and DN cells transfected with luciferase 
constructs under the promoter of UGP2, compared to control GFP cells, after 5 days of DOX 
treatment. Promoter activity measured by Renilla luciferase was normalized by Cypridina 
luciferase and to MCF10A+GFP cells. The experiment was repeated 3 times. Data are represented 
as mean ± SD. 
 
Treatment with a MAPK inhibitor does not affect significantly the UGP2 protein levels 
Since UGP2 is induced after an increase in ERK2 signaling through the DEF-motif, we tested if 
a MEK inhibitor, the upstream kinase of ERK, could lower UGP2 levels. However, a 4-hour 
treatment with AZD6244 (Yeh et al. 2007), which has an impact on ERK1/2 phosphorylation, did 
not significantly alter the expression of UGP2 in ERK2-WT, -DN nor in GFP control cells (Fig. 
31). This could be related to the duration of the treatment and so a longer treatment should be 
tested. 
 
 
Fig. 31: Protein expression of UGP2 in ERK2 WT and DN cells after 7 days, compared to control 
cells of DOX treatment, treated for 4h with 1µM or 2 µM of AZD6244, a MEK1 inhibitor (or 
DMSO control). ppERK1/2 expression was used as a control. 
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Association between UGP2 mRNA and relapse free survival of breast cancer patients 
To understand if UGP2 expression is associated with prognosis in breast cancer patients we used 
the Kaplan Meier plotter, a software that combines gene expression data and patients prognosis 
information (Lánczky et al. 2016). We saw that higher mRNA expression of UGP2 is significantly 
associated with poor relapse free survival in a breast cancer patient cohort (Fig. 32). 
 
 
Fig. 32: Kaplan-Meier survival plot from breast cancer patients with high and low levels of UGP2 
expression. Gene expression data and relapse information are downloaded from GEO (Affymetrix 
microarrays only), EGA and TCGA. The database is handled by a PostgreSQL server, which 
integrates gene expression and clinical data simultaneously. To analyze the prognostic value of a 
particular gene, the patient samples are split into two groups according to various quantile 
expressions of the proposed biomarker. The two patient cohorts are compared by a Kaplan-Meier 
survival plot, and the hazard ratio with 95% confidence intervals and logrank P value are 
calculated. Each database is updated biannually. Data from the open source Kaplan Meier plotter 
for Breast Cancer (Lánczky et al. 2016). 
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Discussion 
In this work, we identified a link between UDP-glucose metabolism and the acquisition of 
mesenchymal properties driven by ERK2, in the context of cancer-associated EMT. Specifically, 
UGP2, the enzyme that produces UDP-glucose, is essential for the acquisition of a mesenchymal 
phenotype in cells overexpressing ERK2-DN. This may be mediated by the production of HA, 
through HAS2. 
With the goal of unravelling the metabolic requirements of EMT, we took advantage of a 
previously characterized model where EMT is induced by the signaling downstream of the DEF 
motif of ERK2 in mammary epithelial cells (Shin, Dimitri et al. 2010). We used a DOX-inducible 
approach for a controlled induction of ERK2 expression, enabling us to map the resulting 
molecular alterations over time. This model allowed us to uncover interesting alterations in the 
metabolic landscape during EMT, in agreement with recent studies also reporting links between 
metabolism and EMT, using other model systems. A metabolic reprogramming was shown when 
EMT is induced by TGF-β signaling (Soukupova et al. 2017) or Snail overexpression (Bhowmik 
et al. 2015; N. H. Kim et al. 2017), and this last one also leads to differential expression of several 
metabolic enzymes (Bhowmik et al. 2015; De Craene et al. 2005). Moreover, a few direct links 
between metabolic enzymes and EMT effectors have already been found. For example, Snail 
binds directly and regulates the expression of fructose-1,6-bisphosphatase and 
phosphofructokinase (Dong et al. 2013; Kim et al. 2017).  
The metabolic reprogramming of cells undergoing ERK2-driven EMT is characterized by 
alterations in the UDP-glucose pathway. Specifically, the levels of UDP-glucose become 
heightened, together with an upregulation of UGP2, the only human enzyme that catalyzes UDP-
glucose production. Importantly, we found that UGP2 is required for the maintenance of the 
mesenchymal phenotype. To the best of our knowledge, no studies have addressed the role of 
UDP-glucose and UGP2 in EMT and previous work has been limited to descriptions of their 
increased levels in EMT models (Lucena et al. 2016; Mulvihill et al. 2014). In a study by Mulvihill 
et al., a metabolomics approach in several in vitro breast models of cellular transformation and 
malignant progression, driven by the HRAS and Hippo pathways, identified UDP-glucose as one 
of the metabolites predominantly increased in cells undergoing EMT (Mulvihill et al. 2014). 
UGP2 was also found to be upregulated in a proteomics analysis of the same study (Mulvihill et 
al. 2014) as well as in a TGF-β-driven EMT model of lung cancer cells (Lucena et al. 2016). 
UDP-glucose is also increased in a Twist-induced EMT model (Bhowmik et al. 2015). These 
reports suggest a potentially important role for UGP2 for the acquisition of migration properties 
during the first step of metastasis. In fact, UGP2 was considered a biomarker in gallbladder cancer 
patients, since its expression was associated with invasion, metastasis and poor patient prognosis. 
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Besides, UGP2 was frequently associated with positive expression of vimentin, MMP-9, MMP-
2 and β-catenin (Wang et al. 2016). However, in hepatocellular carcinoma patients, UGP2 was 
included in a panel of potential markers that distinguish “metastatic relapse” and “non-relapse” 
patients, being downregulated in the primary tumors of the “metastatic relapse” patients. 
Interestingly, UGP2 is highly expressed in non-tumor liver tissue (Tan et al. 2014), which might 
explain such apparently contradictory findings.  
We noticed that UGP2 has two main isoforms in MCF10A cells, being the longer isoform the one 
that is upregulated. Interestingly, alternative transcription start site usage of UGP2 has been 
identified in colorectal cancer patient samples (both adenoma and carcinoma) relative to normal 
mucosa (Thorsen et al. 2011). Although the authors do not provide further information, it is 
possible that this reflects the two isoforms that we describe in the model presented on fig. 12 and 
if so, it may indicate that their expression is regulated in tumors. 
To understand how UGP2 expression is regulated in ERK2-DN cells, we performed a promoter 
assay that, contrarily to our expectations, showed a less active UGP2 promoter in cells undergoing 
EMT than in controls. To note that the promoter sequence used in the assay is expected to be 
regulating the transcription of the longer UGP2 isoform, the one that is upregulated during EMT. 
The apparent lack of consistency between upregulated UGP2 mRNA levels and lower UGP2 
promoter activity can be attributed to the promoter sequence used in this assay that, although 
having an approximate length of 1kb, may not include all the regulatory sequences for UGP2 
transcription. However, if our results are confirmed, an increased stability of UGP2 mRNA in 
cells undergoing EMT would also explain the higher mRNA levels. This can be tested by treating 
cells with an inhibitor of transcription (actinomycin D) and collecting mRNA in several time-
points to analyze its stability over time. Indeed, some ERK2 substrates may regulate RNA 
stability (Cargnello and Roux 2011). Additionally, we used a MEK inhibitor in order to evaluate 
the effect of blocking ERK pathway on UGP2 levels. This preliminary experiment showed that, 
after 4h of treatment, although the ERK pathway is efficiently inhibited, there were no striking 
effects on UGP2 protein expression. However, it is important to point that we do not know if, in 
the conditions used, UGP2 mRNA levels are affected by MEK inhibition and how stable UGP2 
mRNA is in these cells. Besides, these results should be interpreted with caution since we need 
to understand the proteins that are mediating the upregulation of UGP2 by ERK2-DN signaling 
and their turnover rates. So, a time-course analysis of UGP2 mRNA and protein levels including 
longer treatments with the MEK inhibitor should be performed. Alternatively, we could also 
perform an experiment where DOX is washed out from the cells and analyze UGP2 turnover. 
Our results further suggest that the UDP-glucose pathway provides substrates that contribute for 
the mesenchymal phenotype. UDP-glucose is the form by which glucose is incorporated into the 
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glycogen molecule. A higher glycogen content has been associated with brain metastasis of 
human breast cancer patients, when compared to the primary tumor, although the analysis was 
only performed in 5 brain metastasis samples (Chen et al. 2015). In our study, however, glycogen 
content of the mesenchymal cells was not significantly altered when compared with epithelial 
cells. An alternative link between UDP-glucose and EMT highlighted in our study is the 
convergence of UDP-glucose metabolism and hexosamine biosynthetic pathway into HA. HA is 
a polymer of glucunorate, a product of UDP-glucose, and GlcNAc; the precursors metabolites - 
UDP-glucuronate and UDP-GlcNAc – were also found increased in cells acquiring mesenchymal 
properties. Accordingly, UGDH and UAP1, the enzymes that produce both precursors of HA 
molecule, are upregulated in cells undergoing EMT, warranting further studies aiming at 
understanding if these enzymes are also required for ERK2-driven EMT. Although HA levels in 
ERK2-DN overexpressing cells could not be measured due to methodological limitations 
(sensitivity of the technique), UDP-sugar availability in the cytosol can impact HA synthesis 
(Jokela et al. 2008; Vigetti et al. 2014). It has also been already shown that overexpression of 
UGP2 and UGDH leads to an increase of HA accumulation (Magee, Nurminskaya, and 
Linsenmayer 2001; Vigetti et al. 2006). Thus, we anticipate that silencing of the enzymes 
involved in UDP-sugar production will lead to decreased levels of HA. HA is associated with 
cancer cell microenvironment, playing an important role in tumor progression (Toole, Biswas, 
and Gross 1979). A recent publication using breast cancer patient biopsies showed that UDP-
glucose, UDP-glucuronate and UDP-GlcNAc are increased, and UDP-GlcNAc and UDP-
glucuronate correlate with the increased hyaluronan levels (Oikari et al. 2018). Several studies 
have associated HA with EMT. For example, when cells are treated with HGF or overexpress β-
catenin, the resulting increased invasion and anchorage-independent growth are reversed by 
perturbation of endogenous hyaluronan polymer interactions, by treatment with hyaluronan 
oligomers (Zoltan-Jones et al. 2003). In TGF-β-induced EMT, HA production is increased, in a 
process dependent on the upregulation of HAS2 and on the activation of the p38 MAPK. HAS2 
is the most abundant HA synthase in adult cells, produces high molecular weight HA (Itano et al. 
1999) and has an active role on EMT during development (Camenisch et al. 2000). Additionally, 
HAS2 is in part required for the increased cell migration triggered by TGF-β in mouse mammary 
epithelial cells, although, intriguingly, this seems to be independent of CD44 – a cell membrane 
receptor that can bind HA – or of HAS2 enzymatic activity to synthetize HA (Porsch et al. 2013). 
Moreover, increasing the hyaluronan content by overexpressing HAS2 in breast and kidney 
epithelial cells, is sufficient to induce EMT in normal epithelial cells (Zoltan-Jones et al. 2003).  
HAS2 is associated with several poor prognostic features (such as higher grade, lymphovascular 
invasion, basal-like breast cancer subtype, high cell proliferation and basal marker expression) in 
androgen receptor negative breast cancer. The adverse prognostic effect of the androgen receptor 
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negative and HAS2 positive expression was independent of the expression of CD44 (Zhang et al. 
2016).  
Future studies aiming at clarifying the role of HA in ERK2-DN cells are needed. For example, 
whether EMT blockage caused by silencing of UGP2 or HAS2 occurs in a HA-dependent manner 
can be assessed by rescuing cells with HA or conditioned media from mesenchymal cells 
(Goncharova et al. 2012). Besides, HA can bind several receptors at the cell membrane, including 
the CD44 receptor, so we hope that further tests will indicate if CD44 is mediating the effects of 
HA on EMT. The CD44 surface glycoprotein has multiple isoforms, generated by alternative 
splicing, being the short CD44 isoforms associated with a mesenchymal phenotype upon EMT 
induction (Brown et al. 2011). In ovarian cancers, binding of HA to CD44 leads to the activation 
of ERK signaling, in a process where ERK2 is phosphorylated, resulting in Elk-1 phosphorylation 
and activation (Bourguignon et al. 2005). Interestingly, HAS2, as well as the other HAS isoforms, 
have been shown to be phosphorylated and activated by ERK, resulting in increased HA 
production in human ovarian tumor cells (Bourguignon, Gilad, and Peyrollier 2007). The receptor 
for hyaluronic acid-mediated motility (RHAMM) also contributes to activation of ERK and for 
CD44-ERK mediated signaling required for wound repair (Tolg et al. 2006; Zhang et al. 1998).  
On the other hand, UDP-glucose itself (and other UDP sugars such as UDP-galactose, UDP-
glucuronic acid, and UDP-N-acetylglucosamine) can be secreted, bind and activate the P2Y14 
receptor, a seven-transmembrane-spanning G protein-coupled receptor, leading to a signaling 
cascade that results in the activation of MAPK signaling pathway through ERK1/2 
phosphorylation (Chambers et al. 2000; Fricks et al. 2009). Moreover, P2Y14 receptor activation 
by UDP-glucose also enhances transcription of HAS2 and HA production (Jokela et al. 2014). 
Finally, extracellular UTP also increases pericellular HA and induces HAS2 expression, in a 
process mediated in part by ERK (Jokela et al. 2017). As such, the role of UDP-glucose and HA 
in EMT may be explained by their signaling properties, which occur via the interaction with cell 
surface receptors, ultimately leading to ERK2 activation, in positive feedback loop that sustains 
ERK activation, being crucial in maintaining the mesenchymal commitment of the cells. 
We are aware that a downside of our metabolomics approach is that it only gives us the steady 
state picture of the metabolites’ levels at the moment of collection. For a better notion of the 
glucose fate, we would have to perform a flux experiment by growing the cells in 13C-labeled 
glucose and tracing the labeled carbons in the product metabolites. The metabolomics approach 
will also allow us to analyze the levels of the UDP-glucose pathway metabolites after UGP2 
silencing.  
Our results stimulate interesting hypotheses: is ERK2 regulating the fine tuning of UDP-glucose 
fate? Is ERK2 coordinating the expression of the different enzymes of UDP-sugar metabolism, 
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that lead to the production of HA? These thoughts warrant further research in order to fully 
understand the relationship between EMT, ERK2 and metabolism  
Taken together, our results provide further evidence that metabolism is important for cancer 
progression, specifically for the acquisition of migration properties that facilitate the initiation of 
metastasis formation. Our results also indicate that UDP-glucose pathway is one of the targets of 
ERK2 signaling. 
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Supplementary data 
Table 1: List of antibodies and binding proteins  
Protein Source Identifier Clonality Species Dilution Protein 
size (kDa) 
HA SCBT sc-7392 Monoclonal mouse 1:5000  
E-cadherin BD Transduction 
Laboratories 
610181 Monoclonal mouse 1:3000 120 
Fibronectin BD Transduction 
Laboratories 
610077 Monoclonal mouse 1:1000 240 
Slug       
UGP2 Abcam ab157473 Monoclonal rabbit 1:5000 50 
UGDH SCBT sc-137005 Monoclonal mouse 1:500 57 
UAP1 Sigma HPA014659 Polyclonal rabbit  60 
ppERK1/2 
(T202/Y204) 
CST 4370 Monoclonal rabbit 1:1000 44 and 42 
pAKT (S473) CST 4060 Monoclonal rabbit 1:1000 60 
pS6 (S235/S236) CST 2211 Polyclonal rabbit 1:1000 32 
S6 CST 2317 Monoclonal mouse 1:1000 32 
pS6K (T389) CST 9234 Monoclonal rabbit 1:1000 70, 85 
Glut1 Abcam ab652 Polyclonal rabbit 1:1000 55 
O-GlcNAc SCBT sc-59624 Monoclonal mouse 1:1000 N/A 
Vinculin Sigma-Aldrich V9264 Monoclonal mouse 1:5000 116 
Actin SCBT sc-1615 Polyclonal goat 1:1000 43 
Alexa Fluor 488 
goat anti-mouse 
IgG (H+L)  
Thermo Fisher 
Scientific 
A11001 Polyclonal goat 1:1000 N/A 
Streptavidin, 
Alexa Fluor™ 568 
conjugate 
Thermo Fisher 
Scientific 
S11226 N/A N/A 1:1000 N/A 
Hyaluronic Acid 
Binding Protein-
Biotin bovine 
Sigma-Aldrich H9910 N/A bovine 10µg/mL N/A 
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Table 2: List of lectins 
Lectin Antigen Source Identifier Concentration 
PHA-E  Galβ4GlcNAcβ2Manα6 
(GlcNAcβ4) 
(GlcNAcβ4Manα3) 
Manβ4 
Vector 
Laboratories 
B-1125 0.5µg/mL 
PHA-L  Galβ4GlcNAcβ6 
(GlcNAcβ2Manα3) 
Manα3 
Vector 
Laboratories 
B-1115 0.5µg/mL 
Sambucus nigra lectin NeuAcα2,6Gal- or 
NeuAcα2,6GalNAc- 
Vector 
Laboratories 
B-1305 0.25µg/mL 
 
 
 
 
 
Table 3: List of critical commercial assays 
Critical commercial assays Source Identifier 
RNeasy Mini Kit QIAGEN 74106 
PureLink™ RNA Mini Kit Ambion  12183018A 
iScript™ cDNA Synthesis Kit Bio Rad 1708891 
DCTM Protein Assay Kit II Bio-Rad 5000112 
Periodic Acid-Schiff (PAS) Kit Sigma-Aldrich 395B 
Gateway™ LR Clonase™ II Enzyme mix Invitrogen 11791100 
Gateway™ BP Clonase™ II Enzyme mix Invitrogen 11789100 
LightSwitch™ Dual Assay Kit Active Motif 32035 
PureLink™ Quick Plasmid Miniprep Kit Invitrogen K210011 
E.Z.N.A.® Cycle Pure Kit (V-spin) Omega D6492 
VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Standard) Vector Laboratories PK-6100 
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Table 4: List of chemicals, peptides and recombinant proteins 
Chemicals, peptides and recombinant proteins Source Identifier 
Doxycyclin Calbiochem 324385 
Recombinant human TGF-β1 PeproTech 100-21 
Recombinant human TNF-α PeproTech 300-01A 
Recombinant human EGF PeproTech AF-100-15 
Insulin (human) Sigma-Aldrich I9278 
Cholera toxin from Vibrio cholerae Sigma-Aldrich C8052 
Hydrocortisone Sigma-Aldrich H4001 
Puromycin dihydrochloride from Streptomyces alboniger Sigma-Aldrich P7255 
G418 disulfate Caisson Labs G030 
Hoechst 33258, Pentahydrate (bis-Benzimide) ThermoFisher Scientific H3569 
Lipofectamine® 2000 Transfection Reagent Invitrogen 11668500 
DNase I Amplification Grade Sigma-Aldrich AMP01 
Lambda Protein Phosphatase (Lambda PP) New England BioLabs P0753 
X-tremeGENE™ HP DNA Transfection Reagent Roche 06366546001 
Odyssey® Blocking Buffer (TBS) LI-COR 927-50150 
SYBR™ Green PCR Master Mix Life Technologies 4334973 
Platinum™ Pfx DNA Polymerase Invitrogen 11708013 
T4 DNA Ligase New England BioLabs M0202S 
 
 
 
Table 5: Cell culture media and serum 
Cell media and serum Source Identifier 
Dulbecco's Modification of Eagle's Medium (DMEM) / Ham's F-12 50/50 
Mix containing L-glutamine and 15 mM HEPES 
Corning 10-092 
DMEM, high glucose Gibco  11965118 
Horse serum Gibco  16050122 
Fetal bovine serum Sigma-Aldrich F6765 
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Table 6: List of oligonucleotides and recombinant DNA 
Oligonucleotides and recombinant DNA Source Identifier 
Lentiviral packaging and envelope plasmids Dr. David Baltimore N/A 
pTRIPZ-ERK2-YA This paper N/A 
pTRIPZ-ERK2-YA This paper N/A 
pINDUCER-ERK2-WT This paper N/A 
pINDUCER-ERK2-YA This paper N/A 
pINDUCER-ERK2-DN This paper N/A 
pRRL-Lenti-miRE-Ren713 Dr. Lukas Dow N/A 
pRRL-Lenti-miRE-Ren713-shUGP2 #1 This paper N/A 
pRRL-Lenti-miRE-Ren713 -shUGP2 #2 This paper N/A 
pRRL-Lenti-miRE-Ren713 -shRenilla 713 Dr. Lukas Dow N/A 
pLKO.1-puro-shHAS2 #1 Broad Institute TRCN0000045393 
pLKO.1-puro-shHAS2 #6 Broad Institute TRCN0000045396 
pLKO.1-puro-shHAS2 #8 Broad Institute TRCN0000418983 
pLKO.1-puro-shGFP Broad Institute TRCN0000072181 
pOTB7 UGP2 isoform 2 PlamID - Harvard plasmid HsCD00325250 
pENTR223 UGP2 isoform 1 PlamID - Harvard plasmid HsCD00376643 
pENTR-GFP Addgene 15301 
pCW57.1 destination vector Addgene 41393 
pCW57.1-UGP2 isoform 1 This paper N/A 
pCW57.1-UGP2 isoform 2 This paper N/A 
pCW57.1-GFP This paper N/A 
Cypridina TK control promoter construct SwitchGear Genomics SN0322S 
LightSwitch™ UGP2 promoter construct SwitchGear Genomics S708263 
 
 
Table 7: List of other reagents 
Other reagents Source Identifier 
Transparent PEM Membrane 24-well 8.0 µm pore size VWR 62406-198 
Cultrex® 5X BME Solution Trevigen 3455-096-02 
Matrigel® Invasion Chamber 24-well Plate 8.0 Micron  Corning 354483 
Nitrocellulose membranes GE Healthcare  10600002 
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Table 8: List of qPCR primers 
Primers Sequence Source 
UGP2 forward ATGTCTCAAGATGGTGCTTCTCA IDT 
UGP2 reverse GGTGTGCTCAAATTCATGTGATG IDT 
UGDH forward TGCCCAGAGAATAAGCAGCAT IDT 
UGDH reverse CCATTCCAATCGCTGTTGCTA IDT 
UAP1 forward AATGACCTCAAACTCACGTTGT IDT 
UAP1 reverse GCTCTGCATAAAGTTCTACCTGT IDT 
HAS2 forward GATGCATTGTGAGAGGTTTC Sigma 
HAS2 reverse CCGTTTGGATAAACTGGTAG Sigma 
Actin forward  GAGCGCGGCTACAGCTT IDT 
Actin reverse  TCCTTAATGTCACGCACGATTT IDT 
TBP forward GAGCCAAGAGTGAAGAACAGTC IDT 
TBP reverse GCTCCCCACCATATTCTGAATCT IDT 
 
 
 
Table 9: List of oligonucleotides for shRNAmir cloning (97mer) 
97mer 
oligonucleotides 
Sequence Source 
UGP2_1 TGCTGTTGACAGTGAGCGAAGTGTTGATTTTTAAAATAGA
TAGTGAAGCCACAGATGTATCTATTTTAAAAATCAACACT
GTGCCTACTGCCTCGGA 
Invitrogen 
UGP2_2 TGCTGTTGACAGTGAGCGAGGCTAGTTTCTTACAATGAAA
TAGTGAAGCCACAGATGTATTTCATTGTAAGAAACTAGC
CCTGCCTACTGCCTCGGA 
Invitrogen 
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4 - DISCUSSION 
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In this thesis, I focused on unifying the theme of metabolism and the acquisition of metastatic 
properties by cancer cells, namely increased migration. I believe to have contributed for this goal 
with two studies, in distinct settings, where the role of metabolism in the migratory properties of 
cells is evaluated. Chapters 3.1 and 3.2 provide a detailed discussion of the results obtained in 
each of those two studies. In this final chapter, I will try to unify our own data with data previously 
published in the literature and draw the main conclusions.  
Migration is a fundamental cellular phenotype that endows cancer cells the ability to disseminate 
from the primary tumor, a crucial step in metastasis formation. Understanding the metastasis 
process is of utter importance, since most of cancer-related deaths are directly related with the 
presence of metastases. In this context and considering the growing evidence pointing to an 
important role of metabolism in cancer progression, I first concentrated my efforts on 
understanding how altered metabolism, more specifically OXPHOS dysfunction, has an impact 
on cellular phenotypes associated with tumorigenesis, namely increased migration. Indeed, we 
showed that OXPHOS dysfunction in vitro, caused a mtDNA mutation, leads to increased 
migration in tumor cells (chapter 3.1) in a process that seems to mediated by integrin-α5β1. This 
prompted us to ask if, on the other hand, a more migratory and invasive phenotype is accompanied 
by a metabolic rewiring. For that, we optimized an EMT model in mammary epithelial cells and 
we found profound metabolic alterations, affecting multiple pathways, when cells engaged on 
EMT. We decided to focus our attention on the UDP-glucose pathway, a less-well known glucose 
destiny that may be crucial for providing regulators of cellular migration (chapter 3.2). 
The role of mitochondrial dysfunction was the first proposed cause for the aerobic glycolysis 
phenotype of cancer cells, by Warburg himself (Warburg 1956). Indeed, nowadays only a few 
metabolic enzymes have been identified as directly contributing to cell transformation and the 
most well-known examples are mitochondrial proteins. Mutations in SDH have been shown to 
predispose for neuroendocrine tumors paragangliomas and phaeochromocytomas (Astuti, 
Douglas, et al. 2001; Astuti, Latif, et al. 2001; Baysal et al. 2000; Burnichon et al. 2010; Gimm 
et al. 2000; Hao et al. 2009; Niemann and Müller 2000) and we have identified a highly prevalent 
founder germline SDHB mutation in the Portuguese population (Martins and Nunes et al. 2013 - 
manuscript in annex I). SDHB mutations might be of particular relevance for the clinical 
management of paraganglioma and pheochromocytoma patients, since they have been proposed 
to be a risk factor for malignancy and poor prognosis (Amar et al. 2007; Gimenez-Roqueplo et 
al. 2003). Interestingly, SDHB-mutant metastatic PGL/PCC tumors cluster together in an 
unsupervised hierarchical cluster analysis using microarray data of EMT-related genes and Twist 
is one of the genes that is overexpressed in this subset of PGL/PCC, when compared with non-
metastatic tumors or non-SDHB-metastatic tumors (Loriot et al. 2012). Besides, in PGL/PCC 
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tumors, Snail/Slug displays a nuclear localization in the SDHB-related metastatic tumors, further 
supporting the activation of EMT in these tumors (Loriot et al. 2012). In PGL/PCC tumor 
biopsies, immunohistochemistry staining analysis indicated that Snail may be predictive of the 
metastatic potential of PCC (Häyry et al. 2009). The association of SDHB inactivation with EMT 
has also been described for other neoplasias, like CRC, HCC and ovarian cancer. In CRC and 
HCC, lack of expression of SDHB is correlated with advanced tumor staging and in vitro 
experiments showed that with SDHB knock-down cells become more migratory, downregulate 
E-cadherin and upregulate several mesenchymal associated proteins and EMT TFs like Snail, 
which is consistent with EMT (Tseng et al. 2018; Wang, Chen, and Wu 2016). In ovarian cancer, 
loss of SDHB expression leads to a hypermethylated epigenome that is sufficient to promote 
EMT, characterized by overexpression of Snail and Twist1/2, loss of membrane-bound E-
cadherin, together with enhanced ability to form colonies in soft agar (Aspuria et al. 2014). In 
terms of metabolic phenotype, in HCC cells, SDHB loss also causes increased glucose uptake and 
lactate secretion while in ovarian cancer, its results in a diversion of glucose towards the pentose 
phosphate pathway and nucleotide biosynthesis rather than the TCA cycle, to which glutamine 
makes an increased contribution (Aspuria et al. 2014; Tseng et al. 2018). Interestingly, while in 
HCC and ovarian cancer cells SDHB loss promotes tumor cell proliferation, in CRC cells it does 
not affect cell population growth (Aspuria et al. 2014; Tseng et al. 2018; Wang, Chen, and Wu 
2016), illustrating the importance of cell context. Concerning mtDNA genes, alterations in the 
mtDNA have been described in several cancers (Copeland et al. 2002; Fliss et al. 2000; He et al. 
2010; Petros et al. 2005), in some instances, like breast cancer, being associated with poor disease-
free survival (Tseng et al. 2006).  
We contributed to further enlighten the role of mitochondrial dysfunction in cancer cells by 
showing that a mtDNA mutation that affects all mtDNA-encoded ERC complexes leads to 
increased tumorigenic and metastatic potential in vivo (chapter 3.1). Surprisingly, OXPHOS 
dysfunction decreased cell growth in vitro but led to formation of larger tumors in mice, 
highlighting the importance of the cellular microenvironment in modulating the consequences of 
metabolic alterations. Other mice studies have showed a link between mtDNA mutations and the 
ability to form tumors, like those of Petros et al. and Shidara et al. (Petros et al. 2005; Shidara et 
al. 2005) that corroborate our findings. It was also shown that the ability of HeLa cells to form 
tumors is dependent on the presence of mtDNA (Hayashi, Takemitsu, and Nonaka 1992); 
however, Kulawiec et al. observed that breast cancer cells depleted from mtDNA have higher 
tumorigenic potential in vivo (Kulawiec et al. 2008). Interestingly, it was subsequently 
demonstrated that stable cell lines derived from primary subcutaneous tumors that grew from ρ0 
cells acquired host mtDNA and recovered respiration (Tan et al. 2015). Therefore, it is pertinent 
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to point out that mitochondrial dysfunction due to mtDNA depletion can be very different from 
the one caused by mtDNA mutations.  
The link between mtDNA mutations and metastasis formation was established when Ishikawa et 
al. showed that the metastatic potential of highly metastatic Lewis lung carcinoma mouse cells 
accompanies the mtDNA molecules harboring a complex I mutation (Ishikawa et al. 2008). The 
authors showed that specific mtDNA mutations that induce mitochondrial respiration defects can 
control the malignant transformation of tumor cells to develop the metastatic potential (Ishikawa 
et al. 2008); accordingly, the presence of mutated mtDNA is also important for the capacity of 
breast cancer cells to form metastasis (Imanishi et al. 2011). On the other hand, a recent study 
highlighted the dynamic nature of metabolism: when cells depleted of mtDNA were injected into 
mice, the mitochondrial function recovered in a stepwise manner, from cancer cells of the primary 
tumor, to tumor circulating cells and finally to the cells of the metastasis, suggesting an essential 
requirement for OXPHOS in tumor progression (Tan et al. 2015). 
The higher metastatic capacity conferred by mtDNA mutations has been linked to the production 
of ROS by dysfunctional mitochondria (Ishikawa et al. 2008; Petros et al. 2005), although in some 
cases ROS overproduction by metastatic cells does not disappear when the mtDNA mutation is 
corrected (Imanishi et al. 2011). Another hypothesis is that mtDNA mutation-triggered OXPHOS 
dysfunction induces a metabolic rewiring that changes the availability of substrates for 
glycosylation, affecting the abundance of β-1,6 GlcNAc branched N-glycans (Sasai et al. 2002). 
Accordingly, we detected alterations in the glycosylation pattern of genes that regulate migration, 
namely integrin β1 (chapter 3.1). The mtDNA-mutated cybrids also showed increased fibronectin 
expression, a finding already reported in mammary epithelial cells depleted of mtDNA that show 
enhanced migration and invasion capacity (Kulawiec et al. 2008). 
Since most of the cancer metabolism studies are performed under the perspective of proliferation, 
trying to understand how metabolic reprogramming supports cancer cells’ proliferative capacity, 
much less is known about the metabolic requirements of metastasis. This, together with our results 
on mtDNA-mutant cybrids, prompted us to investigate possible metabolic alterations that involve 
the formation of metastasis. For that purpose, we used an EMT model, which is a developmental 
cellular-biological program that allows cancer cells to acquire features that support their 
dissemination from the primary tumor site (Brabletz et al. 2018).  
We induced EMT in breast epithelial cells by changing ERK2 signaling (chapter 3.2), a pathway 
that has been shown to be at the crossroads of several EMT inducers (Buonato and Lazzara 2014; 
Gonzalez and Medici 2014; Xie et al. 2004; Zhang et al. 2012).  
ERK signaling through the RAS–RAF–MEK–ERK pathway is an evolutionary conserved 
signaling cascade that transmits signals from cell surface receptors to promote proliferation and 
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survival programs (Roux and Blenis 2004). ERK signaling is frequently over-activated in human 
tumors, usually owing to mutations in RAS or BRAF (Dhillon et al. 2007), while ERK genetic 
alterations, although very rare, were described in cervical carcinomas (Ojesina et al. 2013). The 
downstream signaling of ERK is still not fully understood, but ERK signaling seems to be 
essential for EMT and HGF-induced motility in lung cancer cells (Buonato and Lazzara 2014; 
Radtke et al. 2013). Depending on the pool of substrates that is activated, ERK can trigger 
different phenotypes. For example, DEF motif-signaling of ERK2 can have a specific role in 
EMT, in a process mediated by Fra1 stabilization and ZEB activation (Shin et al. 2010). A newly 
identified ERK substrate MCRIPT was shown to regulate EMT through E-cadherin (Ichikawa et 
al. 2018). The regulation of cellular metabolism by ERK is a poorly explored field. The few 
existing studies revealed that ERK mediates the signaling triggered by ECM attachment and 
ErbB2, which promotes the entry of glucose in the TCA cycle by upregulation of PDK4 (Grassian 
et al. 2011). Interestingly, ERK2 activation promotes mitochondria fragmentation through Drp1 
phosphorylation, which is required for tumor growth in Ras-expressing cells (Kashatus et al. 
2015). The fragmentation of mitochondria via Drp1 is enhanced in invasive breast cancer and it 
is associated with increased metastatic potential (Zhao et al. 2012). 
In chapter 3.2, we showed that EMT induction upon ERK2-DEF motif signaling increased the 
abundance of UDP-sugar metabolites, especially UDP-glucose. Besides, UGP2, the enzyme that 
produces UDP-glucose, is not only increased in the cells becoming mesenchymal, but it is actually 
required for EMT. There are a few metabolomics studies that indicate the increase in UDP-
glucose and UGP2 in EMT models (Lucena et al. 2016; Mulvihill et al. 2014), although they do 
not address the importance of the UDP-glucose pathway for the mesenchymal phenotype, namely 
for the acquisition of migratory and invasive features. We propose that UDP-glucose and UGP2 
may be important for EMT by mediating the production of HA, which is a glycosaminoglycan 
generated from UDP-glucuronate (derived from UDP-glucose) and from UDP-GlcNAc. In 
support of our hypothesis, both UDP-glucuronate and UDP-GlcNAc and the enzymes that 
catalyze their production are increase in our mesenchymal cells (Fig. 13). We demonstrated, for 
the first time, that ERK2-driven EMT underlies a metabolic reprograming, involving UDP-
glucose pathway, and that ERK pathways is coordinating the expression of several enzymes of 
the UDP-sugar metabolism. 
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Fig. 13: Proposed model for how is UGP2 and UDP-glucose metabolism regulating EMT-
associated migration. 
Some papers have already reported metabolic alterations after EMT induction using several 
methods: treatment with TGF-β, HGF, overexpressing EMT TFs (like Snail) or activating other 
pathways (such as Wnt or Hippo). Despite the fact that the majority of studies focuses on glucose 
metabolism, these changes are very diverse and encompass several different pathways, of which 
the regulation of the production of fructose-1,6-bisphophate from fructose-6-phosphate and the 
reverse reaction stands out: both PFK platelet (PFKP) and FBP1 are directly regulated by Snail 
through binding to the respective promoters (Dong et al. 2013; Kim et al. 2017). On the other 
hand, metabolic alterations can also result in the acquisition of mesenchymal features by epithelial 
cells. This topic is discussed in more detailed in annex II.  
Recently, some studies have been published concerning the metabolism of metastatic cells. For 
instance, PGC-1α (peroxisome proliferator-activated receptor-γ co-activator 1α), a transcriptional 
coactivator that regulates the genes involved in energy metabolism, was shown to be essential for 
migration capacity and metastasis of breast cancer cells (LeBleu et al. 2014). The authors showed 
that circulating cancer cells originated from breast tumors respire more, display increased levels 
of mtDNA and have increased PGC-1α expression. The expression of this enzyme, in turn, was 
shown to determine the in vitro invasive capacity of cancer cells. Moreover, suppression of PGC-
1α expression suppresses cancer cell dissemination and metastasis in vivo, by facilitating 
intravasation and extravasation of cancer cells (LeBleu et al. 2014). These results are in line with 
the previously described study where circulating tumor cells derived from tumors that emerged 
after injection of breast cancer cell line depleted of mtDNA show increased respiration compared 
to cells from the primary tumor and decreases when compared with cell from the metastasis (Tan 
et al. 2015). On the other hand, using a xenograft mouse model of melanoma, Luo et al. showed 
that PGC-1α suppression increased metastasis and circulating tumor cells derived from these 
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tumors had lower PGC-1α expression. The authors suggest that PGC1α has a dual function in 
cancers: promoting growth and survival of tumors, while suppressing cell motility, cell–cell 
interaction, adhesion and invasion that promote metastasis formation (Luo et al. 2016). The 
difference between these two studies concerning PGC-1α role in metastasis may be due to 
differences in cell of origin: breast cancer cells are of epithelial origin while melanoma cells 
originate from neural crest cells and are mesenchymal. 
In a different study, Piskounova et al. studied the metabolism of melanoma cells that are more 
successful at forming metastasis (denominated by the authors as “efficiently metastasizing 
melanomas”) using patient derived xenografts. These cancer cells are more efficient at forming 
metastasis due to their increased ability to survive in the blood and in the secondary tumor site 
(Piskounova et al. 2015). Metastatic tumors originated from the “efficiently metastasizing 
melanomas”, when compared to the subcutaneous tumors, display an altered metabolism that is 
characterized by an enhanced contribution of glucose carbon to tissue serine and glycine levels 
and increased expression of folate pathway enzymes (Piskounova et al. 2015). This pathway is a 
major source of NADPH, an important intermediate that allow cells to cope with oxidative stress 
and in fact, the authors show that circulating melanoma cells and metastases have elevated ROS 
compared to primary tumors and that oxidative stress is a limiting factor for the establishment of 
metastasis (Piskounova et al. 2015).  
Together, these studies highlight the active role of mitochondrial function for metastasis 
formation. Besides, it is crucial that cells adapt their metabolism to cope with the oxidative stress 
in hostile environments like the circulation and the secondary tumor site. Further studies have 
highlighted the importance of other metabolic pathways for metastasis formation such as proline 
or lysine metabolism (Elia et al. 2017; Wu et al. 2015). Importantly, Dupuy et al. showed that 
breast cancer cells show metabolic heterogeneity depending on the metastatic site and that 
metastatic cancer cells can engage both glycolytic and oxidative metabolism (Dupuy et al. 2015). 
In fact, breast cancer cells that metastasize to the lung show increased pyruvate carboxylase-
dependent anaplerosis, which is modulated by nutrient availability within the lung 
microenvironment (Christen et al. 2016).  
The two studies that compose this thesis were performed in vitro, which comes with limitations, 
the most relevant probably being the culture conditions in which most of the experiments were 
made. Like in any eukaryote cell, the metabolism of cancer cells is an adaptation of cells to the 
extracellular conditions, hence being highly influenced by the tumor microenvironment. As such, 
our results obtained should be interpreted in the light of culture conditions where cells have 
immediate access to nutrients and are exposed to excess oxygen. Besides, a tumor functions as a 
collective entity composed of multiple cell types and a complex matrix, similarly to an organ, 
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which differs greatly from our culture conditions. On the other hand, the simplicity of in vitro 
studies allows for an increased control of the variables and these studies have given us insightful 
cues about the importance of old and new pathways. Nowadays, a huge effort has been put to 
finding in vitro conditions that, for example in terms of nutrients availability, most appropriately 
mimic the in vivo conditions, as described in Cantor et al. and Muir et al. (Cantor et al. 2017; 
Muir et al. 2017). Importantly, the intracellular abundance of the UDP-sugars studied in this thesis 
is similar when comparing cells cultured in standard media from cells cultured in a media which 
better reflects the polar metabolite composition of human plasma, as evidence in the article by 
Cantor et al. (Cantor et al. 2017).  
In order to understand the metabolic requirements of cancer cells during tumor progression, 
namely during the acquisition of migratory and invasive properties that enable metastasis, we 
used an in vitro EMT model that consisted in overexpressing ERK2 in MCF10A cells. MCF10A 
cells are immortalized mammary epithelial cells and although non-transformed, they harbor 
genetic abnormalities: a deletion of the locus containing p16 and p14ARF, as well as 
amplification of Myc (Debnath, Muthuswamy, and Brugge 2003). This in vitro model presents, 
therefore, limitations but it consists of a good platform to identify and unravel the mechanism of 
potential new candidates that regulate EMT, like UGP2, and as a first screening system for 
pharmacological interference with the process. Future studies should, consequently, focus on 
translating the findings presented here concerning UDP-glucose pathway and UGP2 expression 
into other models closer to in vivo natural systems. MCF10A cells have the advantage of being 
able to form three-dimensional structures when cultured in a matrix such as Matrigel®, providing 
an important tool to model early events involved in carcinoma formation (Debnath et al. 2002; 
Debnath, Muthuswamy, and Brugge 2003). In fact, it has been shown that these cells when 
overexpressing Ras-V12, form large colonies exhibiting widespread protrusive extensions and 
disruption of acinar morphogenesis (Shin and Dimitri et al. 2010). Hence, it would be interesting 
to understand if the formation of these extensions is impaired upon UGP2 silencing. Besides, the 
analysis of UGP2 expression in a breast cancer cell lines panel and in breast cancer tumor biopsies 
would allow to understand if it correlates with tumor aggressiveness and patient survival. 
Additionally, it would be important to look into tumor specimens and evaluate where UGP2 is 
mainly expressed: if in the center of the tumor or in the invasive front and whether it is associated 
with the expression of EMT markers. Ultimately, mouse models of breast cancer should be used 
to understand if UGP2 and the UDP-glucose metabolic pathway are limiting for tumor 
progression and if they cause liabilities that can be exploited as an innovative approach to manage 
metastasis.  
Altogether, the data presented in this thesis establishes a clear link between metabolic alterations 
and the migration and invasion capacities of cells, using a model of EMT. For the first time, we 
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demonstrated that ERK2, a pivotal molecule that coordinates several oncogenic pathways, 
regulates UDP-sugar metabolism, in this way favoring two major features of metastasis: increased 
migration and invasion. The observations in this thesis may present useful opportunities in clinical 
oncology, particularly the use of the metabolic pathways and enzymes as predictive biomarkers 
or even imaging techniques. Finally, our results support the notion of the dependence on certain 
types of metabolism as an important target for the development of new drugs to control cancer 
dissemination and metastasis, which could have a significant impact in decreasing cancer-
associated deaths.  
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Research Letter
R G Martins, J B Nunes et al. SDHB founder mutation in
Portuguese PGL
20 :6 L23–L26A founder SDHB mutation in
Portuguese paraganglioma patientsDear EditorWe would like to report a genetic screening of SDHB,
SDHC, SDHD and SDHAF2 genes (hereafter abbreviated to
SDHx) in patients with paragangliomas (PGL) and phaeo-
chromocytomas (PCC) from northern Portugal.
PGL and PCC are neuroendocrine tumours that can be
caused by heterozygous germline loss-of-function
mutations in SDHx genes (Gimenez-Roqueplo et al.
2012). The spectrum of germline SDHx mutations varies
considerably among different countries, a circumstance
that is related to the existence of several founder
mutations. This is particularly marked in The Netherlands
(Hensen et al. 2012), where six founder mutations were
discovered, but evidence for founder effects was also
observed for SDHx mutations in Austrian (Janecke et al.
2010), Italian (Simi et al. 2005) and Spanish (Cascon et al.
2009) populations. In addition to familial PGL or PCC,
germline SDHx mutations have also been observed in
patients without familial history of disease, sometimes
classified as ‘occult’ familial cases (Lima et al. 2007). This
phenomenon may be associated with the low penetrance
of SDHx mutations, which is about 50%, although
increasing in older individuals (Burnichon et al. 2009),
and with the genomic imprinting observed in SDHD and
SDHAF2 genes (Gimenez-Roqueplo et al. 2012).
We report the genetic study of 37 individuals
diagnosed with PGL or PCC between 2009 and 2012, of
which three were familial cases and 34 were sporadic.
Sporadic cases were defined as those having no familial
history of PGL or PCC in the parental and grandparental
generations and disease was considered to be inherited
when at least two first-degree relatives or two second-
degree relatives were affected by these tumours. Only the
index cases from familial PGLs were considered for all the
analyses. Patients displaying syndromic features associ-
ated with VHL, MEN2 or NF1 were excluded from the
study. Written informed consent for genetic testing was
obtained from all patients.
Themajority of patients developed PGL (27/37; 73.0%)
and ten developed PCC (27.0%). The clinical and patho-
logical features of the 37 patients are shown in Table 1.http://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-12-0399 Printed in Great BritainWe have identified seven different germline SDHx
mutations that were present in 20 of the 37 (54.1%)
patients. One mutation was located in SDHD and six were
located in the SDHB gene, while no alterations were found
in SDHC or SDHAF2 genes.
We identified three cases of familial PGL. In the first,
the index case (multiple HN PGLs and a thoracic PGL) was
found to harbour a germline SDHD frameshift mutation
(L139FfsX29) that was shared by the two relatives with
disease (one with multiple abdominal PGLs and another
with multiple head and neck PGLs). Two additional
families with PGL were identified: in one, the index case
developed a malignant abdominal PGL (with bone
metastases) and her uncle had also developed a malignant
abdominal PGL with brain metastases; in a third family,
the index case presented abdominal PGL and his mother
had developed multiple head and neck PGLs. All the
affected relatives of these two families harboured a large
germline 15 678 bp deletion in the SDHB gene, which
encompasses the promoter and exon 1.
In the 34 patients in whom no familial relationships
could be established (considered as sporadic cases), we
have identified six germline SDHxmutations, all in SDHB,
that were present in 17 patients (50.0% of sporadic cases).
The majority of the germline-mutated patients harboured
the SDHB 15 678 bp deletion (9/17, 52.9%), four patients
presented SDHB frameshift mutations (P56delYfsX5 and
S198AfsX22 in three patients) that lead to premature stop
codons and four patients presented germline missense
mutations (A43P, R11H and R230H in two patients). All
the aforementioned SDHB mutations were previously
described as pathogenic (Bayley et al. 2005). In patients
without SDHx mutations, we have screened for VHL,
TMEM127 and MAX mutations, but none were disclosed.
The finding that a large number of patients in this
series (11/37; 29.7%) presented the germline SDHB
15 678 bp deletion prompted us to study the haplotypic
variability in the flanking regions upstream (using the
SNPs: rs1569754, rs3946080, rs2143811 and rs5772743)
and downstream (using the SNPs: rs7545518, rs7545499Published by Bioscientifica Ltd.
Table 1 Clinical characteristics of PGL and PCC patients with or without SDHx mutations
All patients
(nZ37)
Patients with germline
mutationsa (nZ20)
Patients without
germline mutations
(nZ17)
Mutated vs
non-mutated
cases P valueb
Mean age at diagnosis (years) 40.0G16.0 33.8G14.6 47.4G14.8 0.008
Gender
Male 21 (56.8) 14 (70.0) 7 (41.2) 0.078
Female 16 (43.2) 6 (30.0) 10 (58.8)
Multiple tumours 1 (2.7) 1 (5.0) 0 NS
Mean tumour size (cm) 7.2G3.6 7.1G3.2 7.3G4.1 NS
Localizationc
Adrenal glands 10 (27.0) 2 (10.0) 8 (47.1) 0.023
Extra-adrenal
Head and neck 7 (18.9) 4 (20.0) 3 (17.6)
Thorax 4 (10.8) 4 (20.0) 0
Abdomen 17 (45.9) 11 (55.0) 6 (35.3)
Hormonal hypersecretiond
Norepinephrine 21 (67.7) 12 (75.0) 9 (60.0) NS
Epinephrine 5 (17.2) 0 (0) 5 (38.5) 0.011
Dopamine 14 (46.7) 7 (43.8) 7 (50.0) NS
Metanephrine 6 (20.0) 0 6 (35.3) 0.005
Normetanephrine 21 (67.7) 11 (68.8) 10 (66.7) NS
None 7 (23.3) 3 (18.8) 4 (28.6) NS
Locally invasive disease without
metastases
6 (16.2) 3 (15.0) 3 (17.6) NS
Distant metastases 11 (29.7) 7 (35.0) 4 (23.5) NS
Mortality 4 (10.8) 3 (15.0) 1 (5.9) NS
The numbers in parentheses indicate percentage values.
aOnly the index cases of familial PGLs are shown.
bP!0.05 is considered statistically significant.
cOne familial case had PGL in head, neck and thorax.
dPercentages were calculated considering only the patients that had hormonal measurements; hormonal hypersecretion was defined as any value above
normal range.
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Research Letter R G Martins, J B Nunes et al. SDHB founder mutation in
Portuguese PGL
20 :6 L24and rs7536679) of the deletion breakpoint, in order to
assess whether this deletion occurred in multiple inde-
pendent events or whether it was a single event that
settled in the population. After selective amplification of
the deleted allele in the 11 deletion-positive patients, weTable 2 Haplotypes detected in PGL patients, control population
Haplotype
SNPs
rs1569754 rs3946080 rs2143811 rs5772743 rs7545518 rs75
Hap1 C A C A A
Hap2 C A C A G
Hap3 C A C –b A
Hap4 C A C –b G
Hap5 T G T A A
Hap6 T G T A G
NPO, North of Portugal (control population); GBR, British in England and Sc
Genomes Project population); TSI, Toscani in Italia (1000 Genomes Project pop
alleles.
aPGL, includes only the deleted alleles from the 11 patients harbouring the SD
bDash indicates adenine deletion.
http://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-12-0399 Printed in Great Britainobserved that, in all cases, the deletion was associated with
the same haplotype (haplotype 3 – Table 2); selective
amplification of the WT alleles (in the same 11 deletion-
positive patients) disclosed two different haplotypes.
Furthermore, haplotype reconstruction (using the sameand other European populations
Chromosome frequency (%)
45499 rs7536679
PGLa
nZ11
NPO
nZ80
GBR
nZ178
FIN
nZ186
TSI
nZ196
A T 0 5.0 0 0 0
G C 0 22.5 28.7 29.6 29.6
A T 100 45.0 52.3 54.8 47.5
G C 0 13.8 7.3 8.6 8.2
A T 0 1.3 0 0 0
G C 0 12.5 11.8 7.0 14.8
otland (1000 Genomes Project population); FIN, Finnish in Finland (1000
ulation); Hap3, given in bold, indicates the haplotype found in all deleted
HB 15 678 bp deletion.
Published by Bioscientifica Ltd.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research Letter R G Martins, J B Nunes et al. SDHB founder mutation in
Portuguese PGL
20 :6 L25SNPs) in 40 healthy individuals from northern Portugal
(in whom we confirmed the absence of the deletion)
identified four additional haplotypes (Table 2). Four of
these haplotypes were detected in other European
populations (Great Britain, Finland and Italy) in
comparable frequencies (Table 2). The frequency of
haplotype 3 in the deleted chromosomes is significantly
different from its frequency in the control population
(PZ0.0005).
SDHA and SDHB immunohistochemistry in the
tumour tissue showed that all patients with SDHx
mutations had loss of SDHB and presence of SDHA
expression in the tumour. On the other hand, patients
without SDHxmutations presented both SDHB and SDHA
expression, discarding the existence of additional SDHx
alterations, such as large deletions, that would be missed
by Sanger sequencing.
When performing genotype–phenotype correlations,
we observed that patients with SDHx mutations had a
lower mean age at diagnosis (PZ0.008), developed
tumours that were more frequently located in extra-
adrenal sites (PZ0.023) and were predominantly men
(PZ0.078) (Table 1). The tumours that occurred in
patients with SDHx mutations presented a signature of
low secretion of epinephrine (PZ0.011) and metanephr-
ine (PZ0.005) (Table 1) when compared with tumours
without SDHx mutations. Malignant and lethal tumours
were more frequently observed in patients with SDHx
mutations (35.0 and 15.0% respectively) than in non-
mutated cases (23.5 and 5.9% respectively), although the
difference was not statistically significant.
In the series of PGL/PCC presented here, half of the
patients without familial history of disease (17/34; 50.0%)
harboured germline SDHxmutations; altogether, germline
SDHx mutations were the primary cause of PGL and PCC
in 54.1% (20/37) patients.
The prevalence of SDHx mutations in this cohort is
high and comparable to the one found in a large series of
French PGL patients (Burnichon et al. 2009). The high
frequency of SDHx mutations in our series is likely
attributable to the prevalence of the SDHB 15 678 bp
deletion (55.0% of the SDHx-mutated patients). To the
best of our knowledge, this is only the second report of
the SDHB 15 678 bp deletion in PGL/PCC patients, despite
the large number of studies in this topic, raising the
hypothesis that the high frequency of this deletion in
Portuguese patients can be related to a founder effect.
A founder effect for this specific deletion had already been
proposed by Cascon et al. (2008), who studied five families,
all of them harbouring this deletion and showing ahttp://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-12-0399 Printed in Great Britainconserved breakpoint. Notably, of the five families, one
was from Porto, Portugal, a second was a Brazilian family
and the remaining three were of Spanish origin, more
specifically from Galicia (Cascon et al. 2008).
Our results show that the deletion breakpoint is
conserved among 11 patients with PGL/PCC and also
matches the previously reported breakpoint (Cascon et al.
2008). None of these 11 patients have familial relation-
ships, but all come from northern Portugal. Furthermore,
we have shown that all deleted alleles share a common
haplotype (haplotype 3), in a significantly higher fre-
quency than in control, healthy individuals (45.0%). The
lack of variation in the up- and downstream flanking
regions of the deleted allele (in contrast to the normal
alleles from the control population, where six different
haplotypes were found) fits with a founder effect for this
deletion, which has probably settled in the northern
Portuguese/Galician populations. A recent study of SDHx
mutations in Portuguese PGL/PCC patients from central
and southern Portugal did not find this deletion
(Domingues et al. 2012), further suggesting that the
founder effect is related to northern Portuguese/Galician
populations.
Our results support the previously reported associ-
ation between SDHxmutations and lower age at diagnosis
and extra-adrenal location (Burnichon et al. 2009). The
association between absence of SDHx mutations and
higher levels of epinephrine and metanephrine hyper-
secretion may reflect the higher proportion of PCC in this
subgroup of patients, as epinephrine is synthesized and
stored only in the adrenal medulla (and metanephrine is
its main metabolite) whereas norepinephrine and
dopamine are also synthesized in the peripheral
sympathetic nerves.
Summing up, we present data showing that the
majority of PGL in northern Portugal patients develop as
a consequence of germline SDHxmutations, in particular a
founder mutation in the SDHB gene (15 678 bp deletion).
Our results support the suggestion by Hensen et al. (2012)
that population specificities, regarding the presence of
founder germline SDHx mutations, should be taken into
account whenever deciding about the genetic testing in
PGL/PCC patients.
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Abstract 
The epithelial to mesenchymal transition (EMT) program can be reactivated during metastasis, 
especially in its first step, when tumor cells detach from the primary tumor, invade the adjacent 
tissue and intravasate into the vascular system. EMT confers tumor cells the ability to migrate 
and invade, having been proposed to be one of the cell-biological programs that enables 
dissemination. Recent research suggests that cellular metabolism is reprogrammed during EMT. 
In fact, different metabolic pathways, from glycolysis, the TCA cycle and oxidative 
phosphorylation to hexosamine biosynthetic pathway and lipid metabolism are rewired and 
contribute to EMT. However, the variety of EMT inducers, read-outs and cell phenotypes make 
it difficult to understand if there are key metabolic pathways that drive and maintain the 
mesenchymal phenotype. Here, we tried to build a clearer picture of the metabolism during EMT, 
according to the signaling pathways involved. There is a lot of enthusiasm in unraveling of the 
link between metabolism and EMT, although the number of mechanistic studies is still very 
limited. With this review, we hope to integrate enough evidence to highlight the role of 
metabolism in the signaling landscape of EMT. 
 
METABOLIC REPROGRAMMING IN CANCER 
The metabolism of tumors has been subject of study since the beginning of the twentieth century. 
The pioneer in the field, Otto Warburg, described a high consumption of glucose and release of 
lactate by malignant cells, when compared with non-neoplastic cells, even in the presence of 
oxygen (Warburg 1924). This phenomenon is known as aerobic glycolysis or the “Warburg 
effect”. Warburg hypothesized that this aerobic glycolysis was irreversible and due to an 
impairment of mitochondrial respiration (Warburg 1956). Nowadays, with an exponential interest 
in this field of research and the inclusion of the “reprogramming of energy metabolism” as a 
hallmark of cancer (Hanahan and Weinberg 2011), a more complex picture has emerged.  
The adaptation of the cellular metabolism is very important in the sense that it allows cells to 
maintain cellular homeostasis and survive under different environmental conditions, being part 
of the adjustment to a phenotypic alteration. Therefore, during malignant transformation and 
tumor progression, cancer cells rely on specific changes in metabolic activity in order to meet 
their energetic demands and biomass production. Nowadays, we know that these changes are not 
limited to carbohydrate metabolism but they also comprise lipids, nucleotides, amino acids, as 
well as alterations in reductive equivalents and redox power. Besides, different types of tumors 
display different metabolic adaptations and even within the tumor microenvironment there is 
metabolic cooperation between cancer cells and stromal cells. The role of metabolism in 
tumorigenesis is also linked to other cancer-related aspects, such as stemness, angiogenesis, 
immune escape, among other. Importantly, cancer cell metabolism reflects the stage of the tumor, 
implying that it may vary according to the proliferation rate and to the migratory and invasive 
capacities of cancer cells. Indeed, much less is known about the metabolism of migratory cancer 
cells and of those that are detaching from the primary tumor, as the first step of metastasis.  
 
Epithelial to mesenchymal transition  
Epithelial to mesenchymal transition (EMT) is a reversible process by which epithelial cells 
acquire mesenchymal properties. It was initially characterized during embryonic development 
and it plays a crucial role during gastrulation and neural crest formation. Additionally, it has also 
been described in other contexts such as wound-healing, fibrosis and cancer (Thiery et al. 2009). 
During cancer progression, EMT is one of the important mechanisms enabling dissemination of 
cells from the primary tumor towards the formation of secondary tumor sites, a process known as 
metastasis (Thiery et al. 2009). Although the contribution of EMT for metastasis is still matter of 
debate (Fischer et al. 2015; Zheng et al. 2015), EMT can be viewed as part of the more general 
concept of cell plasticity, which allows cancer cells to adapt and endure different environmental 
settings, being crucial for cancer progression (Nieto 2013).  
Cancer-related EMT is characterized by alterations in cell morphology, namely in the apico-basal 
polarity and cell-cell adhesion, in the ability to modulate the extracellular microenvironment, by 
increased capacity to migrate and invade and increased survival. Moreover, EMT is sometimes 
accompanied by changes in cell proliferation and also in the stemness of cancer cells (Thiery et 
al. 2009). Such a distinct phenotype naturally reflects the existence of global alterations inside the 
cells, including dramatic changes in gene expression as well as cellular metabolism. 
The most common features of EMT are changes in cell morphology and increased migration and 
invasion. Epithelial cells display an apical basal polarization and usually form monolayers, 
contacting with the neighboring cell through cell-to-cell junctions. During EMT, cell junctions 
undergo re-structuring, reflecting changes in the expression and localization of the proteins that 
form them. One such protein is E-cadherin, a main component of adherens junctions encoded by 
the CDH1 gene, whose expression is frequently suppressed in cancer and associated with the loss 
of the epithelial phenotype (Batlle et al. 2000; Cano et al. 2000; Grooteclaes and Frisch 2000; 
Petrova, Schecterson, and Gumbiner 2016). Additionally, post-translational modifications control 
the activity and localization of E-cadherin during EMT (Fujita et al. 2002; Pinho et al. 2011). 
Zonula occludens-1 (ZO-1) is a protein also expressed in epithelial tissues, forming tight junctions 
at the membrane, whose loss of functional activity has been associated with EMT (Huang, 
Guilford, and Thiery 2012). On the other hand, EMT is characterized by the upregulation of 
another type of cadherin - N-cadherin - which is associated with an invasive phenotype (Hazan et 
al. 2000; Islam et al. 1996). The elongated shape and migratory and invasive phenotype of cells 
undergoing EMT, also reflect changes in the cytoskeleton, for example, the upregulation of the 
intermediate filament vimentin (Mendez, Kojima, and Goldman 2010). In addition to cellular 
components, there are also important modifications in the extracellular microenvironment, which 
becomes more permissive to cellular migration and invasion. This happens with the expression 
of proteins that modulate the extracellular matrix, regulate cell adhesion and mediate the 
interaction of cells with the microenvironment, such as fibronectin, metalloproteases and integrins 
(Park and Schwarzbauer 2014; Yu and Stamenkovic 2000). The expression and the localization 
of the aforementioned proteins that characterize an epithelial or a more mesenchymal state are 
used as markers of EMT. 
EMT is orchestrated by transcription factors that translate the signals from the microenvironment 
to specific intracellular pathways. These so called EMT transcription factors (EMT TFs) belong 
to three main families – Snail, Twist and Zeb - and constitute a complex interactome (Nieto et al. 
2016). Snail and Slug (in humans SNAI1 and SNAI2, respectively) belong to the Snail 
superfamily of zinc-finger transcription factors, while Twist (TWIST1 in humans) is a basic 
helix–loop–helix transcription factor, a family that includes several master regulators of lineage 
specification and differentiation (Barnes and Firulli 2009; Manzanares, Locascio, and Nieto 2001; 
Simpson 1983). The zinc-finger E-box-binding (ZEB) transcription factors consists of two 
members in vertebrates, ZEB1 and ZEB2 (or SIP1), which bind regulatory gene sequences at E-
boxes to repress or activate transcription (Vandewalle, Van Roy, and Berx 2009). These EMT 
TFs target crucial regulators of EMT, such as E-cadherin, which can be repressed by Snail (Batlle 
et al. 2000; Cano et al. 2000), Slug (Bolós et al. 2003; Hajra, Chen, and Fearon 2002), Twist 
(Vesuna et al. 2008; Yang et al. 2010) and Zeb1/2 (Comijn et al. 2001; Grooteclaes and Frisch 
2000). Moreover, these transcription factors also lead to the upregulation of key mesenchymal 
proteins: for example, Snail regulates the expression of integrin-αV and induces migration 
(Haraguchi et al. 2008) and Twist upregulates N-cadherin through binding to the first intron in 
prostate cancer cells (Alexander et al. 2006). In the last years, several studies uncovered a 
complex regulatory network of EMT, not only at the transcriptional level but also in the 
epigenome, alternative splicing and post translational modifications, all of which modulate the 
stability, activity and localization of various EMT-related proteins (Nieto, Huang, Jackson and 
Thiery. 2016). For example, the activity of EMT TFs is also regulated by post translational 
modifications mediated by know players in tumorigenesis (Zhang et al. 2012; Zhou et al. 2004). 
EMT can be induced by a variety of extracellular agonists, including hepatocyte growth factor 
(HGF), epidermal growth factor (EGF), transforming growth factor β (TGF-β), Wnt and Notch 
(Thiery et al. 2009). Other tumor extracellular signals also induce Snail expression and/or 
stabilization, like the availability of nutrients and oxygen or signals from other cells in the tumor 
microenvironment. As an example is hypoxia that results in Snail upregulation, together with a 
decreased E-cadherin and β-catenin expression (Imai et al. 2003). Moreover, macrophages 
produce inflammatory cytokines like interleukin-1β (IL-1β) that has been associated with 
progression of head and neck squamous cell carcinoma (HNSCC) and promotes Snail 
upregulation and Snail-mediated CDH1 downregulation. Interestingly, in colon cancer cells, IL-
1β ability to stabilize Snail is dependent on the Wnt pathway (Kaler, Augenlicht, and Klampfer 
2012). These various agonists, TFs and cellular systems have been utilized by researchers to help 
defining the molecular mechanisms associated with EMT. 
 
EMT AND METABOLISM 
Metabolic Reprogramming during EMT 
There are several studies that show a metabolism re-wiring during EMT. This is conceivable since 
metabolism is highly dynamic and crucial for the adaptation to a new cellular phenotype with 
distinct needs in terms of nutrient demands for anabolism and energy production.  
Snail is one of the EMT effectors where wiring with metabolism has been shown in greater detail. 
In a microarray analysis performed in colorectal cancer (CRC) cells and in breast epithelial cells, 
Snail overexpression resulted in differential expression of enzymes from several metabolic 
pathways (Bhowmik et al. 2015; De Craene, van Roy, and Berx 2005). Moreover, using a 
metabolomics approach, Snail was shown to induce a metabolic reprogramming in breast 
epithelial and breast cancer cells (Bhowmik et al. 2015; Kim et al. 2017). In the case of Twist, its 
role in regulating metabolism during EMT is less well studied than the role played by Snail, but 
its overexpression in human mammary epithelial cells also caused alterations in the cellular 
metabolic profile (Bhowmik et al. 2015). 
The metabolic changes induced by TGF-β seem to be highly dependent on the cellular context. 
This is probably not dissociated from the fact that TGF-β has pleiotropic effects on cells 
(Massagué 2008) and that several transcription factors, such as Snail, Slug or Zeb, have been 
shown to directly mediate some of the TGF-β-related metabolic changes. Soukupova et al. 
analyzed the metabolic profile of hepatocellular carcinoma (HCC) cells upon TGF-β modulation 
(either treating cells with TGF-β or inhibiting the pathway) and revealed a number of metabolites 
whose abundance was altered (Soukupova et al. 2017). Similarly, when transformation and 
malignant progression are induced in mammary epithelial cells through RAS and the Hippo 
pathway, with a concomitant EMT, there is reprogramming of the metabolism of cells as 
evidenced by alterations in metabolite levels and differential expression of metabolic enzymes 
(Mulvihill et al. 2014).  
Other EMT models also show a metabolic reprogramming. For example, Halldorsson and Rohatgi 
et al. revealed interesting differences in metabolism following EMT when building a genome 
scale metabolic model of a breast epithelial cell line and its mesenchymal counterpart, following 
three-dimensional (3D) culture conditions (Halldorsson and and Rohatgi et al. 2017). The 
clustering of tumors according to the expression levels of metabolic genes revealed a tumor 
cluster with a “mesenchymal metabolic signature” (Shaul et al. 2014). The genes that are required 
for Twist-induced mesenchymal cell survival and are shared with the “mesenchymal metabolic 
signature” include several enzymes important for lipid signaling, glycan metabolism and 
glutathione associated redox regulation (Shaul et al. 2014). 
On the other hand, the alterations in metabolic enzymes and metabolic pathways are also linked 
to EMT. This is the case of several metabolic enzymes that are mutated or whose expression is 
dysregulated in cancer such as isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH) 
and fumarate hydratase (FH) (Colvin et al. 2016; Grassian et al. 2012; Sciacovelli et al. 2016; 
Tseng et al. 2018; Wang, Chen, and Wu 2016). These models, directly implicate metabolic 
dysregulation with cancer development and also with metastasis.  
 
Metabolic Pathways Altered during EMT 
Glycolysis and Lactate Production 
The literature concerning the cellular metabolism during EMT focuses on the carbohydrate 
metabolism, and particularly glycolysis. Glycolysis is a central cellular metabolic pathway that 
occurs in the cytoplasm. The catabolism of glucose into pyruvate produces intermediate 
metabolites for several anabolic reactions and generates 2 ATP molecules (per molecule of 
glucose). The glycolytic pyruvate can be further oxidized in the mitochondria in the tricarboxylic 
acid (TCA) cycle where ATP production is maximized.  Alternatively, pyruvate can be converted 
into lactate in the cytoplasm, with the regeneration of NAD+ from NADH. An increased glucose 
uptake has been reported by several studies in cells undergoing EMT triggered by commonly used 
EMT inducers like TGF-β treatment and Snail or Twist overexpression (Kim et al. 2017; Lee et 
al. 2012, 2015; Li et al. 2010; Liu et al. 2016; Lucena and Carvalho-Cruz et al. 2016; Teo et al. 
2017; Yu et al. 2017).  
The demonstration of major metabolic changes during EMT makes it crucial to identify the 
metabolic enzymes that are responsible for wiring EMT signaling with metabolism. One of the 
most crucial points of regulation occurs during the interconversion of fructose 1,6-biphosphate 
and fructose-6-phosphate by phosphofructokinase (PFK) and fructose-1,6-bisphosphatase (FBP), 
which belong to glycolysis and gluconeogenesis, respectively. In luminal breast cancer and gastric 
cancer cell lines, Snail was shown to inhibit the expression of FBP1, a rate-limiting enzyme in 
gluconeogenesis that limits the glycolytic rate (Dong et al. 2013; Yu et al. 2017). In the case of 
gastric cancer cell lines, FBP1 downregulation is important for the Snail-induced increase in 
glucose uptake and lactate production, since these could be reversed by re-expressing FBP1 (Yu 
et al. 2017). Furthermore, in MCF-7 and T47D luminal cell lines the Snail-induced E-cadherin 
downregulation can be reversed when the downregulation of FBP1 is corrected. Importantly, 
Snail was shown to directly bind to the FBP1 promoter, probably causing its downregulation 
through the formation of a complex with the histone methyltransferase G9A and concomitant 
increase in H3K9me2 and decrease in H3K9ac (Dong et al. 2013). This hypothesis is strengthened 
by the observations that Snail and FBP1 expressions are inversely correlated in gastric cancer and 
in triple negative breast cancer patient samples (Dong et al. 2013; Yu et al. 2017). The 
aforementioned findings suggest that one mechanism by which Snail increases glycolysis and 
impacts EMT features (E-cadherin downregulation) is through downregulation of FBP1. On the 
other hand, Kim et al. showed, in a breast cancer model, that a metabolic reprogramming 
associated with Snail knock-down was linked with an overexpression and increased kinase 
activity of the glycolysis enzyme PFK, platelet (PFKP), a PFK-1 isoform which produces fructose 
1,6-biphosphate from fructose-6-phosphate (Kim et al. 2017). Moreover, the impact of Snail 
silencing – metabolic phenotype, increased cell death, decreased colony formation and decreased 
metastasis formation – was dependent on PFKP expression. The relationship between Snail and 
PFKP seems to be through direct binding of Snail to the PFKP promoter, thus regulating its 
expression (Kim et al. 2017). Interestingly, the downregulation of FBP (in this case FBP2) and 
the downregulation and binding of Snail to PFKP promoter was also described in a CRC model 
of Snail overexpression (De Craene et al. 2005).  
These four studies (De Craene et al. 2005; Dong et al. 2013; Kim et al. 2017; Yu et al. 2017) 
demonstrate an active role of Snail in promoting a metabolic reprogramming, in the case by 
regulating glycolysis through binding and regulating the promoter of key glycolysis and 
gluconeogenesis enzymes. It would be interesting to understand which are the relevant aspects of 
the cellular context, namely the type of signaling that characterizes each cell system, that might 
underlie the selective binding of Snail to the promoters of FBP1 and PFKP enzymes.  Noteworthy, 
mammosphere-induced EMT also results in FBP1 downregulation in breast cancer cells. In these 
cells, ZEB1, ZEB2 and Slug are upregulated (Kondaveeti, Guttilla Reed, and White 2015), but it 
remains to be elucidated if Snail is also upregulated and regulating the expression of these 
enzymes in this EMT model.  
It is important to point out that EMT is frequently associated with decreased proliferation 
(Mejlvang et al. 2007; Salt, Bandyopadhyay, and McCormick 2014; Turner et al. 2006; Vega et 
al. 2004), while increased glucose uptake is often associated with proliferation (Vander Heiden, 
Cantley, and Thompson 2009). Therefore, in the context of EMT, it is also important to 
understand the flux of glucose, i.e. into which metabolic pathways are the glucose carbons being 
directed to.  
The fate of glucose seems to depend on the EMT inducer and on the cell type. Lactate is 
fundamental in driving extracellular acidification, which, in turn, is important for promoting 
cancer cell migration and invasion, as well as improving cancer cell evasion of the immune system 
(Busco et al. 2010; Calcinotto et al. 2012; Kato et al. 1992; Rozhin et al. 1994). Several studies 
have reported an enhanced production of lactate in EMT models, such as in Panc-1 pancreatic 
cancer cells (Liu et al. 2016), MCF-7 breast cancer cells (Lee et al. 2012, 2015) upon TGF-β 
treatment and also of gastric cancer cells after Snail overexpression (Yu et al. 2017). However, in 
the case of the breast cancer cell line MDA-MB-231, which display mesenchymal features, two 
independent studies have reached different conclusions when measuring lactate production upon 
Snail knock-down: one reports an increased lactate production and the other decreased (Kim et 
al. 2017; Lee et al. 2012). Such differences may be attributed to distinct culture and experimental 
conditions, and knock-down efficiency.  
Mammosphere culture has also been used to induce EMT and analyze metabolism but two distinct 
studies in breast cell lines reported different observations concerning glycolysis and lactate 
secretion. Kondaveeti, Guttilla Reed and White used BT-474 and MCF-7, two breast cancer cell 
lines, and saw a higher glucose consumption and lactate production in mesenchymal cells 
(Kondaveeti, Guttilla Reed, and White 2015). In the same model, cells undergoing EMT 
upregulate glucose transporters (GLUT) (specifically GLUT3 and GLUT12) and enzymes related 
to lactate production and export (lactate dehydrogenase [LDH] B and monocarboxylase 
transporters [MCT] 2 and 4, respectively) (Kondaveeti, Guttilla Reed, and White 2015). On the 
other hand, Halldorsson and Rohatgi et al. observed that the breast non-tumorigenic epithelial 
D492 cells rely more on glycolysis since they display higher glucose consumption and lactate 
secretion rates, when compared with the more mesenchymal counterparts that were 
spontaneously-derived from 3D co-culture with endothelial cells. The epithelial cells also have a 
higher extracellular acidification rate, a phenomenon commonly correlated with lactate secretion 
(Halldorsson and Rohatg et al. 2017). This may be explained by the fact that the cell lines used 
are different and BT-474 and MCF-7 cells after undergoing EMT proliferate more, while D492 
cells proliferate less compared to the mesenchymal counterpart (Halldorsson et al. 2017; 
Kondaveeti, Guttilla Reed, and White 2015).  
 
Hexosamine Biosynthetic Pathway and Pentose Phosphate Pathway 
Besides lactate, glucose may also be supporting other metabolic pathways. This is the case of the 
hexosamine biosynthetic pathway (HBP), which is crucial for substrate production and post-
translational protein modifications (Lucena and Carvalho-Cruz et al. 2016). Glycosylation is 
important for the function of proteins with key roles in EMT, such as Snail (reviewed in Taparra, 
Tran, and Zachara 2016). Snail can undergo a O-GlcNAc modification at serine 112, which 
prevents its degradation, thus leading to decreased activity of the E-cadherin promoter. This can 
be reversed by silencing O-GlcNAc transferase (OGT), one of the enzymes that adds O-GlcNAc, 
and is increased with higher glucose concentration in the cell culture media (Park et al. 2010). 
HBP thus seems to play an important role in Snail regulation of EMT, which is further suggested 
by the finding that OGT overexpression increases migration and invasion (Park et al. 2010). On 
the other hand, Snail regulates glutaminases (Haraguchi et al. 2013) which have been shown to 
alter the activity of GFPT1 and the O-glycosylation status of specific enzymes (Donadio et al. 
2008). 
Pentose phosphate pathway (PPP) originates from the phosphorylated form of glucose, glucose 
6-phophate, and generates reducing equivalents and intermediates important for the synthesis of 
lipids and nucleotides and for antioxidant responses, being, therefore, crucial in sustaining cell 
survival and proliferation (Stincone et al. 2015). Twist overexpression in non-transformed 
mammary epithelial cells (MCF10A) results in the upregulation of the rate limiting enzyme of the 
oxidative branch of PPP glucose-6-phosphate dehydrogenase (G6PD), together with an increase 
in glucose consumption (Yang and Hou et al. 2015). Despite the fact that cell proliferation was 
not analyzed, other studies showed that Twist promotes proliferation: Twist knock-down induces 
a G1 arrest and decreases proliferation in prostate, breast and in gastric cancer cells (Qian et al. 
2013; Shiota et al. 2008) and Twist overrides oncogene-induced senescence (Ansieau et al. 2008). 
On the other hand, mammosphere induced EMT leads to a downregulation of G6PD and the PPP 
enzymes from the non-oxidative branch transketolase and transaldolase. Surprisingly, the cells 
with a more mesenchymal phenotype proliferate more (Kondaveeti, Guttilla Reed, and White 
2015). The downregulation of these enzymes may reflect a decreased flux of glucose towards PPP 
which, as suggested by the authors, may point to a decreased need for redox control mediated by 
the intermediates of PPP due to a reduced dependency on oxidative phosphorylation (OXPHOS) 
which generates ROS (Kondaveeti, Guttilla Reed, and White 2015). To complement this 
hypothesis, it would be interesting to analyze the mitochondria metabolic function in these cells.  
 
Mitochondrial Metabolism: TCA Cycle, OXPHOS and Glutamine Metabolism 
Several mitochondrial metabolic reactions have been studied in the context of EMT. They include 
the tricarboxylic acid (TCA) cycle (also called the Krebs cycle), where carbon fuels like 
carbohydrates, fatty acids and amino acids are oxidized and the OXPHOS, where high energy 
electrons are donated to the electron transport chain (ETC) to generate a proton gradient across 
the membrane that culminates in the generation of ATP and concomitant transfer of electrons to 
oxygen. The TCA cycle can also produce precursors for the generation of lipids, proteins 
modifications or signaling molecules. Some reactions can replenish components of the TCA 
cycle, such as those that produce α-ketoglutarate from glutamine and glutamate. In the context of 
cancer, increased glycolysis is frequently associated with decreased respiration (Vander Heiden, 
Cantley, and Thompson 2009). This has been described in EMT models like pancreatic cancer 
cells treated with TGF-β (Ji et al. 2016), breast cancer cells overexpressing Snail or inducing Wnt 
signaling (Lee et al. 2012) and in kidney cells overexpressing Snail (Haraguchi et al. 2013). 
Conversely, in non-small cell lung cancer (NSCLC), the carbon from glucose can also flux 
through the TCA cycle and lead to increased respiration in TGF-β- and Snail-induced EMT (Jiang 
et al. 2015; Yuting Sun et al. 2014), although contradictory results have also been reported using 
TGF-β (Ulanet et al. 2014).  
The fate of pyruvate is central to the kind of metabolism that is driving the cell. Through the key 
enzyme pyruvate dehydrogenase (PDH) in the mitochondria, pyruvate can be converted into 
acetyl CoA that feeds the TCA cycle. Snail is able to regulate this enzyme that acts as a metabolic 
hub inside the cell: indeed, Snail overexpression in MDCK cells results in reduced activity of 
PDH, through the increased promoter activity and consequent mRNA upregulation of its negative 
regulator, pyruvate dehydrogenase kinase (PDK) 1 (Haraguchi et al. 2013). Concerning the TCA 
cycle, the enzymes IDH2, aconitase 2, SDH all have decreased activity after Snail overexpression 
in MDCK cells, although their expression remains unaltered (Haraguchi et al. 2013), suggesting 
that Snail can regulate the mitochondrial enzymes activity at the at the post-translational level. 
Moreover, complexes II and IV from OXPHOS also present a diminished activity, which is in 
accordance with the reduced ATP content, mitochondrial respiration and mitochondrial 
membrane potential observed in these cells (Haraguchi et al. 2013). In summary, Snail modulates 
the mitochondrial metabolism in kidney cells by regulating either the expression or the activity 
of metabolic enzymes. 
Snail and TGF-β signaling are able to regulate the conversion of glutamine to glutamate. 
Glutamine is commonly used by cancer cells to support their rapid growth and proliferation 
(DeBerardinis et al. 2007). Glutamine can be converted directly into glutamate by glutaminase 
(GLS), which in turn can produce α-KG by several enzymes such as glutamate dehydrogenase 
(GDH) or transaminases. The expression of GLS1 is increased in cells with activated TGF-β 
signaling, a finding that will be discussed in the TGF-β subsequent section (Lee et al. 2016; 
Soukupova et al. 2017). Additionally, there seems to be a reciprocal regulation between GLS2 
and Snail. Not only GLS2 is downregulated after Snail overexpression in normal kidney cells 
(Haraguchi et al. 2013) but it also represses Snail expression in HCC cells, which results in 
decreased motility and metastasis (Kuo et al. 2016). This downregulation occurs at the 
translational level and is mediated by the binding and stabilization of Dicer, possibly through the 
proteasome, which promotes miR-34 maturation. The GLS2-Dicer binding occurs in an 
enzymatic activity-independent manner although further studies should clarify the impact of 
glutamine metabolism (Kuo et al. 2016). GLS2 expression is inversely correlated with advanced-
stage, vascular invasion, early recurrence and poor prognosis in HCC patients (Kuo et al. 2016). 
Finally, glutamate dehydrogenase 1 (GDH1), which converts glutamate to α-ketoglutarate, is 
upregulated after Twist expression in MCF10A cells (Farris et al. 2016).  
 
Lipid Metabolism 
Some studies explored how lipid metabolism is affected during EMT induced by TGF-β and Snail 
(Jiang et al. 2015; Yang et al. 2016). Particularly, it has been described that EMT affects the levels 
of fatty acid synthase (FASN), the enzyme that uses acetyl-CoA and malonyl-CoA to produce 
palmitate (Jiang et al. 2015; Yang et al. 2016) and the synthesis of ceramides (Edmond et al. 
2015). Interestingly, the synthesis of sphingolipids and glycosphingolipids has also been explored 
during EMT (Guan et al. 2010; Guan, Handa, and Hakomori 2009; Mathow et al. 2015).  
 
 
 
SIGNALING PATHWAYS AND EMT 
The TGF-β, Wnt and Hippo signaling pathways are crucial in the maintenance of cellular 
homeostasis, while also playing a role in cancer progression. In this section, we will describe the 
alterations in cellular metabolism taking place during EMT mediated by TGF-β, Wnt and Hippo 
pathways.  
   
TGF-β 
The TGF-β signaling has an especially prominent role in regulating EMT. The binding of TGF-β 
and related ligands to the respective receptors leads to the phosphorylation of serine and/or 
threonine residues (more rarely tyrosine) in their cytoplasmic domain, which results in 
transduction of the signal to the nucleus. This is mediated by a group of intracellular signaling 
molecules, called SMAD proteins, or by other signaling pathways such as mitogen-activated 
protein kinase (MAPK) signaling, thereby initiating a program of gene expression that regulate 
growth, apoptosis, adhesion, migration and differentiation (Wu and Hill 2009). TGF-β treatment 
activates several intracellular effectors involved in the EMT phenotype such as Snail (Peinado, 
Quintanilla, and Cano 2003). The ligand TGF-β itself has 3 variants and all have been described 
as EMT inducers, being TGF-β1 is the most commonly used in the literature related to the 
metabolism of EMT (Xu, Lamouille, and Derynck 2009). TGF-β also has an important role in 
cancer, namely in EMT associated with malignant progression in vivo (Cui et al. 1996). This 
cytokine has been shown to be produced by several tumors, either by the tumor cells themselves 
or by the cells that constitute the tumor stroma. However, TGF-β effects on tumorigenesis and 
cancer progression can be very complex and depend on intrinsic characteristics of the cells that 
are receiving the signal. TGF-β has been shown to promote homeostasis and suppress tumor 
progression in a premalignant stage, while cancer cells commonly use TGF-β signaling in their 
favor to undergo EMT, invade the surrounding tissues, evade the immune response and ultimately 
promote metastatic dissemination and the colonization of secondary tumor sites (Massagué 2008).  
In general, cells undergoing EMT upon treatment with TGF-β show an increased glucose uptake. 
This has been described in lung cancer (Lucena and Carvalho-Cruz et al. 2016), pancreatic cancer 
(Liu et al. 2016), breast cancer (Lee et al. 2015; Li et al. 2010) and gastric cancer cells lines (Teo 
et al. 2017). In MCF-7 cells, a cell line generated from a breast cancer metastasis with an epithelial 
morphology, TGF-β treatment leads to an EMT phenotype characterized by morphological 
changes, upregulation of vimentin, downregulation of E-cadherin and increased migration. In 
addition to several EMT features, TGF-β triggers metabolic alterations that affect several 
pathways. In fact, MCF-7 cells respond to TGF-β by upregulating GLUT1, increasing the glucose 
uptake (Li et al. 2010) and also secreting more lactate to the medium (Lee et al. 2015). 
TGF-β not only seems to regulate the glucose uptake in cells undergoing EMT but also the way 
that glucose is metabolized. When comparing two HCC cell lines that express E-cadherin, 
vimentin and TGF-β at different levels, the cells associated with a more mesenchymal phenotype 
show an upregulation of PPP enzymes G6PD and transketolase. TGF-β receptor I silencing in 
HCC cells expressing TGF-β and associated with a more mesenchymal phenotype results in 
decreased expression of G6PD, its paralog hexose-6-phosphate dehydrogenase/glucose 1-
dehydrogenase and also 6-phosphogluconolactonase (Soukupova et al. 2017). The authors 
suggest that the higher expression of the enzymes, together with the lower levels of some 
intermediates of this pathway observed in the mesenchymal cells, can result from a higher shunt 
to the PPP. However, according to the authors, these differences in PPP did not correlate with 
differences in proliferation, but with a switch from fatty acid oxidation to synthesis (Soukupova 
et al. 2017). Indeed, PPP not only provides intermediates for nucleotide synthesis that are crucial 
in sustaining cancer cell proliferation but also generates reducing equivalents and intermediates 
important for the synthesis of lipids and for redox control. So, increased or decreased PPP may 
be associated with other cellular needs besides proliferation like ROS control. On the other hand, 
in lung cancer cells A549 treated with TGF-β, showed decreased expression and activity of G6PD 
suggesting that the increased glucose uptaken by these cells is not being diverted to PPP (Lucena 
and Carvalho-Cruz et al. 2016).  In the same model, glucose actually seems to be used in the HBP 
and cells display changes in cell surface glycosylation (Lucena and Carvalho-Cruz et al. 2016). 
HBP comprises the series of metabolic reactions that produce UDP-N-acetylglucosamine (UDP-
GlcNAC), which is a substrate for O-, N-glycosylation and O-GlcNAcylation (Pinho and Reis 
2015). UDP-GlcNAC is indeed increased in A549 cells treated with TGF-β, as well as several 
enzymes important for its formation, namely UDP-glucose pyrophosphorylase 2 (UGP2) and 
glutamine-fructose-6-phosphate transaminase 1 (GFPT1) together with proteins responsible for 
the N-linked glycans biosynthesis. The product of the GFPT1 gene is the rate enzyme of HBP, 
which is not only upregulated, but also shows increases activity after TGF-β treatment. 
Furthermore, O-linked β-N-acetyl glucosamine (O-GlcNAc) levels were also increased, while the 
enzymes that add or remove it from target proteins, were shown to regulate the phenotype of cells, 
namely the mesenchymal morphology, EMT markers and migration (Lucena and Carvalho-Cruz 
et al. 2016). The study by Alisson-Silva et al. showed another interesting link between the HBP, 
EMT and TGF-β (Alisson-Silva et al. 2013). A549 cells cultured in high glucose conditions 
showed N-cadherin and vimentin upregulation, mesenchymal morphology, increased motility 
concomitantly with increased TGF-β secretion. Besides, hyperglycemia induces an upregulation 
of fibronectin and the synthesis of the fibronectin splicing isoform that undergoes the addition of 
an O-glycan to the peptide, oncofetal fibronectin (onfFN) (Alisson-Silva et al. 2013). This 
fibronectin isoform got its name from being almost exclusively associated with fetal tissue or 
related fluids, but it can also be detected in tumor cells and it has been suggested as a clinical 
biomarker in several cancer types (Alías-Melgar et al. 2013; Inufusa et al. 1995; Matsuura and 
Hakomori 1985; Mhawech et al. 2005). Similarly to what happens in lung cancer models 
(Alisson-Silva et al. 2013), TGF-β treatment of prostate epithelial cell lines induces upregulation 
of oncofetal fibronectin and total fibronectin, together with N-cadherin upregulation, E-cadherin 
downregulation and increased motility (Freire-de-Lima et al. 2011), being these alteration 
reversed by the knock-down of the enzymes that are involved in oncofetal fibronectin synthesis 
(Freire-de-Lima et al. 2011; Wandall et al. 2007). 
The mitochondrial metabolic reprogramming driven by TGF-β in the context of EMT seems to 
be dependent on the cell type. In a study by Jiang et al. using NSCLC A549 cells, TGF-β treatment 
causes a higher oxygen consumption (Jiang et al. 2015), while Snail overexpression triggered 
similar effects in mitochondrial respiration. Another group of researchers showed that in several 
lung cancer cell lines with distinct genetic backgrounds - either KRAS or EGFR driven - treatment 
with TGF-β results in a decreased glycolysis to OXPHOS ratio (measured by proton production 
rate and oxygen consumption rate) (Sun et al. 2014). When becoming mesenchymal, these 
NSCLC cells show increased TCA cycle and OXPHOS activity. Moreover, the expression of the 
PDH-regulating kinase, PDK4, is reduced in NSCLC cells after treatment with TGF-β; if PDK4 
overexpression partially inhibits TGF-β-driven EMT, on the other hand its knock-down in A549 
and HCC827 cells is sufficient to promote vimentin and Zeb1 expression (Sun et al. 2014). These 
cells also showed a larger contribution of glucose to the TCA cycle intermediates and glutamate 
(Sun et al. 2014). The same authors also observed PDK4 downregulation upon TGF-β treatment 
both in human mammary epithelial MCF10A cells and in the same cells transfected with T24 c-
Ha-Ras oncogene (MCF10AT) (Sun et al. 2014). The induction of EMT with TGF-β treatment in 
MCF10A neo T cells lowers the basal ROS levels (measured with DCFDA) (Farris et al. 2016). 
On the other hand, the NCI-H358 NSCLC cell line, after TGF-β treatment, shows a lower 
respiratory capacity, which can be rescued by the addition of pyruvate (Ulanet et al. 2014). These 
authors treated cells with the isoform 3 of TGF-β (TGF-β3), which may be behind the differences 
in metabolism. Despite the fact that all the TGF-β ligands have been shown to bind the type II 
receptors, their expression varies spatially and temporally and they may have distinct functions 
according to mice knock-out data (Akhurst and Hata 2012). In the case of EMT, a distinct role 
for the 3 isoforms of TGF-β had, in fact, already been suggested during development (Boyer et 
al. 1999; Brunet, Sharpe, and Ferguson 1995). More studies are needed to clarify each isoform is 
expressed during EMT in cancer of different organs and what are the effects on metabolism. 
Intriguingly, TGF-β-induced EMT also results in different outcomes concerning oxygen 
consumption in pancreatic cancer cells, probably depending on the duration of the TGF-β 
treatment or the cell culture conditions, reflecting the extremely dynamic nature of metabolism. 
In Panc-1 cells oxygen consumption was shown to be decreased by Ji et al. (Ji et al. 2016), while 
Liu et al. reported no differences in oxygen consumption or in the amount of glucose that is 
oxidized to CO2, which is supported by the absence of alterations in the expression of NDUFB8, 
SDHB and UQCRC2, enzymes that belong to the mitochondrial complexes I, II and III, 
respectively (Liu et al. 2016).   
In MCF-7 cells, Lee et al. (2015) showed that TGF-β, which induces Snail upregulation, leads to 
a downregulation and a decrease in cytochrome c oxidase (COX) activity (or complex IV from 
the electron transport chain), which is reversed by Snail knock-down. These cells also consume 
less oxygen after TGF-β treatment (Lee et al. 2015). In another studied, it was shown in MDA-
MB-231 and MCF-7 cells that Snail silencing by itself causes an increase in COX activity and 
oxygen consumption (Lee et al. 2012).  
In CRC cells, loss of SDHB expression promoted EMT and cell migration and was associated 
with the expression of TGF-β pathway members, namely increased expression of SMAD3 and 
SMAD4 (in a way that can be rescued by SDHB expression) and upregulation of Snail in a TGFβ 
receptor 1- and SMAD4-dependent manner (Wang, Chen, and Wu 2016). When dividing CRC 
into SDHB high vs SDHB low (at the mRNA level), the tumors with low expression of SDHB 
tended to have higher levels of SMAD4, N-cadherin, Snail and lower levels of E-cadherin, when 
compared with the ones with high SDHB expression (Wang, Chen, and Wu 2016). SDH loss is 
associated with succinate accumulation and interestingly, succinate showed increased levels after 
Twist overexpression in mammary epithelial cells (Bhowmik et al. 2015). Not only SDH but also 
knock-down of FH, the enzyme that catalyzes the reaction after SDH in the TCA cycle, causes 
EMT with Twist and Slug upregulation (Sciacovelli et al. 2016). IDH mutations and the resulting 
2-HG accumulation also induces EMT in a process mediated by ZEB1 (Colvin et al. 2016; 
Grassian et al. 2012). 
TGF-β-induced EMT is also characterized by changes in the glutamine metabolism. Glutaminase 
is encoded by 2 genes - that encode for GLS1 and GLS2 isozymes - and each of these genes can 
give rise to two different isoforms (Aledo et al. 2000; Szeliga and Albrecht 2015). GSL1 and 
GLS2 show differential expression according to the tissue type (Aledo et al. 2000) and have been 
proposed to have different roles in cancer, although the mechanisms remain unknown. For 
example, GLS1 seems to be associated with oncogenic transformation and it is necessary for 
P493-6 human B lymphoma cells, PC3 human prostate cancer cells growth and its downregulation 
limits glioblastoma cell growth (Cheng et al. 2011; Gao et al. 2009), while GLS2 is a p53 gene 
target and when overexpressed inhibits colony formation ability of several tumor cell lines (Hu et 
al. 2010). In MCF-7 cells, GLS1 was found to be upregulated after TGF-β treatment in a SMAD 
2, 3 and 4 and distal-less homeobox-2 (Dlx-2) -dependent manner (Lee et al. 2016). Experiments 
with GLS1 knock-down and glutamine deprivation revealed that both GLS1 and glutamine are 
essential for TGF-β-induced E-cadherin downregulation and Snail upregulation, although 
overexpression of Snail does not affect GLS1 expression. The effects glutamine absence can be, 
in part, attenuated by the addition of a permeable form of α-ketoglutarate (Lee et al. 2016). In 
addition to regulating Snail expression, GLS1 also regulates Snail-induced metabolic phenotype. 
Snail overexpression increased glucose and lactate uptake, while decreasing oxygen consumption, 
in a process that could be reverted by GLS1 knockdown (Lee et al. 2016).  
Glutamine anaplerosis of the TCA cycle was demonstrated in HCC cell lines, in a TGF-β context. 
HCC cells that show mesenchymal features, namely TGF-β and vimentin expression, in addition 
to E-cadherin downregulation, are more sensitive to glutamine depletion from the culture media 
(Soukupova et al. 2017). These cells show a higher contribution of glutamine to glutamate and to 
TCA cycle which is supported by a GLS1 upregulation and glutamine synthase downregulation, 
alongside a reduced mitochondrial respiration (Soukupova et al. 2017). Besides, inhibition of 
GLS1 impacts cell migration and inhibition of the receptor I for TGF-β results in GLS1 and 
glutamine transporter SLC7A5 downregulation (Soukupova et al. 2017).  
Interestingly, when analyzing a panel of NSCLC cell lines according to their sensitivity to the 
GLS1 inhibitor BPTES (bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide), low E-
cadherin/high vimentin phenotype was positively correlated with enhanced cell sensitivity to the 
presence of BPTES (Ulanet et al. 2014). The same was observed after inducing EMT with TGF-
β3 in the NSCLC NCI-H358 cell line, suggesting a link between increased GLS dependence and 
the EMT phenotype. In these mesenchymal cells, there is a differential expression balance of 
GLS1 isoforms, namely an increased GAC:KGA ratio (Ulanet et al. 2014). These GLS1 isoforms 
have different subcellular localizations in several tumor cell lines, with KGA localized in the 
cytosol but not in the mitochondria, while GAC is the only isoform present in the mitochondria 
(Cassago et al. 2012). This increased GAC:KGA ratio was also seen in primary NSCLC tumors 
and caused by a significant decrease of KGA expression (van den Heuvel et al. 2012). Moreover, 
this study suggests that the increased sensitivity to GLS1 inhibition of mesenchymal cells may be 
associated with a lower ability to adapt to other carbon sources to replenish the TCA cycle, 
resulting in a lower respiratory capacity and a decreased ability to control redox stress (Ulanet et 
al. 2014).  
In NSCLC, TGF-β coordinates the expression of enzymes that control fatty acid synthesis from 
glucose (Jiang et al. 2015), for example by downregulating of FASN in A549 cells (Jiang et al. 
2015). How can the modulation of lipids be important for these mesenchymal cells? In NSCLC 
cells, FASN knock-down itself (which also leads to a decreased contribution of glucose carbon 
to fatty acid synthesis) is able to increase motility, lung colonization in vivo and induce 
upregulation of vimentin and N-cadherin and downregulation of E-cadherin. The authors suggest 
that this type of metabolism may increase the availability of substrates for OXPHOS and favor 
energy production (Jiang et al. 2015). On the other hand, a positive feedback loop between TGF-
β and FASN expression was shown in NSCLC cisplatin-resistant cells, which acquire EMT 
features in a TGF-β1 and FASN dependent manner (Yang et al. 2016). This was not observed in 
non-resistant cells (Yang et al. 2016), in accordance with the results from Jiang et al. (Jiang et al. 
2015). Cisplatin-resistance associated EMT was characterized by increased levels of fatty acids 
and a strong upregulation of FASN, which, in turn, induces and is necessary for high TGF-β 
expression levels in cisplatin-resistant cells (Yang et al. 2016). The aforementioned studies show 
a tight regulation of FASN by TGF-β, which may be dependent on the alterations that are related 
with the acquisition of resistance. Indeed, EMT was shown to be important for chemoresistance 
in pancreatic and breast cancers (Fischer et al. 2015; Zheng et al. 2015). These results highlight 
the importance of the cellular context for the metabolic adaptations in cancer, which are highly 
dynamic and may play a crucial role in chemoresistance.  
In HCC cell lines, an increase in fatty acid synthesis is concomitant with a decrease in fatty acid 
oxidation. In fact, HCC cells in vitro show increased expression of TGF-β and vimentin, together 
with decreased E-cadherin expression, in association with a downregulation in fatty acid β-
oxidation enzymes and with upregulation of fatty acid synthesis enzymes and the transcription 
factor peroxisome proliferator-activated receptor gamma (PPARγ). Accordingly, the cells 
associated with mesenchymal proteins show higher levels of sphingolipids and phospholipids, 
which is reversed by TGF-β receptor I inhibition (Soukupova et al. 2017). This suggests that the 
autocrine TGF-β signaling in HCC cells promotes lipid synthesis. 
 
 
 
 
 
 
 Fig. 1: The TGF-β pathway is tightly connected with metabolism. TGF-β treatment usually leads 
to increased glucose uptake through GLUTs. TGF-β has an important impact on two crucial 
metabolic processes – glycolysis and respiration – although the effects (positive or negative) are 
largely dependent on the tissue type. Glutamine metabolism and hexosamine biosynthesis are 
activated by TGF-β, through upregulation of GLS1 and GFPT1, respectively. (+) represents 
positive regulation; (-) represents negative regulation and (+/-) represents positive or negative 
regulation (both have been described). TGF-β, transforming growth factor β; GLUT, glucose 
transporter; glucose-6-P, glucose-6-phosphate; UDP-GlcNAc, UDP-N-acetylglucosamine; 
GLS1, glutaminase 1; GFPT1, glutamine-fructose-6-phosphate transaminase 1. 
 
WNT 
The Wnt pathway consists on the signaling cascade downstream of the Wnt ligands. Wnt1 was 
identified as Int-1 by Nusse and Varmus as a proto-oncogene that becomes activated upon 
integration of mouse mammary tumor virus (MMTV) proviral DNA which originates breast 
tumors (Nusse and Varmus 1982);  subsequently, Wnt1 was found to be an homolog of the 
Wingless gene of Drosophila, a gene important for patterning decisions during embryonic 
development (Rijsewijk et al. 1987). Wnt ligands are secreted glycolipoproteins that act through 
autocrine and paracrine mechanisms to influence the fate of many cell types, either during 
embryonic development or in adult tissues  (Van Camp et al. 2014; Dorsky, Moon, and Raible 
1998). The binding of Wnt ligands to their cognate receptors, namely Frizzled receptor and LDL 
receptor family coreceptors, triggers the activation of a signaling cascade (MacDonald, Tamai, 
and He 2018). The Wnt signaling is commonly divided into two pathways: the Wnt/ß-catenin or 
canonical pathway (the focus of this review) and the Wnt noncanonical pathway that includes the 
β-catenin-independent signaling (Zhan, Rindtorff, and Boutros 2017). In the canonical pathway, 
Wnt transduces downstream signals by stabilizing β-catenin, allowing its accumulation and 
subsequent translocation to the nucleus, where it forms a complex with TCF (T-cell-specific 
transcription factor)/LEF (lymphoid enhancer-binding factor) family of transcription factors and 
induces the expression of specific target genes. In unstimulated cells, cytosolic β-catenin is 
constitutively degraded by a ubiquitin ligase-proteosome system, in a process that is regulated by 
a complex of proteins such as axin, GSK-3β, casein kinase 1 and APC (Zhan, Rindtorff, and 
Boutros 2017).  
Aberrant activation of the Wnt signaling pathway is associated with tumor development and/or 
progression, particularly in CRC (Bienz and Clevers 2000). The Wnt pathway involves important 
regulatory elements, whose genes are commonly dysregulated in cancer, often showing genetic 
and epigenetic alterations (Zhan, Rindtorff, and Boutros 2017). Of particular relevance are the 
APC mutations since they are the underlying cause of familial adenomatous polyposis, an 
hereditary colon cancer syndrome (Kinzler et al. 1991; Nishisho et al. 1991). Moreover, Wnt 
signaling has been described as affecting the maintenance of cancer stem cells and metastasis in 
breast cancer (Jang et al. 2015).  
The Wnt signaling pathway incorporates and regulates several molecules that are important in 
mediating EMT or in defining the epithelial and mesenchymal phenotypes. In fact, β-catenin 
regulates the expression of mesenchymal proteins, such as fibronectin (Gradl, Kühl, and Wedlich 
1999), metalloprotease 7 (Crawford et al. 1999) and vimentin (Gilles et al. 2003), the latter being 
able to promote β-catenin/TCF transcriptional activity (Satelli et al. 2016). On the other hand, β-
catenin can also interact with E-cadherin cytoplasmic domain to maintain cell-cell adhesion. The 
balance between E-cadherin-bound and cytoplasmic-accumulated β-catenin is regulated by a 
series of kinases and phosphatases. It has been suggested, therefore, that E-cadherin and Wnt 
signaling can regulate each other through the pool of β-catenin (Nelson and Nusse 2004), although 
some authors argue against the regulation of Wnt signaling by E-cadherin (Vargas et al. 2016). 
Interestingly, N-glycosylation mediates the crosstalk between E-cadherin and the Wnt signaling: 
Wnt/β-catenin signaling regulates the expression of DPAGT1 (dolichyl-phosphate N-
acetylglucosaminephosphotransferase 1), an enzyme that participates in the synthesis of  
glycoproteins such as E-cadherin and, consequently, modulates the function of adherens junctions 
(Sengupta, Bouchie, and Kukuruzinska 2010). N-glycosylation and the HBP are also involved in 
the activation of the Wnt signaling. Indeed, in macrophages, glucose leads to an increase in β-
catenin protein levels and promotes β-catenin TCF/LEF family-dependent transcriptional events, 
in a process that requires the HBP and N-glycosylation, possibly through an autocrine activation 
of the Wnt signaling system (Anagnostou and Shepherd 2008).  
Glycosylation is not the only post-translational modification that depends on cellular metabolism: 
acetylation, for example, is regulated by the concentration of metabolic fuels (Zhao et al. 2010). 
Interestingly, acetylation of β-catenin was shown to regulate Wnt signaling: in conditions of Wnt 
stimulation, high levels of glucose promote the nuclear accumulation of acetylated β-catenin, by 
supporting the formation of LEF-1/β-catenin complex; the latter associates with the acetylase 
p300 and displaces the SIRT1 deacetylase, resulting in increased transcriptional activity 
(Chocarro-Calvo et al. 2013).  
GSK-3, which takes part in the β-catenin destruction complex, is another component of the Wnt 
signaling that is regulated by a metabolic enzyme, namely the mitochondrial enzyme SDHF2, an 
assembly factor for SDH complex of the ETC. Knock-down of SDHF2 in lung cancer cells 
induces EMT and leads to an increase in β-catenin transcriptional activity. Particularly, this 
metabolic enzyme leads to an increase in GSK-3β activity, by decreasing the phosphorylation 
levels of serine 9, a negative regulatory site, in a process mediated by protein phosphatase 2A, 
resulting in decreased β-catenin levels and β-catenin/TCF transcriptional activity (Liu et al. 2013). 
GSK-3β is a serine-threonine kinase that, besides integrating the Wnt pathway, regulates cellular 
and body metabolism (Chen et al. 2016; Jellusova et al. 2017). In fact, GSK-3β was first identified 
as a regulator of glycogen synthase, a key enzyme in glycogen synthesis (Embi, Rylatt, and Cohen 
1980). GSK-3β phosphorylates and inhibits glycogen synthase, having an inhibitory effect on 
glycogen synthesis (Eldar-Finkelman et al. 1996).  
Another interesting link between cellular metabolism, Wnt pathway and EMT is through hypoxia. 
Although in some contexts hypoxia inhibits Wnt proliferative effects through several mechanisms 
(Kaidi, Williams, and Paraskeva 2007; Lim, Chun, and Park 2008; Verras et al. 2008), in 
conditions where hypoxia induces EMT, β-catenin plays an important role in mediating the 
downregulation of epithelial proteins, upregulation of mesenchymal proteins and EMT TFs, as 
well as in the acquisition of migratory features. Wnt/β-catenin can actually enhance hypoxia-
induced EMT (Liu et al. 2010; Zhang et al. 2013; Zhao et al. 2011).  
Wnt ligands have been shown to trigger cancer-associated EMT. For example, Wnt-1 and Wnt-3 
overexpression leads to E-cadherin downregulation and to an invasive phenotype (Qi et al. 2014; 
Yook et al. 2005), whilst Wnt signaling also increases the protein level of several EMT TFs, such 
as Snail, Slug, Twist, Zeb (Howe et al. 2003; Qi et al. 2014; Sánchez-Tilló et al. 2011; Wu et al. 
2012; Yook et al. 2005). In the case of Snail, Wnt signaling leads to its upregulation by enhancing 
protein stabilization: in the absence of Wnt signaling, Snail can be phosphorylated by GSK-3β, 
leading to its ubiquitination and proteosomal degradation. Conversely, active Wnt signaling 
induces Axin2 expression, in a process mediated by β-catenin–TCF complex. Axin2 acts as a 
nucleocytoplasmic chaperone for GSK-3β, promoting Snail stabilization (Yook et al. 2005, 2006; 
Zhou et al. 2004). Wnt-triggered EMT, either by Wnt1 overexpression or Wnt3 ligand treatment 
is characterized by metabolic changes in MCF-7 cells, which cells show an increased glucose 
uptake (Lee et al. 2012, 2016) and a decreased oxygen consumption (Lee et al. 2012, 2016). 
Previously, a gene expression analysis in livers from transgenic mice overexpressing liver-
specific β-catenin had also identified pyruvate kinase and glyceraldehyde 3-phosphate 
dehydrogenase as among the upregulated genes (Tan et al. 2005). Pate et al. also showed that 
CRC cells exhibit decreased glycolysis after Wnt signaling inhibition (Pate et al. 2014).  
Cells undergoing EMT upon Wnt1 overexpression or Wnt3 treatment show decreased oxygen 
consumption together with a reduction in COX activity and diminished transcriptional activity of 
its subunits, in a process possibly mediated by Snail binding to its promoter (Lee et al. 2012). 
Another study, using MDA-MB-231 cells (a triple negative breast cancer cell line), showed that 
Wnt modulates mitochondrial homeostasis since Wnt5B knock-down not only impairs cell 
motility but also results in mitochondrial morphological alterations, decreased mtDNA content 
and a downregulation of several mitochondrial proteins, namely mitochondrial import receptor 
TOMM20 (translocase of outer mitochondrial membrane 20), cytochrome c1 and the subunit of 
mitochondrial ATP synthase ATP5MC1 (ATP synthase membrane subunit c locus 1) (Yang et al. 
2014). Concerning lactate production, two studies showed different results, probably related with 
the cell culture conditions: Lee et al. reported an increased lactate production after Wnt signaling 
activation (Lee et al. 2012) while Kim et al. observed a decreased production of lactate (Kim et 
al. 2017). A third study showed that blocking Wnt signaling, through overexpression of dominant 
negative LEF/TCF isoforms that lack the β‐catenin binding domain, results in a decrease lactate 
production in CRC cells (Pate et al. 2014). Interestingly, this Wnt signaling reduction leads to 
downregulation of PDK1 and MCT1, both being direct Wnt target genes (Pate et al. 2014).  
Additionally, GLS1 is upregulated upon Wnt-induced EMT, in a β-catenin, axin, TCF4 dependent 
and Snail independent manner (Lee et al. 2016). Experiments with GLS1 knock-down and 
glutamine deprivation revealed that GLS1 is essential for Wnt-induced mesenchymal morphology 
and E-cadherin downregulation (Lee et al. 2016). Besides, the increased glucose consumption, 
lactate production and decreased oxygen consumption in this system are dependent on GLS1 
expression (Lee et al. 2016).  
Myc is a target gene of the Wnt pathway (He et al. 1998; Sansom et al. 2007; van de Wetering et 
al. 2002) that is at the cross-roads of EMT and metabolism. Myc has been associated with EMT 
and it is an important regulator of cancer cell metabolism, with effects on glycolysis and 
glutamine metabolism (Goetzman and Prochownik 2018). The oncogene c-Myc stimulates 
glutamine utilization through the coordinate transcription of genes necessary for cells to engage 
in glutamine catabolism (Wise et al. 2008). For example, c-Myc can upregulate GLS by regulating 
miR-23a and miR-23b, being glutamine and GLS required for Myc-mediated cancer cell 
proliferation and survival (Gao et al. 2009). The translation efficiency of c-Myc is, in turn, 
regulated by mTOR/S6K1 signaling, via eIF4B, leading to a mTOR-dependent control of the 
glutamine flux through regulation of GLS (Csibi et al. 2014). Myc has also been implicated in the 
regulation of other metabolic enzymes like LDHA (Shim et al. 1997). Although the role of c-Myc 
in EMT is still underexplored, there is some evidence that its overexpression in mammary 
epithelial cells (MCF10A and IMECs) and in transformed human bronchial epithelial cells leads 
to downregulation of E-cadherin and upregulation of mesenchymal associated proteins such as 
N-cadherin, vimentin, Snail and Zeb1/2 (Cho et al. 2010; Cowling and Cole 2006; Larsen et al. 
2016). Myc is required for an effective induction of EMT by TGF-β, namely E-cadherin 
downregulation, E-cadherin and β-catenin decrease at the cell surface and fibronectin 
upregulation in breast epithelial cells and prostate cancer cells (Amatangelo et al. 2012; Smith et 
al. 2008). In the particular case of mammary epithelial cells and breast cancer cells (MDA-MB-
231 cells), Myc binds to the Snail promoter, facilitating a rapid Snail upregulation upon TGF- β 
treatment (Smith et al. 2008). Also in MDA-MB-231 cells, Myc has been proposed to mediate 
the role of Wnt signaling in the maintenance of mitochondrial physiology (Yang et al. 2014).  
 
Fig. 2: The WNT pathway has been shown to regulate metabolism during EMT, namely 
mitochondrial metabolism – glutamate synthesis through GLS1 or OXPHOS through COX - and 
glycolysis, either directly or through Myc. GLUT, glucose transporter; glucose-6-P, glucose-6-
phosphate; GLS1, glutaminase 1; COX, cytochrome c oxidase; TCF/LEF, T-cell-specific 
transcription factor / lymphoid enhancer-binding factor; DPAGT1, dolichyl-phosphate N-
acetylglucosaminephosphotransferase 1; Zeb, zinc-finger E-box-binding. 
 
HIPPO 
The Hippo pathway was first characterized in Drosophila and it is named after the hpo gene, 
which encodes a kinase involved in tissue growth restriction in this model organism (reviewed in 
Pan 2007). The Hippo pathway can be triggered and regulated by several extracellular cues like 
adhesion between cells, interactions with the matrix and extracellular ligands, playing important 
roles in cell proliferation, growth, differentiation and organ growth (Hong et al. 2005; Kim and 
Gumbiner 2015; Park et al. 2015; Yu et al. 2012; Zhao et al. 2007, 2012; Zhou et al. 2015). In 
mammals, the activity of the core Hippo pathway is mediated by several kinases, namely the 
mammalian Ste20-like kinases (MST) 1, 2 and the large tumor suppressor (LATS) 1, 2 kinases, 
adaptor proteins, downstream effectors - Yes-associated protein (YAP) and transcriptional 
coactivator with PDZ-binding motif (TAZ) - and nuclear transcription factors (being TEAD 
family of transcription factors the main transcriptional output) (Meng, Moroishi, and Guan 2016). 
TAZ and YAP are two main effectors of the Hippo pathway in mammals and work as transcription 
co-activators, regulating the expression of a variety of genes important for cellular proliferation, 
apoptosis and differentiation (Dong et al. 2007; Hong et al. 2005). The Hippo pathway inhibits 
YAP/TAZ activity, in a process mediated by TAZ phosphorylation by MST and LATS, which 
results in YAP/TAZ cytoplasmic retention (Lei et al. 2008; Zhao et al. 2007). TAZ/YAP can also 
be regulated independently of Hippo pathway core kinases, for example by activation of the 
actomyosin cytoskeleton and Rho GTPase upon mechanical signals exerted by extracellular 
matrix rigidity and cell shape (Dupont and Morsutet al. 2011). Importantly, the Hippo pathway 
effectors YAP/TAZ also respond to metabolic cues. Energetic stress, such as ETC inhibition, 
glucose withdrawal and inhibition of glucose metabolism by 2-DG, leads to phosphorylation and 
consequent inhibition of YAP activity, in a process mediated by AMPK (DeRan et al. 2014; Wang 
et al. 2015). Not only phosphorylation, but also other post-translational modifications can 
modulate YAP/TAZ activity, including SET-7-mediated methylation (Oudhoff et al. 2018) and 
acetylation by CREB binding protein and p300 (Hata et al. 2012). The substrates for these 
reactions are the products of several metabolic pathways and therefore, the availability of 
metabolic fuels and the cellular metabolism may regulate Hippo pathway (Filipp 2017; Zhao et 
al. 2010).  
The Hippo pathway is tightly associated with epithelial cell polarity and cell junctions, both of 
which are lost during EMT (Martin-Belmonte and Perez-Moreno 2011). In fact, epithelial cell 
polarity suppresses YAP/TAZ activity through the Crumbs polarity complex, while interference 
with the Crumbs complex in epithelial cells activates YAP/TAZ, which in turn promotes SMAD 
nuclear accumulation, TGF-β signaling and EMT (Varelas et al. 2010). Scribble, another cell 
polarity protein localized in the cell membrane, also inhibits TAZ by regulating the Hippo 
pathway (Cordenonsi et al. 2011). In MCF10A breast epithelial cells, the overexpression of a 
constitutively active form of TAZ actually results in a mesenchymal morphology, together with 
E-cadherin and occludin downregulation and the upregulation of N-cadherin, vimentin and 
fibronectin (Lei et al. 2008). Overexpression of active TAZ also confers cells increased migratory 
properties and proliferation (Lei et al. 2008). As an important regulator of stem cell differentiation 
and renewal, the Hippo pathway may have an active role in the context of cancer, where EMT 
has been associated with stem-like features (Bae et al. 2015; Sun et al. 2014). In MCF10A cells 
overexpressing HRas, TAZ not only results in decreased E-cadherin expression and increased 
migration but also increases soft-agar colony formation and mammosphere formation capacity 
(Cordenonsi et al. 2011; Mulvihill et al. 2014). In this system, TAZ overexpression is associated 
with changes in the expression of several metabolic enzymes and in the abundance of metabolites 
(Mulvihill et al. 2014). Particularly, in cells that were selected to mimic cellular transformation 
and malignant progression of breast cancer (through HRAS transfection, selection for 
spontaneous progression in vivo and overexpression of TAZ), FASN, platelet activating factor 
acetylhydrolase (PAFAH) 1B2 and PAFAH1B3 (two different lipases) were found to be 
upregulated and dysregulated in their serine hydrolase-directed activity. PAFAH1B is essential 
for the maintenance of aggressive features in triple-negative breast cancer cells, which is possibly 
mediated by alterations in the lipid landscape (Mulvihill et al. 2014). 
Other studies have also showed a link between metabolism and TAZ/YAP. For example, YAP 
induces GLUT3 expression to promote glucose uptake, and YAP and GLUT3 expression 
positively correlated in human liver and colon cancer (Wang et al. 2015). In TNBC cells, YAP 
induces hexokinase (HK) 2 and PFKB3 expression, leading to increased glycolysis; this metabolic 
effect is mediated by the lncRNA, breast cancer anti-estrogen resistance 4 (BCAR4) and the 
Hedgehog signaling, which are required for TNBC metastasis.  
 Fig. 3: In the Hippo pathway there is upregulation of GLUT3 and HK2 to increase glucose uptake 
and catabolism, respectively. Increased glycolysis seems to be mediated by BCAR4 and the 
Hedgehog pathway. There is also a close relation with lipid metabolism, namely upregulation of 
FASN, PAFAH1B2 and PAFAH1B3. GLUT3, glucose transporter 3; glucose-6-P, glucose 6 
phosphate; HK2 hexokinase 2, LDH, lactate dehydrogenase; PAFAH, platelet activating factor 
acetylhydrolase; FASN, fatty acid synthase; BCAR4, breast cancer anti-estrogen resistance 4. 
 
 
CONCLUSIONS 
The interplay between metabolism and metastasis is an emerging area of research. Some studies 
are particularly focused on EMT, a transdifferentiation program associated with metastasis, where 
the rewiring of several metabolic pathways appears as an important phenomenon. Noteworthy, 
some of the studies described in this manuscript show that metabolism is not only a consequence 
of changes in the cellular phenotype, rather playing an active role in EMT induction and 
maintenance. However, few studies explore the mechanism by which metabolism regulates EMT. 
Likewise, there is little data distinguishing the metabolic changes that are specifically related with 
the transition itself from those that are required for the maintenance of a mesenchymal phenotype.  
The majority of the EMT models display changes in metabolism towards an increased glycolysis, 
characterized by enhanced glucose uptake and lactate production, showing also alterations in 
OXPHOS activity. These metabolic shifts are supported by alterations in the expression or activity 
of metabolic enzymes, through mechanisms that involve, for example, direct binding of Snail to 
the gene promoter. Moreover, the TCA cycle, glutamine and lipid metabolism might also play 
important roles for the acquisition of mesenchymal properties. 
It should be pointed out that the link between EMT and metabolism needs to be integrated in the 
cellular context. In cancer cells, the uptake of nutrients is controlled not only by growth factor 
signaling but also by the aberrantly activated signaling pathways as consequence of their 
oncogenic alterations (Hanahan and Weinberg 2000). Indeed, the reprogramming of tumor 
metabolism has been shown to be under the control of various oncogenic signals (Edinger and 
Thompson 2002; Levine and Puzio-Kuter 2010; Thompson 2011). Major signaling pathways 
associated with cancer progression, such as TGF-β, Wnt and Hippo play a key role in the 
acquisition of mesenchymal characteristics in several cancer types. They regulate several players, 
in a complex network, that, in the case of EMT, includes the upregulation of EMT TFs. Indeed, 
Bhowmik et al. showed that the differential expression of EMT TFs results in distinctive 
metabolic profiles, although with some common alterations (Bhowmik et al. 2015). Nonetheless, 
a deeper analysis of the signaling landscape and its role in mediating the metabolic alterations in 
the context of EMT is lacking. The data is still limiting for the signaling pathways analyzed in 
this review and even more for other key signaling cascades like the Ras-MAPK. Besides, there is 
also a need of studies that analyze EMT and metabolic changes in a temporal manner, in order to 
distinguish early changes from later ones. 
In this review, we could further conclude that, even when evaluating the metabolism of EMT 
under the perspective of specific signaling pathways there is still heterogeneity. One might ask: 
why is there so much diversity in the metabolic reprogramming that characterizes EMT? 
Metabolism is a highly dynamic and plastic process, probably reflecting the tissue of origin and 
the genetic alterations that characterize the cells models, which go from nontransformed cells to 
cancer-derived cells, most commonly from the primary tumor but in some cases from metastatic 
sites. This heterogeneity conceivably translates what happens in vivo, especially because tumor 
cells are exposed to multiple signals from the microenvironment, adding another layer of 
complexity. 
Although this review focused on the literature about cancer-associated EMT, metabolism likely 
plays an important role in EMT during embryonic development and fibrosis. Different metabolic 
profiles have been reported in specific phases of embryonic development and metabolism plays 
a key role in the function of embryonic stem cells (Pereira et al. 2014) However, there is still a 
very limited number of studies addressing metabolism during the EMT that occurs in embryonic 
development and fibrosis. 
Targeting metabolism in combination with anti-neoplastic drugs holds promise as a strategy to 
disrupt the formation of metastasis. The study of metabolism during EMT may expose metabolic 
vulnerabilities that can be explored as therapeutic targets for cancer metastasis. Reversing EMT 
by targeting cellular metabolism might for example, contribute to drug sensitivity. Besides, the 
metabolic players in EMT can become promising new biomarkers of cancer progression. 
It is important to note that TGF-β, Wnt/β-catenin and Hippo pathways are currently being 
explored as therapeutic targets (Akhurst 2017; Johnson and Halder 2014; Krishnamurthy and 
Kurzrock 2018), so it is imperative to understand the crosstalk between signaling and metabolic 
networks during EMT. 
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